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Human islet amyloid polypeptide (hIAPP), also known as amylin, is the main 
constituent of the amyloid deposits present in approximately 95% of people with 
type 2 diabetes. Amylin aggregates into oligo-/polymeric  sheet structures which 
are considered to be cytotoxic to pancreatic -cells. Inhibiting the early stages of 
amylin aggregation could provide a potential therapeutic strategy for the treatment 
of type 2 diabetes. In this study, overlapping peptides were designed to target the 
binding region (RLANFLVHSS, residues 11-20) of human amylin and their effects 
on amylin fibril formation were studied. The first generation of peptides, IO1, IO2, 
IO3, IO4, IO5, IO6 and IO7, showed less than 50% inhibition of amylin 
aggregation as observed using a Thioflavin T (Th-T) fluorescence assay. The next 
generation of peptides, IO8 and RI-IO8, were assessed using Th-T, Congo red and 
transmission electron microscopy (TEM) techniques. IO8 (H2N-RGANFLVHGR-
NH2) showed strong inhibitory effects on amylin aggregation, up to 71% inhibition, 
with TEM studies revealing a total inhibition of amylin fibril formation at a 1:1 
molar ratio of peptide to amylin. MTS and LDH cytotoxicity studies revealed that 
IO8 protected human pancreatic islet β PANC-1 insulin producing cells from the 
toxic effects of human amylin. IO8 proved to be a significantly more potent 
inhibitor than the NMeG24 NMeI26 peptide reported in literature. In fact, contrary 
to reports in the literature, NMeG24 NMeI26 significantly enhanced amylin fibril 
formation. In addition, a homoarginine version of IO8, designed by replacing the 
arginine residues in IO8 (H2N-RGANFLVHGR-NH2) with homoarginine (H2N-
HarGANFLVHGHar-NH2) also significantly impeded amylin fibril formation as 
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observed by Th-T assay. To completely stabilise IO8 from proteolytic degradation, 
we designed RI-IO8 (Ac-rGhvlfnaGr-NH2), a retro-inverso peptide with L- 
replaced by D-amino acids. RI-IO8, however, significantly enhanced amylin fibril 
formation. Th-T experiments, Congo red assay and TEM revealed that two  N-
methylated versions of IO8, N1-IO8 (H2N-RGAmNFmLVmHGR-NH2) and N2-
IO8 (H2N-RGANmFLmVHmR-NH2) significantly inhibited amylin aggregation by 
up to 85% and 87%, respectively, as observed by Th-T assay. TEM images 
revealed complete inhibition of fibril formation by N1-IO8 at a 1:1 molar ratio of 
peptide to amylin, and by N2-IO8 even at a 1:5 molar ratio of peptide to amylin. 
N1-IO8 and N2-IO8 were found to be stable against proteolytic enzymes, and in 
plasma, unlike IO8, and also protected  human pancreatic islet β PANC-1 cells 
from the toxic effects of human amylin, and were themselves non-toxic to cells. 
These studies show that these N-methylated peptides, N1-IO8 and N2-IO8, are 
potent inhibitors of amylin aggregation and could be developed as a novel 
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1.1 Amyloid Protein Misfolding and Disease 
 
Amyloid is a generic term for abnormal protein fibrils that accumulate when 
protein molecules in a predominantly β-pleated sheet conformation bind to each 
other, mainly, but not exclusively, by hydrogen bonds (Dobson, 1999; Rochet 
and Lansbury, 2000). More than 30 proteins are known to form amyloid fibrils 
in a variety of different diseases in humans (Westermark et al., 2007; 
Westermark, 2005), including Alzheimer’s disease (Humpel 2011; Marchesi, 
2011), Huntington’s disease (Lee et al., 2011), Parkinson’s disease (Dillin and 
Cohen, 2011), prion disease (Brown and Mastrianni, 2010) and type 2 diabetes 
mellitus (T2DM) (Ahmad et al., 2011; Kapurniotu, 2001; Westermark, 2011). 
The misfolded proteins in these diseases are amyloid beta (A𝛽) and Tau, 
huntingtin, 𝛼-synuclein, prion protein (PrP) and amylin, respectively. The 
presence of amyloid deposits, which are predominantly made up of islet amyloid 
polypeptide (IAPP), also known as amylin, is a major pathological feature of 
T2DM. These deposits are found in about 90% of people with T2DM (Kahn, 
2003a; Zraika et al., 2010). Amylin aggregation is strongly linked with the 
development of β cell failure in this disease (Hull et al., 2004), and the protein 
has other regulatory functions in normal physiology (Kahn et al., 1999). This 
review aims to provide an in-depth overview of diabetes and the molecular 
mechanism of amylin aggregation, as well as amylin-mediated toxicity. This 
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study aims to develop peptide-based inhibitors that are designed to prevent 
amylin aggregation. 
 
1.2    Diabetes 
 
The World Health Organisation (WHO) defines diabetes as a chronic disease, 
resulting from insufficient insulin production by pancreatic β cells, and/or 
failure of the body to utilize the insulin being produced, leading to an increased 
blood glucose level, a condition referred to as hyperglycaemia (WHO, 2016). 
This can lead to secondary defects in many body systems, such as blood vessels 
and nerves (Spellman, 2010). Insulin is a hormone that helps cells to take up 
glucose from the blood, for energy production. There are two major types of 
diabetes; type 1 and type 2 diabetes. The symptoms of diabetes include 
excessive urination (polyuria), fatigue, persistent hunger, thirst (polydipsia), 
weight loss and vision impairment. These symptoms appear suddenly in type 1 
diabetes, but are less marked in T2DM, and the latter disease is often diagnosed 
many years after onset, following the appearance of secondary complications 
(Taniguchi et al., 2006). 
 
1.2.1 Diabetes Prevalence 
 
The prevalence of diabetes is constantly growing. Currently, approximately 425 
million people globally have diabetes and this figure is expected to rise to 642 
million by 2040 (Diabetes UK, 2015). About 4.8 million people worldwide died 
of diabetes in 2012, and approximately 4.7 billion US dollars was spent on 
diabetes in the same year (IDF, 2012). Total deaths from diabetes have been 
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predicted to increase by 50% in the next 10 years (WHO, 2014). Approximately 
3.5 million people are currently living with diabetes in the UK, and this number 
has been estimated to increase to 5 million by 2025 (Diabetes UK, 2015). 
Approximately 1 in 2 adults with diabetes worldwide are undiagnosed (IDF, 
2015), and in the UK, about 549,000 people are estimated to have undiagnosed 
diabetes (Diabetes UK, 2015). Diabetes is predicted to be the 7th leading cause 
of death in the world by 2030 (WHO, 2014). 
 
Type 1 diabetes is also known as insulin dependent diabetes and is a chronic  
disease in which insulin-producing β cells are destroyed so that the pancreas is 
unable to produce sufficient insulin (Abreu and Roep, 2013). The initial cause of 
the β cells destruction in type 1 diabetes is not fully understood. It is thought 
that genetic and environment factors like viruses may trigger the development of 
type 1 diabetes (Knip et al., 2005). Insulin injections are often used in these 
patients to control blood glucose levels, but many of them cannot maintain 
stable blood sugar levels (Coppieters et al., 2012) and so they often experience 
hypo- and hyperglycaemic states, which progress into long term complications. 
Type 1 diabetes accounts for around 10% of all people with diabetes (Diabetes 
UK, 2016). 
 
T2DM is the most common form of diabetes and accounts for approximately 
90% of the diabetic population (Diabetes UK, 2016). The pathogenesis of 
T2DM is multifaceted and is a topic that has been studied intensely (DeFronzo, 
2004; Taniguchi et al., 2006). Two major factors, each based on varying 
mechanisms, play a role in the pathogenesis of this disease (Kahn, 2003a; Kahn 
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et al., 2009). The first is insulin resistance, resulting in the reduced effectiveness 
of, and a high demand for insulin (figure 1.1). The second major factor is the 
failure of pancreatic β cells to produce enough insulin, due to a decrease in both 
β cell mass (Clark et al., 1998; Kayed et al., 2009) and β cell function (Kahn, 
2000).  
 
Type 1 diabetes typically appears before the age of 40, and T2DM occurs 
majorly in middle aged and older adults from about age 40 onwards. However, 
in recent times, T2DM has also been reported among children. In the UK, 8 
overweight girls of Arabic, Indian and Pakistani origin between the ages of 9 to 
16 were diagnosed with T2DM (Ehtisham et al., 2000). It is estimated that about 
31,500 children and young people currently have diabetes in the UK (Diabetes 
UK, 2015). Out of this number, 95.1% have type 1 diabetes, while 1.9% have 
T2DM, and the remaining 3% have other rarer conditions, such as diabetes 








Figure 1.1: The regulatory pathways of glucose, controlled by the pancreas. After insulin 
secretion from the β cells of the pancreas a number of activities take place including, glucose 
uptake, gluconeogenesis by the liver, up-regulation of the GLUT-4 glucose transporter in 
muscle, and attenuation of glucagon secretion from the islets. Glucagon secreted by the α cells 
triggers the breakdown of glycogen by the liver, thereby releasing glucose when required. 
Somatostatin secreted from the δ cells decreases the secretion of insulin and glucagon. Amylin 
secreted by β cells delays gastric emptying, reduces appetite, and suppresses the secretion of 
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1.2.2     Diabetes Risk Factors 
Several risk factors have been associated with diabetes. Genes, lifestyle and 
environmental factors all influence the risk of developing T2DM (Diabetes UK, 
2015). Obesity is a major risk factor, constituting 80-85% of the overall risk 
(Hauner, 2010). Approximately 2 in every 3 persons in the UK are obese (WHO, 
2016). The increasing prevalence of T2DM may be due to the increasing aging 
population and the increasing number of overweight and obese people. 
Additionally, some women develop diabetes during pregnancy; this condition is 
called gestational diabetes. About 5% of all pregnant women develop gestational 
diabetes (Inkster et al., 2006), and women who have gestational diabetes are 
more likely to develop T2DM in their later life. 
People who have a family history of diabetes are 2 to 6 times more likely to 
develop the disease than those without a family history (Vaxillaire and Froguel, 
2010). With regards to ethnicity, South Asian individuals are 6 times more likely 
to have diabetes, while individuals of African and Caribbean origin are 3 times 
more likely to have diabetes than people from other populations (NSF, 2013). In 
2015, it was estimated that approximately 14.2 million people in Africa had 
diabetes, with 75% of this estimate being undiagnosed (IDF, 2015). 
A number of genes have been found to play key roles in susceptibility to 
diabetes. Of particular importance is the gene for transcription factor 7-like 2 
(TCF7L2), which was first regarded as a diabetes susceptibility gene following a 
strong signal that mapped to chromosome 10q in a Mexican-American 
population. Fine mapping of this region was carried out in Danish and United 
States cohorts with the risk locus being located to intron 3 of the TCF7L2 gene 
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(Ali, 2013). TCF7L2 variants have been linked with T2DM in various ethnic 
groups (Scott et al., 2006; Cauchi et al., 2006; Sale et al., 2007). TCF7L2 is a 
transcription factor that plays a key role in the Wnt signaling pathway and in the 
development of various cell lineages (Klaus and Birchmeie, 2008). Its role in β 
cell survival, pancreatic islet development, insulin secretory granule function, 
adipogenesis and myogenesis, all reflect its impact on diabetes (Shu et al., 2008; 
da Silva et al., 2009). It is also a key component in the transcriptional regulation 
of the genes for proglucagon and the glucagon-like peptides GLP-1 and GLP-2, 
which are major players in postprandial insulin secretion (Doria et al., 2008). 
TCF7L2 polymorphisms have been linked with glucose tolerance and impaired 
insulin secretion by direct impact on pancreatic islet β cells (Lyssenko et al., 
2007; Schafer et al., 2007). Moreover, studies have shown that elevated levels of 
gastric inhibitory peptide and glycated hemoglobin (HbA1c), decreased 
processing of proinsulin, and dysregulation of glucose metabolism, have all been 
seen in normoglycemic individuals with particular TCF7L2 polymorphisms 
prior to the development of T2DM (Gjesing et al., 2011; Gautier et al., 2011). In 
addition, studies have shown that genetic tests for TCF7L2 are useful in 
predicting the incidence of this disease (Silbernagel et al., 2011). These studies 
suggest that detection of TCF7L2 variants could be a good strategy for the early 
detection, intervention and prevention of T2DM (Florez et al., 2006). However, 
there is currently no clinically approved role for routine screening for these 
variants in potential diabetics. 
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1.2.3 Secondary Complications of Diabetes 
Diabetes leads to a number of secondary complications including blindness, 
heart disease, kidney failure and stroke (WHO, 2015), and people with diabetes 
have a two times higher risk of developing cardiovascular disease than healthy 
individuals (Sarwar et al., 2010). Diabetes is a common cause for lower limb 
amputations (ASD, 2007) and 70% of people die within 5 years of amputation 
due to diabetes (Schofield et al., 2006). Nephropathy occurs in approximately 
50% of individuals with diabetes (Diabetes UK, 2015). A healthy diet, weight 
management, keeping active, and using medication including insulin therapy, 
are necessary for managing diabetes and its complications (Colhoun et al., 2004; 
Morrish et al., 2001) as there is currently no cure for the disease. 
 
 
1.2.4     Current Methods for Diagnosis of Diabetes 
The diagnosis of diabetes can be carried out in various ways. T2DM is usually 
diagnosed by symptoms, including polyuria (excessive urination) and polydipsia 
(excessive thirst). Screening tests used in diagnosing diabetes and pre-diabetes 
include the Fasting Plasma Glucose Test, Oral Glucose Tolerance Test, Glycated 
Hemoglobin test (HbA1c Test) which shows the average plasma glucose 
concentration, and Random Blood Glucose Test (Diabetes UK, 2016). The 
Fasting Plasma Glucose Test is the most prevalent of these tests because it is 
more convenient and cheaper to administer than the Oral Glucose Tolerance 
Test. To measure blood glucose levels using this test, a person must have fasted 
for at least 8 hours, and the most accurate results are obtained when the test is 
taken in the morning. A fasting glucose level of 100 to 125 mg/dL indicates 
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impaired fasting glucose or prediabetes, whereas a level of 126 mg/dL or above 
indicates diabetes if confirmed by a second test (NIDDK, 2014). However, the 
Oral Glucose Tolerance Test has a higher sensitivity than the Fasting Plasma 
Glucose Test, even though it is less convenient to administer. Blood glucose 
level is measured by the Oral Glucose Tolerance Test after a person fasts for at 
least 8 hours and 2 hours after the person drinks a liquid containing 75 grams of 
glucose dissolved in water. A person with a 2-hour blood glucose level between 
140 and 199 mg/dL is considered pre-diabetic (NIDDK, 2014). A level of at 
least 200 mg/dL indicates that a person is diabetic, if confirmed by a second test. 
The HbA1c test is also an effective way of detecting T2DM and pre-diabetes. A 
level below 42 mmol/mol indicates that the individual is non-diabetic. A level 
between 42 and 47 mmol/mol indicates impaired fasting glucose (prediabetic), 
whereas a level of 48 mmol/mol and above indicates diabetes (Diabetes UK, 
2016). The Random Plasma Glucose Test is used to detect diabetes during 
routine health checkup. A level of 200 mg/dL or above in addition to the 
presence of diabetes symptoms is a pointer for the diagnosis of diabetes. Other 
diagnostic tests used to differentiate between type 1 and T2DM include ketone 
tests, Glutamic Acid Decarboxylase autoantibody tests, and C-peptide tests. 
 
1.2.5   Current Methods for Treatment of Diabetes  
In addition to life style changes such as diet and exercise, a number of treatment 
options are available for the management of diabetes. Insulin injections are 
usually administered to compensate for the non-production of insulin in type 1 
diabetes (NHS UK, 2015). Patients with T2DM are eventually treated with 
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insulin as their insulin production levels decrease with disease progression 
(Diabetes UK, 2016). There are three main types of insulin; animal insulin, 
human insulin (produced synthetically) and insulin analogues where the 
chemical structure of human insulin is altered to provide a more rapid or long 
lasting effect. Other treatments for T2DM include biguanide, sulphonylureas, 
prandial glucose regulators, alpha glucosidase inhibitor, DPP-4 inhibitors 
(gliptins), thiazolidinediones (glitazones), incretin mimetics and  SGLT2 
inhibitors (Diabetes UK, 2016). These treatment options are only able to manage 
diabetes but do not prevent secondary complications. As there is currently no 
cure for diabetes, there is a need for more research to develop treatment options 
that more effectively manage and potentially cure diabetes (Diabetes UK, 2016). 
Recent animal and human studies showed that berberine, an isoquinoline 
alkaloid extract, is a promising hypoglycemic agent (Chang et al., 2015). 
Interestingly, recent studies have shown that drugs used to treat T2DM may be 
useful for Alzheimer’s disease (Holscher, 2014). Lixisenatide, a diabetes drug, 
shows neuroprotective effects in mouse models of Alzheimer’s disease 
(McClean and  Holscher, 2014). Further studies have also reported that diabetic 
individuals with very poor blood sugar control experience a high risk of 
developing dementia and Alzheimer disease (Luchsinger et al., 2004; Gella and 
Durany, 2009). These data strongly suggest a relationship between T2DM and 
Alzheimer’s disease. Both diabetes and Alzheimer’s disease are characterised by 
accumulation of advanced glycation end products and oxidative damage (Ott et 
al., 1999), further suggesting mechanistic links between these two apparently 
different diseases. Although this correlation is not fully understood, the above 
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data suggest that a cure for diabetes could be an indicator for finding a cure for 
other amyloid related diseases. 
 
 
1.2.5.1   Stem Cell Treatment for Diabetes 
 
Approaches that stimulate replication and regeneration of β cells may lead to 
increased amounts of β cells available for the regulation of blood glucose. Stem 
cell therapy and organ transplantation holds huge possibilities for the treatment 
of diabetes through the isolation and transplantation of β cells or an entire 
pancreas from a donor to a patient (EuroStemCell, 2016). Whole pancreas 
transplants have been used to help the body re-attain its ability to regulate blood 
sugar levels. Islet transplantation is however more prevalent as whole pancreas 
transplant is associated with a high surgical risk. Despite the huge potential 
pancreas transplantation holds for diabetes treatment, it involves a number of 
risk, for example, the immune system has to be suppressed with immune 
suppressing drugs during transplantation, so the foreign organ is not rejected. 
However, suppressing the immune system exposes the recipient to infection and 
may also produce adverse effects (EuroStemCell, 2016). The immune 
suppressing drugs are ultimately destroyed by the immune system and another 
transplant would invariable be required. Thus, most organ transplants are 
rejected. On the other hand cells transplantation hold huge potential for 
replacement tissues in vitro as well as autologous cells specifically from the 
patients. Hanna et al., 2007, showed that hematopoietic progenitors were 
successfully used to treat sickle cell in an anemia mouse. This is supported by a 
previous study which showed that engrafting embryonic stem cell (ESC)-
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derived cardiomyocytes into injured heart muscle effectively impeded 
arrhythmias (Shiba et al., 2012). Furthermore, a study on rats with spinal cord 
injuries showed that ESC-derived oligodendrocyte progenitor cells re-instated 
their mobility (Keirstead et al., 2005). β cells also holds an attractive potential 
for cell replacement strategy as replacement is required for only a single cell 
type, thus replacement can be carried out in non-endogenous sites which 
alleviates the risk of invasive surgeries. β cell transplantation into a non-
endogenous site using immunoprotective devices also protects the cells from 
autoimmune attack (CFRI, 2016; JDRF, 2016; HSCI, 2016). This is supported 
by previous studies where β cell transplantation into the hepatic porta vein 
showed to be very effective in diabetes treatment (Shapiro et al., 2000;  Bellin et 
al., 2012; Shapiro et al., 2006).  
 
A major challenge with islet transplantation is the fact that there are very few 
good quality islets from donors compared to the demand for transplantation. 
Thus, producing β cells from alternative sources in the laboratory could 
significantly help with generating a reliable and unlimited source of islets, given 
that most patients require more than a single donor. Research has shown new 
approaches for making β cells for therapeutic purposes (Lumelsky et al., 2001).  
Studies have shown the transplantation of mature pluripotent stem cells namely 
embryonic and induced pluripotent stem cells, into pancreatic β cells (Hori et 
al., 2002). Pluripotent stem cells can make any cell type in the body and have 
shown to be very beneficial in cell replacement approaches as it is highly 
available, has high expansion and differentiation capabilities and have 
phenotypically established hallmarks (Soria et al., 2000). Mature β cells have 
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also been made from other cell types. For example, acinar cells of the pancreas 
have been shown to form new β cells, Zhou et al., 2007 showed that acinar cells 
differentiate into β cells following overexpression of major transcription factors 
including MafA, Ngn3 and Pdx1 (D’Amour et al., 2006). Also, more β cells can 
be endogenously produced through induction replication of existing β cells. 
Although tissues such as blood and skin regenerate through differentiation of 
tissue specific stem cell, new pancreatic β-cells are often generated from the 
replication of existing β-cells (Dor and Melton, 2004). In spite of the huge 
potential this holds, the main risk associated with this replication induction 
approach is the spontaneous stimulation of tumorigenesis. Inducing acinar tissue 
to proliferate with β cells imposes cancer risk. However, this risk can be 
adverted if the agent used in replication has a high specificity for β-cells 
comparable to other cell types. Stem cell treatment offers a huge potential for 
the treatment of diabetes, however, the likelihood of success for stem cell 
treatment in diabetes mellitus is very narrow, and this procedure is very 
expensive and requires specialist intervention, and given the large population of 
people suffering from diabetes, a more convenient, easily assessable and less 
expensive approach is required. 
 
1.2.6    Animal Models of Diabetes 
A number of animal models of type 1 and T2DM are available for 
pharmacological testing, the study of disease mechanisms, and for genetic 
studies. These animal models have varying degrees of physiological relevance, 
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with some of them depicting the actual human disease condition more accurately 
than others.  
Streptozotocin (STZ) is a chemical broadly used for the induction of 
experimental diabetes in rodents (Szkudelski, 2001; Lenzen, 2008). Ever since 
the discovery of its diabetonegic properties (Rakieten et al., 1963), STZ has 
been used, alone or in combination with other chemicals, for inducing type 1 or 
T2DM. A single STZ injection induces type 1 diabetes (Junod et al., 1969; Yin 
et al., 2006), while T2DM is induced through a number of techniques including 
STZ injection during the neonatal period (Patil et al., 2014; Portha et al., 1989), 
after nicotinamide administration (Wu et al., 2008; Szkudelski, 2012), or low-
dose STZ injection after a high fat diet (Skovs, 2014). These STZ diabetic 
models have been very advantageous in studying the pathogenesis of diabetes 
and for screening of pharmacological agents which can potentially lower blood 
glucose levels (Srinivasan et al., 2005; Kumar et al., 2012). Following 
intraperitoneal or intravenous administration, STZ penetrates into pancreatic β 
cells by means of the Glut-2 transporter, resulting in DNA alkylation 
(Szkudelski, 2001) and eventual inhibition of insulin production (Sandler and 
Swenne, 1983). STZ also produces free radicals, which play a role in DNA 
damage and eventually cell death. Intraperitoneal injections of STZ are 
eliminated within 48 hours of administration (Karunanyake et al., 1974) but β 
cell function still progressively declines even when STZ is no longer detected 
(Rerup, 1970), indicating that acute STZ toxicity induces a sustained 
hyperglycaemic state which facilitates long-term β cell destruction (Matsuda et 
al., 2002). Although STZ induction is a widely accepted and well known system 
for studying the pathogenesis and complications of diabetes, induction of 
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diabetes through STZ is by no means identical to the human disease state. STZ 
does not produce the pathophysiological insulin resistance observed in human 
state diabetic conditions (Wu and Yan, 2015). Additionally, there are no 
standard protocols for STZ administration and the diabetic state is influenced by 
many factors including the specie, sex, body weight and age of animals used 
(Deeds et al., 2011).  
 
Models of type 1 and T2DM have also been created using transgenic mice, 
including humanized mice with aspects of the human immune system, hIAPP 
mice that express human amylin, and mice that permit conditional ablation of β 
cells (Hara et al., 2003). Knock-out and transgenic mice are key players in 
studying the impact of particular genes in glucose metabolism and diabetes 
pathogenesis, including an understanding of insulin signaling pathways (Kahn, 
2003b; Wang and Jin, 2009) and elucidation of the transcription factors involved 
in pancreatic development (Habener et al., 2005). The diabetogic effects of 
human amylin have been studied by using transgenic mice overexpressing 
biologically active amylin in their pancreatic islet β cells (Höppener et al., 1993; 
Ahrén et al., 1998). Here, it is important to note that endogenous rodent amylin 
does not form islet amyloid (Höppener et al., 1993; Ahrén et al., 1998). Studies 
have shown that overexpressing human amylin alone does not stimulate 
hyperinsulinemia, hyperglycemia or obesity in mice (Höppener et al., 1993). 
However, substantial islet amyloid formation with compounding diabetes is 
observed upon cross breeding of amylin transgenic mice with leptin-deficient 
and insulin-resistant ob/ob (ob = obese) mice (Höppener et al., 1999). Studies 
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have also shown that a long-term, high-fat diet stimulates hyperinsulinemia, 
hyperglycemia and obesity in amylin transgenic mice (Surwit et al., 1998; 
Ahrén et al., 1997; Höppener et al., 2008). In addition, a high-fat diet has been 
shown to enhance islet amyloid formation in amylin transgenic mice (Verchere 
et al., 1996). 
When evaluating drug interventions on diabetic animal models, a common 
measurement is determination of blood glucose levels. The presence of glucose 
in urine is also indicative of diabetes. It is, however, important to note that 
different species have different blood glucose levels compared to humans, and 
the diabetic state in humans would not necessarily be regarded as diabetic in 
animals. For example, mice naturally have a higher blood glucose level than 
humans (Leiter, 2009). Also, since diabetes is multifaceted, other measures need 
to be taken into consideration, depending on the drug mechanism and animal 
model used. For example, in studies of type 1 diabetes, it is necessary that the 
animals used are weighed to make certain that any fall in blood glucose levels is 
not linked with weight loss, which could indicate a toxic effect of the treatment, 
or simple loss of appetite. On the other hand, in models of T2DM weight loss 
may be an impact of the glucose lowering effects of the drug (Knudsen, 2010). 
The stages of disease progression should also be considered, depending on the 
purpose of the study, as the disease stage may influence the measurement 
criteria. Because the onset of T2DM appears later in life, it may be necessary to 
use older mice when carrying out studies on this disease. 
In addition, when choosing an animal model, it is important to consider 
variations between species, and between animal strains, as this will have a 
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bearing on their predisposition to diabetes treatment (Brosius III et al., 2009). 
For example, some species and strains of animals do not develop diabetic 
complications, and so other suitable models may be required for studies focused 
on diabetic complications (Breyer et al., 2005; Sullivan et al., 2007). 
 
1.3 Structure of Amylin 
 
Amylin is a 37 amino acid residue peptide belonging to the calcitonin family, 
which also contains adrenomedullin, calcitonin, calcitonin gene-related peptide 
(CGRP) and intermedin (Roh et al., 2004; Wimalawansa, 1997). Members of 
the calcitonin family, including amylin, have a disulphide bridge between Cys 
residues 2 and 7, as well as an amidated carboxyl terminus, which are 
posttranslational modifications necessary for biological activity (Wimalawansa, 
1997). Amylin has sequence homology of 43% and 49% with  human CGRP-1 
(hCGRP-1) and hCGRP-2 respectively (Cooper, 1994). Amylin is thought to 
have a random coil structure (Kayed et al., 1999). On the other hand, circular 
dichroism (CD) (Knight et al., 2006) and nuclear magnetic resonance (NMR) 
(Nanga et al., 2009; Patil et al., 2009) spectroscopy studies have suggested that 
the peptide forms a temporary amphipathic α-helix in the amino terminal 
segment (Abedini and Raleigh, 2009), separate from the very end of the amino 
terminal region, giving rise to the disulphide bridge at residues 2 and 7. The 
helix extends from residues 5-23 in solution (Knight et al., 2006). The carboxyl 
terminal region of the molecule is undefined (Nanga et al., 2009), and the helical 
region is thought to play a key role in its pathological change to amyloid fibrils.  
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Amylin is a polypeptide hormone that is conserved throughout evolution and has 
been characterised in birds, mammals and teleostean fishes (Johnson et al., 
1990; Martínez-Álvarez et al., 2008; Miyazato et al., 1992; Westermark et al., 
2002), where mainly the amino and carboxyl terminal segments are conserved 
(figure 1.3). Amylin deposits are found in the pancreatic islets of humans and 
other mammals and probably lead to pathological symptoms in these organisms. 
Previous difficulty in accepting the role of amylin-derived amyloid in the 
pathogenesis of T2DM may have emerged from the fact that islet amyloid is not 
present in most mammalian species used for diabetic research, such as rats and 
mice (Westermark et al., 1992). Although the amylin molecule is conserved 
throughout evolution, there are interspecies modifications at key amino acid 
residues. The variations at amylin 20-29 region are most apparent, and account 
for five out of six variations between human and rat amylin (table 1). The 
rat/mouse amylin has three proline residues in this region which are known to be 
β sheet breakers. While synthetic human, non-human primate and cat amylin are 
very fibrillogenic, rat/mouse and several other rodent forms of amylin are not 
(Westermark et al., 1990; Betsholtz et al., 1990., Betsholtz et al., 1989b), and 
this can be attributed to these variations in primary structure. Further studies 
suggest that while the amylin 20-29 region is vital in amyloid formation, other 
regions of the molecule also play key roles in fibrillogenesis (Abedini and 
Raleigh, 2006; Goldsbury et al., 2000; Koo and Miranker, 2005; Nilsson and 
Raleigh, 1999). The 14-20 region of amylin located at the amphipathic α-helical 
segment (Nanga et al., 2009) of the molecule may also be of significance. 
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 1 10 20 30           37 
Human 
CGRP1 
ACDTATCVT HRLAGLLSRS GGVVKNNFVP TNVGSKAF 
Human 
CGRP2 
ACNTATCVT HRLAGLLSRS GGMVKSNFVP TNVGSKAF 
Human KCNTATCAT QRLANFLVHS SNNFGAILSS TNVGSNTY 
Rat KCNTATCAT QRLANFLVRS SNNLGPVLPP TNVGSNTY 
Bear KCNTATCAT QRLANFLVRS GNNLGAILSP TNVGSNTY 
Puffer fish KCNTATCVT QRLADFLVRS SNTIGTVYAP TNVGSTTY 
Monkey KCNTATCAT QRLANFLVRS SNNFGTILSS TNVGSDTY 
Macaque KCNTATCAT QRLANFLVRS SNNFGTILSS TNVGSDTY 
Baboon ICNTATCAT QRLANFLVRS SNNFGTILSS TNVGSNTY 
Porcine KCNMATCAT QHLANFLDRS RNNLGTIFSP TKVGSNTY 
Cow KCGTATCET QRLANFLAPS SNKLGAIFSP TKMGSNTY 
Cat KCNTATCAT QRLANFLIRS SNNLGAILSP TNVGSNTY 
Dog KCNTATCAT QRLANFLVRT SNNLGAILSP TNVGSNTY 
Mouse KCNTATCAT QRLANFLVRS SNNLGPVLPP TNVGSNTY 
Guinea pig KCNTATCAT QRLTNFLVRS SHNLGAALLP TDVGSNTY 
Hamster KCNTATCAT QRLANFLVHS NMNLGPVLSP TNVGSNTY 
Degu KCNTATCAT QRLTNFLVRS SHNLGAALPP TKVGSNTY 
Ferret KCNTATCVT QRLANFLVRS SNNLGAILLP TDVGSNTY 
Rabbit   CNTVTCAT QRLANFLIHS SNNFGAFLPP S 
Hare                     T QRLANFLIHS SNNFGAFLPP T 
 
Table 1.1: The primary amino acid sequences of human CGRP and amylin of different species. 
Amylin is highly conserved but with clear variation in the 20–29 region. This corresponds to 
residues 31–40 of proAmylin. The biologically active mature amino acid sequences all have a 
disulfide bridge between Cys-2 and Cys-7 as well as an amidated C-terminus. Primates and cats 
have been shown to form islet amyloid, while cows, rodents, and dogs do not. Ferret and porcine 
amylin has been reported to be significantly less amyloidogenic than human amylin. Islet 
amyloid is found in the degu, but it is insulin-derived rather than being formed from amylin. The 
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1.4 Expression of Amylin 
 
Amylin is initially expressed as part of an 89- amino acid residue pre proprotein, 
made up of a 22 amino acid signal peptide and two short peptides adjacent to 
each other, which are cut off at double basic amino acid residues (Betsholtz et 
al., 1989; Mosselman et al., 1989; Sanke et al., 1988), in a similar way to 
proinsulin (Nolan, 1971). A single-copy gene on the short arm of chromosome 
12 expresses amylin, in contrast to insulin and other members of the calcitonin 
family, including CGPR and calcitonin, which are encoded by evolutionarily 
conserved genes on chromosome 11 (Wimalawansa, 1997). PreproAmylin has 
three exons, with the last two coding for the full length prepro molecule 
(Christmanson et al., 1990, Nishi et al., 1989). In the endoplasmic reticulum 
(ER), the signal peptide is cut off, and proAmylin is converted to amylin in the 
secretory vesicles. Two endoproteases, prohormone convertase 2 (PC2) and 
prohormone convertase 1/3 (PC1/3), as well as carboxypeptidase E (CPE), 
control the course of action of ProAmylin and proinsulin (figure 1.4). This 
process is pH dependent and occurs in the Golgi and secretory granules. The 
carboxyl edge of Arg31 and Arg32 of human proinsulin is cleaved by PC1/3, 
and cleavage after Lys64 Arg65 is facilitated by PC2 (Smeekens et al., 1992). 
The carboxyl terminal of the dibasic amino acids is removed by CPE (Davidson 
et al., 1987). ProAmylin is processed by PC2 at position Lys10 Arg11 and at 
position Lys50 Arg51 by PC1/3 (Marzban et al., 2004; Cao et al., 2013). PC2 
can process proAmylin at the carboxyl terminal, when PC1/3 is absent (Wang et 
al., 2001). The carboxyl terminal glycine residue in several hormonal peptides is 
used for amidation which, along with the disulphide bridge between residues 2 
and 7, is a requirement for complete biological activity. 





A         PreProAmylin 
MGILKLQVFLIVLSVALNHLKA TPIESHQVEKR KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
GKRNAVEVLKREPLNYLPL 
 
B         ProAmylin 
            TPIESHQVEKR          KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY GKR   NAVEVLKREPLNYLPL 
 
C        Amylin                                                                                     O 
                       +NH3 – KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-C-NH2 
 
Figure 1.2: Processing of human PreProAmylin to form mature Amylin.  (A) The primary 
amino acid sequence of human PreProAmylin, the peptide length is 89 residues. The 22 residue 
signal sequence is shown in black, the N- and C-terminal proAmylin flanking regions are shown 
in red, and the mature amino acid sequence is shown in purple. (B) The primary sequence of the 
67-residue human proAmylin with cleavage site for PC(1/3)  at the COOH terminus and PC2 at 
the NH2  terminus, indicated by the arrows.  CPE/PAM  processed the  amidation of the C-
terminus of Amylin. (C) The amino acid sequence of the mature 37-residue human Amylin. The 
biologically active peptide posseses an amidated C-terminus and a disulfide bridge between Cys-






PC2 PC 1/3>PC2 
CPE 
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The two flanking peptides from proAmylin and the C peptide from proinsulin 
stay in the secretory granule, resulting in exocytosis and discharge of equimolar 
concentrations of the isolated peptides and their ultimate hormonal products. 
Insulin and amylin genes contain similar promoter elements (German et al., 
1992) and the pancreatic and duodenal homeobox 1 (PDX1) transcription factor 
controls the effect of glucose on both genes (German et al., 1995; Watada et al., 
1996). In rats, glucose stimulation results in a synchronized increase in protein 
expression for amylin and insulin from the islet β cells (Kahn et al., 1991; 
Mulder et al., 1996). This linked expression pattern for insulin and amylin is, 
however, modified in experimental animal models of T2DM. In the presence of 
dexamethasone, more amylin was secreted by perfused rat pancreas than insulin 
(O’Brien et al., 1991), and insulin secretion was also less than that of amylin at 
high doses of streptozotocin and alloxan (Mulder et al., 1995). The expression 
of amylin and insulin is also regulated differently by fatty acids; for example, in 
MIN6 cells, oleate and palmitate increased the expression of amylin, but not 
insulin (Qi et al., 2010). However, mice refed with intralipid showed 
significantly higher levels of amylin and insulin compared to those refed with 
saline (Qi et al., 2010). Furthermore, plasma amylin was found to be 4.5 times 
greater than insulin in mice fed for 6 months with a high fat diet, compared with 
mice fed with standard food containing 4% fat (Westermark et al., 1998). These 
examples show that under certain conditions, the precise synchronized 
expression of insulin and amylin may be interrupted.  
Furthermore, amylin is expressed in the gut of all mammals including cats, mice 
and rats (Miyazato et al., 1991; Mulder et al., 1996; Mulder et al., 1994; 
Toshimori et al., 1990), and in the sensory neurons of rats and mice (Gebre-
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Medhin et al., 1998; Mulder et al., 1995). In the rat gastrointestinal tract, amylin 
is detected beginning from the pyloric antrum to the large intestine, with the 
antrum having the highest concentration (Miyazato et al., 1991). However, the 
pyloric amount of amylin is only about 1 % of that found in the pancreas 
(Miyazato et al., 1991). On the other hand, in the brain and intestine of the 
chicken, amylin is more highly expressed than in the pancreas (Fan et al., 1994). 
It is, however, unclear how these extra-pancreatic sites regulate synthesis, 
storage and release of amylin (Fan et al., 1994), but this suggests a common 
origin for the amylin and CGRP genes. 
 
In healthy adults, the molar ratio of amylin to insulin is approximately 1:100. 
However, in T2DM, the molar ratio of amylin to insulin is approximately 1:20 
(Knight et al., 2008; Hull et al., 2004), and it is therefore no surprise that small 
changes in the relative amounts of amylin and other β cell granule constituents 
can stimulate amylin aggregation and initiate amyloid fibril formation. The 
presence of amyloid-like fibrils in β cells during the initial stages of the disease 
(Paulsson et al., 2006) also supports this finding. Human amylin is highly 
fibrillogenic in a spontaneous fashion, and thus should be protected from 
aggregation (Abedini et al., 2007).  
 
Amylin works together with insulin in maintaining circulating glucose 
concentrations in quite a narrow range, thus impeding an abnormal rise in 
glucose concentrations (Hirsch, 1999). The pathogenesis of T2DM is 
characterised by decreased insulin sensitivity and β-cell function (Porte and 
Kahn, 1991). Alterations in β-cell function involve a decrease in insulin 
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secretion in response to glucose (Porte, 1999). In addition to decreased insulin 
secretion, there is also a decrease in amylin response. Studies have shown that a 
decrease in insulin and amylin responses are seen in patients with high diabetes 
risk is an indication of early alterations in β-cell function. Amylin deposits have 
been found in patients with T2DM and studies suggest that an increase in amylin 
secretion may be involved in the development of these deposits (Westermark et 
al., 1987; Cooper et al., 1987). Although the relationship between insulin 
sensitivity and amylin response is still being argued, amylin secretion from the 
β-cell of the pancreas may not be regulated by insulin sensitivity. However, 
amylin which is co-secreted with insulin by the pancreatic β-cells (Lukinius et 
al., 1989), have been shown to be elevated in insulin-resistant conditions such as 
obesity (Kautzky-Willer et al., 1994; Kahn et al., 1998).  This suggest a 
relationship between insulin resistance and amylin levels and since increased 
levels of amylin which results in the formation of amylin aggregates is a main 
pathological feature of T2DM, it could be thought that inhibiting amylin 
elevation and aggregation may also impact on insulin resistant states. Given that 
insulin and amylin have a hyperbolic (Landchild et al., 2000) relationship, it 
could be assumed the secretion of insulin-containing granules as rmodulated by 
insulin sensitivity could also be applied to amylin. 
 
It is likely that the interaction with other components such as proinsulin and 
insulin defends against amylin aggregation (Westermark et al., 1996). Insulin 
has been shown to act as a natural inhibitor of amylin (Gilead et al., 2006) and 
to strongly impede the formation of amylin fibrils (Westermark et al., 1996) 
when its concentration is in excess of that of amylin (Janciauskiene et al., 1997). 
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These findings have been supported by several studies which elucidate the 
inhibitory ability of insulin on amylin aggregation (Jaikaran et al., 2004; Larson 
et al., 2004; Sellin et al., 2010). The 9-20 segment of the insulin β-chain binds 
to amylin and this appears to be responsible for the inhibition (Larson et al., 
2004). However, other studies have shown contradictory effects on amylin 
aggregation. One study showed that although insulin is a kinetic inhibitor of 
amylin aggregation, its inhibitory effect on amylin is only apparent for a limited 
time period (Cui et al., 2009). It was also reported that insulin copolymerizes 
with amylin monomers and oligomers, instead of amylin fibrils (figure 1.2). This 
interaction results in inhibition of amylin aggregation, but, in diabetic 
conditions, can stimulate the aggregation of amylin over time (Cui et al., 2009). 
These results suggest that insulin could play different roles in amylin 
aggregation, by inhibiting amylin aggregation in healthy people while promoting 
amylin aggregation during the pathogenesis of T2DM. Given these contradictory 
effects, insulin cannot be used to develop peptide inhibitors of amylin 
aggregation, and more study is required to elucidate the interactions of insulin 

















Figure 1.3: Structural model of the amylin fibril derived from steric zipper studies. (A) Ribbon 
diagram of human amylin fibril structure showing the two stacks of symmetry related 
monomers. (B) Cross section of a single fibril layer, viewing inside the fibril axis, reveals 
several key residues. The aromatic residues Phe15, Phe23 and Tyr37 are shown in space filling 
format together with Arg11, His18 and Ser20. (C) Cross section of a single layer showing the 
tight “steric zipper” interface between two human amylin monomers. Interdigitated residues 
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1.5     Effects of Amylin 
 
1.5.1  General Effects of Amylin 
 
The fact that amylin is conserved across several animal species suggests that it 
has an important function. The role of amylin is not fully understood, a major 
difficulty being the complexity in differentiating its pathological and 
physiological roles, as well as its pharmacological impact in experiments. Since 
amylin is co-secreted and co-stored with insulin, it is logical to think that amylin 
could play a role in the regulation of glucose metabolism, by acting as a 
paracrine molecule in the islets of Langerhans, and there is good evidence to 
support this. There is also evidence that amylin can acts as a hormone with 
impact on the central nervous system (Barth et al., 2003; Lutz, 2006). 
 
1.5.2  Anorectic Effects of Amylin  
 
Studies in humans and animals have proven that amylin has an inhibitory effect 
on eating (Arnelo et al., 1996; Barth et al., 2003; Lutz, 2006). Pramlintide, a 
drug which consists of human amylin with amino acid substitutions that change 
its solubility, has been shown to decrease both meal duration and calorie intake 
in healthy men (Chapman et al., 2007). Amylin binding sites have been found in 
some parts of the brain, including the nucleus accumbens and the postrema area 
(Potes and Lutz, 2010; Christopoulos et al., 1995). Additionally, the postrema is 
outside of the blood-brain barrier and may, perhaps, be a target for amylin 
secreted by the pancreatic islets of Langerhans. Although early studies 
suggested that amylin has no cerebral production, further studies have revealed 
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amylin immunoreactivity in the basal ganglia and hypothalamus (D’Este et al., 
2000; D’Este et al., 2001; Skofitsch et al., 1995).  Additionally, amylin mRNA 
was found in the preoptic region of the lactating rat (Dobolyi, 2009). Amylin 
inhibits gastric emptying (Reidelberger et al., 2001) and it does this by binding 
to the brain (Arnelo et al., 1996). In type 1 diabetes, gastric emptying is fast and 
this is thought to promote the postprandial hyperglycemia observed in the 
disease (Woerle et al., 2008). It is assumed that insufficient islet amylin 
secretion in type 1 diabetes may play a key role in these gastric actions (Woerle 
et al., 2008). 
 
 
1.5.3  Effects of Amylin on Pancreatic Islet Cells 
 
Following the discovery of amylin, it was found that amylin impedes insulin-
stimulated glucose uptake and the synthesis of glycogen in incubated rat skeletal 
muscle (Cooper et al., 1988). A study also revealed that amylin impedes insulin-
stimulated glucose transport in vitro through a post-insulin-receptor effect 
(Zierath et al., 1992). This inhibition may be regulated by the influence of some 
enzymes including glycogen phosphorylase and glycogen synthase (Deems et 
al., 1991). Originally, it was thought that the basic mechanism behind insulin 
resistance in T2DM had been realised with the discovery of amylin, as in vivo 
studies also began to reveal that infiltration of amylin stimulates insulin 
resistance (Johnson et al., 1990). However, these results were attained at very 
high concentrations of amylin compared to those observed physiologically, and 
were thus considered to be pharmacological rather than physiological. Although 
the role of amylin in altering the effect of insulin on peripheral tissues is still 
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disputed, this activity cannot be disregarded. High amylin plasma concentrations 
compared to those observed in physiological conditions have also been found to 
suppress insulin response to glucose load in humans (Bretherton-Watt et al., 
1992; Cooper et al., 1988). Additionally, studies have shown an inhibition of 
insulin secretion by amylin (Degano et al., 1993; Kogire et al., 1991; Sandler 
and Stridsberg, 1994), even at low concentrations (Silvestre et al., 1997), 
although other studies have shown that there is no inhibitory effect of amylin on 
insulin secretion (Broderick et al., 1991; O’Brien et al., 1990; Pettersson and 
Ahrén, 1990). The reason for these discrepancies is unclear, but the strong 




1.5.4  Other Effects of Amylin 
 
The fact that amylin and calcitonin are structurally similar suggests that amylin 
may also play a role in the regulation of calcified tissues (MacIntyre, 1989). 
Studies have shown that amylin inhibits osteoclastic activity (Zaidi, 1990), and 
plays a role in inhibiting bone resorption (Naot and Cornish, 2008). Amylin also 
possesses vasodilative properties, likely based on its binding with CGRP 
receptors, but amylin is two times less effective at this than its relative CGRP 
(Brain et al., 1990). Early findings showed strong binding of radio-labelled 
amylin to the renal cortex (Stridsberg et al., 1993). This binding was initially 
considered to be an unspecific radioactivity uptake owing to reabsorption of 
labelled amylin in the proximal tubules. However, further studies have reported 
specific binding (Wookey et al., 1996). This suggests that amylin may play a 
role in kidney function. 
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1.6 Amylin and Oxidative Stress 
 
In about 90% of patients with T2DM, amylin aggregates into insoluble 
extracellular amyloid deposits (Cooper et al., 1987). It is not clear why amylin 
forms these deposits; however, an increased demand for β cell secretory 
function during T2DM may play a fundamental role in this process (Aston-
Mourney et al., 2011). Changes in glycosylation and deficient enzymatic 
processing of the pro-Amylin precursor may also play a role in the aggregation 
of amylin (Marzban et al., 2003; Park and Verchere, 2001). Amylin aggregates, 
particularly the soluble oligomeric forms, are likely to contribute to the 
destruction of pancreatic β cells in the late phase of T2DM (Lorenzo et al., 
1994). The cytotoxicity of amyloidogenic assemblies may be due to the presence 
of these oligomers (Lorenzo et al., 1994; Lorenzo and Yankner, 1994; 
Konarkowska et al., 2006). Human amylin is thought to form ionic channels in 
the lipid bi-layers of β cells (Mirzabekov et al., 1996). Additionally, studies 
suggest that oxidative stress may play a role in amyloid formation, which 
ultimately results in the destruction of pancreatic islet cells (Zraika et al., 2009). 
Amylin has been shown to generate reactive oxygen species (ROS) directly, 
which could explain some of its damaging effects on the islets of individuals 
with T2DM (Masad et al., 2011). 
 
The aggregation of amylin has been studied extensively in vitro and is due in 
part to intermolecular hydrophobic interactions that occur between the protein 
molecules (Fink, 1998; Vieira et al., 2006). Therefore, hydrophobic compounds 
which block the self-assembly of amylin are a potential therapeutic approach for 
treating or preventing diabetes. Since oxidative stress has been shown to be 
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linked with amyloid formation, inhibition of oxidative stress may also be a 
viable therapeutic strategy.  
 
 
1.7  Amylin Toxicity 
 
Amyloid is characterised by the presence of fibrils with a diameter of 7-10 nm 
(Goldsbury et al., 2000), with the integral monomers being arranged vertically 
into β-sheet structures. The formation of amyloid is nucleation dependent and is 
divided into three distinct phases (figure 1.5). The first phase, being the lag 
phase, is the rate-limiting step where the nucleation of monomeric peptides 
occurs (Wilson et al., 2008). This phase spans from a few minutes to a life time 
subject to variable conditions such as temperature and concentration (Wilson et 
al., 2008). The elongation phase is the second phase in which amyloid fibrils are 
generated. The third phase is the plateau phase where fibrillation is in a steady 
condition, and the fibrillar mass is stable (Wilson et al., 2008). Amyloid 
formation is a spontaneous process which, after initiation, continues if there is a 
satisfactory concentration of amyloidogenic protein (Wilson et al., 2008). In 
systemic amyloidosis,  significant quantities of amyloid deposits are formed in 
various organs such as heart, kidney, liver or spleen, and these deposits are 
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Figure 1.4: Schematic representation of the amyloid forming phases. The formation of amyloid 
fibrils is nucleation dependent.  During the lag phase, the soluble prefibrillar oligomers or nuclei 
are formed. The elongation phase is the phase in which the nuclei grows rapidly by the addition 
of monomers and subsequently forming insoluble mature amyloid fibrils. The plateau phase is 
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In Alzheimer’s disease, the amyloid fibril protein found in senile plaques and in 
the walls of cerebral blood vessels is Aβ, which constitutes a 40-42 amino acid 
segment of the Aβ precursor protein (De Strooper, 2010). Early studies revealed 
Aβ to be neurotoxic in vitro (Yankner et al., 1989; Yankner et al., 1990). Aβ 
molecules naturally exist as soluble monomers, but in the early stages of 
development of Alzheimer’s disease (Teich and Arancio, 2012), they begin to 
aggregate into small oligomers which remain soluble, but eventually coalesce to 
form the insoluble amyloid plaques which are one of the hallmarks of this 
disease. Aβ oligomers can impair synaptic function, and, together with the 
plaques, presumably contribute to nerve cell damage (Pimplikar et al, 2010). 
The protein Tau has also been implicated in Alzheimer’s disease, due to the 
formation of intracellular neurofibrillary tangles composed of a heavily 
phosphorylated form of this protein. Tau is a microtubule-binding protein that 
helps to link neuronal microtubules together in a parallel position, so aiding in 
the transport of nutrients and organelles from the cell body to the axon, and in 
the elimination of any accumulated toxic proteins from nerve cells, as part of the 
axonal transport process (Lonskaya et al., 2014). Failure of this transport system 
would inevitably lead to degeneration of the neuron (Caughey et al., 2003). The 
reason for Tau malfunction in Alzheimer’s disease is not clearly understood, but 
there may be a link between Aβ accumulation and neurofibrillary tangle 
formation (Hardy and Selkoe, 2002) since Aβ can influence the signaling 
pathways that control phosphorylation of Tau (Hardy and Selkoe, 2002; 
Lonskaya et al., 2014) and also inhibit the degradation of hyperphosphorylated 
Tau (Lonskaya et al., 2014). The two closely related proteins Aβ and Tau are 
both therapeutic targets for Alzheimer’s disease. 
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Early studies elucidating the role of protein toxicity in T2DM (Lorenzo et al., 
1994) demonstrated the toxicity of human amylin to cultured islet cells, 
apparently through induction of membrane damage and apoptosis. These 
background findings initially suggested that the toxic forms of both Aβ and 
amylin are the amyloid fibrils themselves (Hiddinga and Eberhardt, 1999; 
Kapurniotu et al., 1998; Lorenzo and Yankner, 1996; Yan et al., 2007). 
However, more recent studies have shown that soluble oligomers are more likely 
to be the toxic form of these molecules (Aitken et al., 2010; Ritzel et al., 2007). 
The role of amylin toxicity is currently an important subject in the pathogenesis 
of T2DM but a key issue is the ill-defined nature of the oligomers, which have 
been studied in vitro to a large extent (Glabe, 2008; Kayed et al., 2009). The 
first identified toxicity process is the disruption of the plasma membrane, 
resulting in effects on intracellular homeostasis (Westermark et al., 1990; 
Lorenzo et al., 1994). Some studies reveal that oligomers are incorporated into 
the cell membrane, where they form channel-like pores that are permeable to 
certain ions, particularly Ca2+ (Anguiano et al., 2002; Mirzabekov et al., 1996; 
Porat et al., 2003). The cytotoxicity of amyloid proteins have been associated 
with this pore forming ability, and lipid bilayers have been found to contain 
oligomeric complexes ranging from trimers to octamers, depending on the 
amyloid protein type (Quist et al., 2005). The incorporated complexes in the 
case of amylin are mainly trimeric and hexameric (Quist et al., 2005). Although 
it has been proposed that amylin permeabilizes membranes by formation of 
these doughnut-like pores, physical membrane disruption could also be 
important due to the extreme negative curvature strain present in small pre-
fibrillar aggregates (Smith et al., 2009). A number of prefibrillar structures can 
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be identified in vitro, with only a few being annular shaped (Kayed et al., 2009). 
Antibodies specific to oligomers have been identified that can recognize these 
structures independent of the type of amyloid protein (Kayed et al., 2003), 
demonstrating the existence of a common structural backbone epitope, and 
hinting at a possible common toxic mechanism. In vivo studies have identified 
soluble oligomers in the brain in transgenic mouse models of Alzheimer mice 
(Lesné et al., 2006) as well as in post-mortem human brain tissue (Tomic et al., 
2009). Likewise, in vivo studies have confirmed the formation of human amylin 
oligomers in transgenic mice (Lin et al., 2007) and in human pancreatic tissue 
(Gurlo et al., 2010). Although, the pathological role of amylin oligomers is still 
being debated, the role of mature amylin fibrils in the destruction β cells in 
T2DM should not be disregarded (Zraika et al., 2010). 
 
Several factors including protein concentration, pH, temperature, and the 
presence of other proteins such as chaperones, play a key role in protein 
aggregation and amyloid formation (Calloni et al., 2008). It is also likely that the 
lipid environment of the cell membrane is particularly conducive to induction of 
aggregation. The kinetic profile of amyloid formation by amylin is very 
dependent on pH and appears to be regulated by protonation of the His-18 
residue and the N-terminus (Charge et al., 1995; Abedini and Raleigh, 2005). 
Amylin is stored together with insulin at very high concentrations within the 
secretory granules of pancreatic β cells, with an acidic pH of 5.5 (Fox et al., 
2010). This acidic environment impedes amylin aggregation and protects the 
cells (Brender et al., 2013; Jha et al., 2014). However, the extracellular matrix 
into which amylin is secreted has a physiological pH of 7.4 and this environment 
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promotes fibril formation (Jha et al., 2014). In general, the lower the pH, the 
longer the time it takes for amyloid formation (Abedini and Raleigh, 2005). In 
addition, cholesterol and other lipids have been reported to play a role in the 
aggregation and toxicity of human amylin (Jean et al., 2010). In the presence of 
cholesterol, exogenic human amylin aggregates within ganglioside-rich lipid 
rafts in the plasma membrane of the cell (Wakabayashi and Matsuzaki, 2009). In 
contrast, cholesterol impedes the aggregation of human amylin on synthetic 
membranes (Cho et al., 2009). Another study has revealed that human amylin 
may induce apoptosis through stimulation of acid sphingomyelinase, resulting in 
ceramide production (Zhang et al., 2009). Amylin could also stimulate the 
inflammasome to release interleukin-1α and interleukin-1β, which would lead to 
inflammation and β cell damage (Masters et al., 2010). In one particular amylin 
cytotoxicity model, once amylin was absorbed into the lipid membrane, the 19 
amino-terminal residues were incorporated into the membrane (Engel et al., 
2006; Khemtémourian et al., 2008), which allowed the amyloidogenic region of 
residues 20-29 to aggregate, with growth of the fibril causing the membrane to 
rupture (Engel et al., 2006; Engel et al., 2008). A significant variation from 
other toxicity models is that this involves monomeric amylin rather than 
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1.8 Amylin and Type 2 Diabetes 
 
Islet amyloid has been strongly associated with T2DM (Clark et al., 1998). It 
can also be found in non-diabetic individuals but affects few islets, apparently 
with no adverse impact (Bell, 1959; Pearse et al., 1972). The evidence of islet 
amyloid in non-diabetic individuals and the fact that overt amyloid deposition is 
not found in all individuals with T2DM, initially led to a rather hasty conclusion 
that islet amyloid plays no significant role in the pathogenesis of this disease. 
However, further careful studies demonstrated that the degree of amyloid 
deposition is linked with the decrease in β cell mass (Clark et al., 1998), and that 
β cells found around amylin deposits show numerous fibrils penetrating deep 
into the cells (Westermark, 2005), suggesting that the function of these cells is 
likely to be compromised. As noted previously, disruption of the cell membrane 
by amyloid oligomers or fibrils results in the upregulation of Ca2+ influx, which 
can severely alter the function of cells (Kawahara et al., 2000). In type 1 
diabetes, the β cell mass has been reported to be decreased by only 10% 
compared to normal, suggesting that individuals with this disease still have a 
significant number of cells that could potentially produce insulin (Willcox et al., 
2009). Similarly, in T2DM the islets with amyloid still possess a significant 
number of insulin-containing β cells. However, in both types of diabetes, the 
remaining islet β cells are likely to be damaged so that they cannot function 
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Figure 1.5: General representation of fibril formation from natively unfolded monomers. 
Oligomers are the most toxic form of these aggregates. Inhibiting the progression of amyloid 
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1.9  Purpose of Study 
 
In conclusion, under normal physiological conditions human amylin is present 
as a soluble monomer, but in T2DM it self-associates to form oligomeric 
structures, protofibrils, and insoluble amyloid fibrils (figure 1.6). The oligomers 
in particular are toxic to pancreatic β cells (Kodali and Wetzel, 2007), 
potentially resulting in their malfunction and destruction. The destruction of 
pancreatic β cells leads to a reduction in insulin production, and is presented as 
T2DM. Therefore, compounds that inhibit the self-assembly of amylin are a 
potential therapeutic target for treating this disease. As noted above, amylin and 
its aggregation could also play a role in insulin resistance, which is the second 
important aspect of T2DM. The overall objective of this study is to develop 
novel peptide based inhibitors of amylin aggregation that impede the 
spontaneous aggregation of amylin into oligomers and fibrils. 
 
It has been challenging to find suitable drug-like therapeutic agents that inhibit 
the aggregation of various amyloid proteins. However, small organic molecules, 
peptides, peptidomimetics and nanoparticles have all been developed for this 
purpose. These inhibitors can interact in different ways involving specific or 
non-specific binding or colloidal inhibition Mata-Cantero et al., 2015). 
In the case of Alzheimer’s disease, a number of inhibitors of Aβ aggregation, 
including small molecules and peptides, have been developed over the years, but 
none of these compounds have been successful in human clinical trials. This is 
partly due to the fact that inhibition of amyloid aggregation involves impeding 
the interactions between protein monomers, and protein-protein interactions are 
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recognized as difficult therapeutic targets (Whitty and Kumaravel, 2006; Hajduk 
and Burns, 2002). Generally, regions for protein-protein interactions are 1500–
3000 Å in size (Keskin et al., 2008; Teichmann, 2002), while the region for 
protein-small molecule interactions is only 300–1000 Å (Smith et al., 2006; 
Cheng et al., 2007). Therefore, small molecules are generally not able to build 
adequate steric interruptions to inhibit protein aggregation (Wells and 
McClendon, 2007). Also, the plasticity of protein surfaces can lodge small 
molecules, thereby obstructing inhibition (Gestwicki et al., 2004). Altogether, 
these challenges make it difficult to develop potent and selective small molecule 
inhibitors of amyloid aggregation. 
A growing strategy for inhibition of amyloid aggregation is the use of peptide-
based inhibitors. A number of peptide fragments that bind to critical regions of 
Aβ have been used to target inhibition of amyloid aggregation (Liu et al., 2012; 
Gibson and Murphy, 2005; Lowe et al., 2001; Taylor et al., 2010). Studies on 
electrostatic interactions to develop new inhibitors of amylin aggregation have 
shown that charge-loaded peptides can impede the elongation of amylin fibrils 
(Sharadrao et al., 2015). Peptide-based inhibitors which target specific amyloid 
sub-regions represent the first generation of amyloid-based therapeutics which 
can then be developed further into more drug-like molecules, and this could be a 
promising avenue for development of a new disease-modifying therapy for 
T2DM.  
The main objective of this study was to develop novel peptide-based inhibitors 
of amylin aggregation. Previous studies have focused almost exclusively on the 
amyloidogenic region of human amylin (amino acid residues 22-27, with 
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sequence NFGAIL), which is the main region involved in protein misfolding 
into the toxic β-sheet conformational structure (Goldsbury et al., 2000; Tenidis 
et al., 2000). These peptide inhibitors are designed to act as β-sheet breakers, 
and are typically compounds that consist of the amyloidogenic motif in 
combination with a β-sheet breaker element. The latter can be comprised, for 
example, of methylated amino acids or prolines (Elgersma  et al., 2006; Soto et 
al., 1996). However, these ‘β-breaker’ peptides do not completely inhibit fibril 
formation and their inhibitory effects are often only seen at very high 
concentrations, when the peptides are present in molar excess (Westermark et 
al., 1990; Abedini et al., 2007; Scrocchi et al., 2002). In contrast, the peptide 
inhibitors described here are designed to interact with amylin at the binding 
region 11-20 (with sequence RLANFLVHSS), peptide derivatives from which 
show maximum binding to full length human amylin (Mazor et al., 2002). This 
binding region is implicated in the interactions that occur when two or more 
misfolded amylin molecules associate together to form oligomers and amylin 
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Figure 1.6: Design of peptide inhibitors. Amino acid sequence of human amylin showing 
binding sites for amylin association and the main amyloidogenic region. The short peptide 
inhibitors are designed to interact with full-length amylin. The binding region (Mazor et al., 
2002) is the region involved when two misfolded amylin molecules bind together, after which 
they continue to aggregate into oligomers and fibrils. The amyloidogenic region (Goldsbury et 
al., 2000) is the main region involved in protein misfolding into the toxic β-sheet conformational 
structure. The arginine-glycine residues (RG-GR)  residues on either side of the peptides contain 
positively charged amino acids which impede self-aggregation and repel the next amylin 








Inhibitor    R G R L A N F L V H S S G R-NH2 
Binding region Amyloidogenic region 
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Most peptides face the challenge of insolubility in aqueous solution. It is 
important to keep peptides soluble in aqueous solution and protected from 
proteolytic degradation. To improve the solubility of these peptides, the 
arginine-glycine residues (RG-GR) were placed at the ends of the peptides 
(figure 1.7), containing positively charged residues. This was done to improve 
the solubility of the peptides as well as inhibit self-aggregation of the amylin 
molecule. This approach is different from the β sheet blockers as seen in other 
studies (Nie et al., 2011; Aitken et al., 2003; Ono et al., 2003), and aims at 
impeding interactions between amylin molecules. This rational is based on 
previous research at Lancaster University where a peptide inhibitor (OR2) with 
the sequence H2N-R-G-K-L-V-F-F-G-R-NH2, was developed for the inhibition 
of Aβ oligomerisation in Alzheimer’s disease (Taylor et al., 2010). A retro-
inverso version (RI-OR2), with sequence reversal and substitution of L-amino 
acids with D-amino acids, H2N-rrGrkrlrvrfrfrGrr-Ac (shown in lower case), was 
made based on the previous inhibitor, OR2 (Taylor et al., 2010). These peptides 
showed significant inhibition of Aβ fibril formation and the retro-inverso 
version was found to be highly stable to proteolysis. The presence of  D-amino 
acids, render the inhibitor stable to proteolysis, and are thus more stable to be 
used as drugs. Seeing that amyloid proteins show numerous similarities in 
structure and biological activities, potential inhibition strategies developed for 
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1.9.1   Objectives of Study 
 To find and develop a suitable peptide-based inhibitor of amylin 
aggregation as a potential therapeutic for the treatment of T2DM. 
Peptides were developed from the binding region of the human amylin 
sequence and assessed at a wide range of concentrations using various 
biochemical and biophysical methods. 
 To assess the ability of the peptides to disaggregate pre-formed amylin 
fibrils. 
 To make the peptides suitable as drug candidates by protecting them 
from proteolytic degradation through retro-inversion and N-methylation. 
 To assess the posissble cytotoxic effects of the peptides on PANC-1 
human pancreatic islet cells, and the ability of the peptides to protect 
cells from the cytoxic effects of human amylin. 
 To assess the ability of the pepetides to penetrate the cell membrane, and 
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2.0  Materials and Methods 
 
2.1 Suppliers and Equipment 
 
Short Name Full Name and Location 
American Peptide American Peptide Co. California, USA 
Anaspec Anaspec EGT Group. California, USA 
BioTek BioTek Instruments Inc. Bedfordshire, UK 
BOC BOC Industrial gases. Surrey, UK 
China Peptide ChinaPeptide Co. Ltd. Shanghai, China 
Corning Corning Inc. Coring. New York, USA 
Eppendorf Eppendorf (UK) Ltd. Cambridge, UK 
Excel Excel Scientific Inc.  California, USA 
Millipore Millipore (UK) Ltd. Watford, UK 
Nunc Nalge Nunc International.  New York, USA 
Pechiney Pechiney Plastic Packaging Company, Illinois, 
USA 
Sigma-Aldrich Sigma-Aldrich Company Ltd. Dorset, UK 
Thermo Electron  Thermo Electron Corporation Inc. 
Gloucestershire, UK 
PerkinElmer PerkinElmer Inc. Massachusetts, USA 
 
Table 2.1: List of suppliers used and location. 
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Equipment 
Joel JEM-1010 electron microscope (Joel) 
Milli-Q deionised water (Millipore) 
Zeiss LSM880 laser scanning confocal microscope  (Zeiss) 
Nanodrop 200c  Spectrophotometer (Thermo Scientific) 
Savant ISS110 SpeedVac Concentrator (Thermo Electron Corporation) 
Synergy 2 multi-label microtitre plate reader (BioTek) 
Wallac Victor 2 1420 multilabel counter (PerkinElmer). 
Dionex HPLC GP50 Gradient pump  (Dionex) 
 





Full length human amylin peptide (1-37), was obtained from American Peptide 
Company (lot numbers 1306086T, 1301022T) with purity of >95% as 
determined by high performance liquid chromatography-mass spectrometry 




K C N T A T C A T Q R L A N F L V H S S N N F G A I L S S T N V G S N T Y-NH2 
 
Di-sulphide bridge 
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The amylin was amidated in a similar way to the amylin formed in vivo with a 
disulphide bridge between Cys 2 and Cys 7. The first batch of peptide inhibitors 
(IO1 – IO8) was made by conventional peptide synthesis and purchased from 
ChinaPeptide Company. The peptides were analysed for purity by HPLC-MS by 
Dr. Fuyuki Kametani (Tokyo, Japan) (Appendix C). Seven peptide inhibitors 
were first designed from the 11-20 amylin binding region (table 2.3). Based on 
the results obtained from these peptides, 2 more peptides were designed from 
the combined amino acid sequence of IO4 and IO5 (table 2.4). The effects of 
two previously published amylin-derived inhibitors on amylin aggregation were 
compared with our own peptide inhibitors. The first peptide, NMeG24 NMeI26, 
is a modification of the amylin 22-27 fragment (NFGAIL), with an N-
methylation of the amide bonds at G24 and I26 (Sellin et al., 2010), and was 
purchased from Anaspec EGT group. The second peptide, with amino acid 
sequence ANFLVH (Potter et al., 2009), was made by conventional peptide 
synthesis and was purchased from ChinaPeptide Company. These peptides were 













Peptide inhibitor ID Sequence Purity % 
IO1 R G R L A N F L V H S S G R-NH2  =95% 
IO2 R G R L A N F G R-NH2  =95% 
IO3 R G L A N F L G R-NH2  =93.094% 
IO4 R G A N F L V G R-NH2  =95% 
IO5 R G N F L V H G R-NH2  =95% 
IO6 R G F L V H S G R-NH2  =96% 




Table 2.3: Peptide inhibitors of amylin aggregation and their sequence (IO1-IO7). These 
peptides were designed from the binding region of human amylin (RLANFLVHSS, residues 11-
20), which is responsible for self-association. However, to promote solubility of these peptide 
inhibitors, while preventing them from self-aggregating, a cationic Arg was added at their N- 
and C-termini, in each case via a Gly spacer. The Gly residues were placed as spacers between 
Arg and the RLANFLVHSS binding sequence to facilitate the interaction between amylin and 
the peptide inhibitors. The part of the peptides that is derived from the amylin sequence is 
underlined. We hypothesize that the binding of these peptides to amylin could prevent another 
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= 96%  
Table 2.4: IO8 and RI-IO8 inhibitors. The IO8 inhibitor was made from the combination of IO4 
and IO5 inhibitors (table 2.3). IO8 was retro-inverted with the amino acid sequence reversed, 
and L-amino acids replaced with D-amino acids (lower case) to give RI-IO8. The part of the 
peptides that is derived from the amylin binding sequence is underlined. Retro-inverted peptides 












Table 2.5: Peptide inhibitors reported in literature to inhibit amylin aggregation. The effects of 
these inhibitors were assessed alongside our own peptide inhibitors.  
 
Following the results obtained from these inhibitors, it was important that our 
most effective inhibitor IO8 was protected from proteolytic degradation. The 
first attempt at this was made by designing a retro-inverso version of IO8 where 
the L-amino acids were replaced with D- amino acids and the sequence was 
reversed. Retro-inverso peptides, also known as a retro-all-D- or retro-enantio-
peptides, exhibit a side chain topology in its expanded conformation that 
resembles the native L-sequence, therefore modelling biological characteristics 
of the parent molecule, and at the same time being protected against proteolytic 
degradation (Chorev and Goodman, 1979). Other inhibitory peptides designed 
were NH2-RGANFLVHSSNNFGR-NH2 and its retro inverso form Ac-
rGfnnsshvlfnaGr-NH2. 
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Another approach for stabilising the IO8 peptide was to replace the first R 
residue (H2N-RGANFLVHGR-NH2) with homoarginine [H2N-
HarGANFLVHGHar-NH2 (HIO8)], an unnatural analogue of arginine. 
Substituting arginine with homoarginine protects proteins against proteolytic 




Figure 2.1: Structure of L-homoarginine. 
 
The final method for protecting our peptides against proteolytic degradation was 
through the N methylation of certain amino acid residues. Methylation is the 
addition of a methyl group to a substrate, or replacing an atom or group of atoms 
with a methyl group (Xue et al., 2014). N-methylation is a simple alteration of 
peptides and proteins to impede the activity of proteolytic enzymes (Chatterjee 
et al., 2013) and is also used to improve the pharmacokinetic properties of 
drugs. Our N-methylated peptides (table 2.6) were produced by Cambridge 
Peptides, UK. We had two different N- methylated peptides made, with the 














Peptide inhibitor ID Sequence 
 
Purity % 
N1-IO8 H2N-R G Am N Fm L Vm H G R-NH2 
 
=86.376% 




Table 2.6: N-methylated peptide inhibitors. The N1-IO8 inhibitor was N-methylated at positions 
3, 5 and 6 (i.e. Ala, Phe and Val), whereas the N1-IO8 inhibitor was N-methylated at positions 4, 
6 and 8 (i.e. Asn, Leu and His). N-methylated peptides are relatively stable to proteolysis and 





2.3 Solutions and Buffers 
 
2.3.1 10 mM Phosphate buffer, pH 7.4, containing 150 mM NaCl (PBS) 
For 100 ml, 0.81 ml of 1 M Na2HPO4 (monobasic salt) was added to 0.19 ml of 
1 M KH2PO4 (dibasic salt) and 0.876 g of NaCl was added. This solution was 
made up to 100 ml with distilled water, which brings the final concentration of 
NaCl in the buffer to 150 mM. This buffer was then stored at room temperature 
for up to 2 months. 
 
2.3.2 10 mM Phosphate buffer, pH 7.4, containing 300 mM NaCl (PB 2.S) 
For 100 ml, 0.81 ml of 1 M Na2HPO4 (monobasic salt) was added to 0.19ml of 1 
M KH2PO4 (dibasic salt) and 1.752 g of NaCl was added. This solution was 
made up to 100 ml with distilled water, which brings the final concentration of 
NaCl in the buffer to 300 mM. This buffer was then stored at room temperature 
for up to 2 months. 
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2.3.3 10 mM Phosphate Buffer, pH 7.4 (PB)  
For 100 ml, 0.81 ml of 1 M Na2HPO4 (monobasic salt) was added to 0.19ml of 1 
M KH2PO4 (dibasic salt). The solution was made up to 100 mls with distilled 
water and stored at room temperature for up to 2 months. 
 
2.3.4 15 mM Thioflavin-T (Th-T) Solution   
Th-T stock solution was made by dissolving 23.9 mg of Th-T powder (Sigma-
Aldrich) in 5 ml of 10 mM  Phosphate buffer (PB). The tube was wrapped in tin 
foil and stored at 4 °C for up to 6 weeks before being replaced with fresh ThT 
solution. 
 
2.3.5 2% Phosphotungstic Acid (solution) 
The 2% phosphotungstic acid was made by dissolving 2 g of phosphotungstic 
acid powder (Sigma-Aldrich) in 100 ml distilled water. The pH was adjusted to 








 53 | P a g e  
 
2.4 Peptide Preparation 
  
2.4.1 Deseeding Human Amylin 
Previous studies have revealed that the presence of pre-existing aggregates 
(‘seeds’) in a starting peptide solution speeds up the formation of amyloid fibrils 
(Cho et al., 2009). Thus the following protocol was used to ‘deseed’ or remove 
any preformed amylin aggregates from the synthetic human amylin (1-37) for 
future experiments. In a fume cupboard, 45 μl of thioanisole was added to a 
glass vial containing 1 ml trifluoroacetic acid (TFA). The mixture was then 
added to 1 mg of human amylin peptide. Due to the corrosive nature of TFA, 
only glass materials were used for this step. A lid of a chemically resistant 
eppendorf tube was used to seal the glass vial, which was further sealed with 
parafilm. This was left for 1 hr, and at every 10 mins, was vortexed, sonicated, 
and vortexed again, for 2 mins each. The liquid was then blown off by passing a 
stream of nitrogen gas over it. After drying, 1 ml of 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) was added to the glass vial and allowed to stand for 10 mins, 
after which it was vortexed, sonicated and vortexed again, for 2 mins each. The 
liquid was then transferred to a 1.7 ml chemically resistant eppendorf tube and 
the HFIP removed using a centrifugal concentrator for 30 mins. 1 ml HFIP was 
added again and left for 10 mins after which it was vortexed, sonicated, and 
vortexed again, for 2 mins each. This was then centrifuged at 10,000 x g for 15 
mins, and aliquots of 50 μg were transferred to chemically resistant eppendorf 
tubes. HFIP was then removed using a centrifugal concentrator, for 15 mins. 
After being fully dried, the samples were stored at -20 °C. To make a 100 μM 
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solution of amylin peptide, 128 μl of PB was added to 50 μg of amylin in an 
eppendorf tube. 
 
2.4.2 Preparation of Peptide Inhibitors 
1mM stock solutions of the peptide inhibitors (table 2.7) were prepared and 
stored in the fridge, as follows: 
 
Peptide ID Stock solution (1mM) 
IO1 1.6 mg in 1 ml PBS 
IO2 1.0 mg in 1ml PBS 
IO3 1.0 mg in 1 ml PBS 
IO4 0.9 mg in 1 ml PBS 
IO5 1.0 mg in 1 ml PBS 
IO6 1.0 mg in 1 ml PBS 
IO7 0.9 mg in 1 ml PBS 
IO8 1.1 mg in 1 ml PBS 
HIO8 1.15 mg in 1 ml PBS 
RI-IO8 1.2 mg in 1 ml PBS 
NFG 1.1 mg in 1 ml PBS 
N1-IO8 1.17 mg in 1 ml PBS 
N2-IO8 1.17 mg in 1 ml PBS 
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2.5 Thioflavin-T (Th-T) Assays  
 
 
2.5.1 Mechanism of Th-T Assay 
 
Th-T is a yellow, cationic, benzothiazole salt which is obtained by the 
methylation of dehydrothiotoluidine with methanol in the presence 
of hydrochloric acid. It is used as a dye to visualize and measure in vivo and in 
vitro fibrillization of misfolded protein aggregates known as amyloid. The 
interaction of the polar and hydrophobic regions increases the possibility of Th-
T molecules forming micelles in aqueous solution, with the positively charged 
hydrophophilic interior N+ (figure 2.1), pointing in the direction of the solvent 
(Khurana et al. 2005). Several studies have elucidated the binding of Th-T to 
amyloid proteins and have suggested that Th-T binds specifically to β-sheet 
structures of the amyloid protein (Biancalana and Koide, 2010; Groenning, 
2010); however, this is not fully understood. Thus, the interaction between 
negatively charged compounds and positively charged Th-T could be 






Figure 2.2: The structure of Th-T. The hydrophobic region terminates with a dimethylamino 
group attached to a phenyl group on the right, and the polar region is a benzothiazole group 
containing the polar N and S. (Khurana et al. 2005). 
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2.5.2 Th-T Assay Protocol 
 
The Th-T assay was used to measure the aggregation of the amylin peptide. The 
Th-T assay measures differences in fluorescence intensity when it binds to 
amyloid fibrils. The Th-T assays were carried out in 384-well clear-bottomed 
microtiter plates (NUNC) by incubating the amylin peptides (25 μM) in the 
presence of Th-T (15 μM) in 10 mM PBS (pH 7.4). The inhibitors were present 
at varying molar ratios relative to amylin, with the total volume of solution in 
each well set at 60 μl. The plates were shaken and the fluorescence read every 
10 mins (λex = 442 nm, and λem = 483 nm) in a BioTek Synergy 2 plate reader, 
at 30°C for 48 hrs. Triplicate readings were taken for each condition and each 
experiment was repeated three times. 
 
 
2.6 Cell Culture 
2.6.1 Cell Maintenance 
 
Human pancreatic β cells; PANC-1 Human pancreatic 1.4E7 (ECACC 
10070102) insulin-secreting cells were obtained from Public Health England 
Culture Collection. The PANC-1 cells were routinely grown in RPMI-1640 
medium with L-Glutamine (Gibco Life Technologies), supplemented with 10% 
fetal calf serum and 1% penicillin/streptomycin. Cell culture was carried out in a 
safety hood which was sterilised with 70% ethanol, and utilised pre-warmed 
media. Monolayers of cells were grown in 75 cm3 flasks at a ratio of 1:10 cells 
to media and incubated at 37 °C, 5% CO2. Cell splitting was required when cells 
reached confluence, often after 1 week of incubation at 37 °C, 5% CO2. At this 
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time, growth medium was removed from the flask using a 10 ml stripette and the 
cell monolayer was washed with 2 mls of trypsin (Gibco Life Technologies) for 
30 secs to remove the serum, and then re-incubated with 2 mls of trypsin at 37 
°C, 5% CO2 for 5 mins. Following this, the cells detach from the bottom of the 
plate. The activity of trypsin was stopped by the addition of 8 mls of media, 
taking the total volume in the flask to 10 mls, then 9 mls of fresh media was 
added to a clean 75 cm3 flask and 1 ml of the cell mixture was added to it (1: 10 
dilution). This was left to grow in the incubator at 37 °C, 5% CO2. Every 2 days, 
media was removed from flask and 10 mls of fresh media was replaced to keep 




2.6.2 The CellTiter 96 Aqueous One Solution Cell Proliferation (MTS)   
            Assay 
 
Cell viability was assessed using the CellTiter 96 aqueous one solution cell 
proliferation assay (Promega). This is a colorimetric method that provides a 
convenient and sensitive way for determining the number of viable cells in 
proliferation or cytotoxicity assays. The CellTiter 96 aqueous one solution 
reagent is made up of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt; 
MTS] as well as an electron coupling reagent (phenazine ethosulphate; PES) 
(Promega, 2012). PES combines with MTS to form a stable solution. The MTS 
tetrazolium compound is converted by cells into a yellow coloured formazan 
product which is soluble in tissue culture medium. This conversion is probably 
carried out by NADPH or NADH produced by dehydrogenase enzymes in 
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metabolically active cells (Promega, 2012). Assays were carried out by adding 
20 μl of CellTiter 96 aqueous one solution reagent directly to cell culture wells 
which were incubated for 1-4 hrs and the absorbance at 490 nm was recorded 
using a Wallac Victor2 1420 multilabel counter (PerkinElmer). The number of 




2.6.3 Cell Toxicity Protocol for MTS Assay 
 
The culture medium was removed from cells which had formed a monolayer of 
non-overlapping confluence in a 75 cm3 flask, and replaced with 2 mls of 
trypsin. After 30 secs, the trypsin was removed, replaced with another 2 mls of 
trypsin, and incubated at 37°C, 5% CO2 for 5 mins. Culture medium (2 mls) was 
then added to the flask and the suspended cells were transferred to a 15 ml tube 
and centrifuged for 5 mins at 3000 xg. The culture medium was removed and 
cell pellet was resuspended in 2 mls of fresh medium, with mixing. A 10 μl 
sample of this suspension was loaded into a haemocytometer chamber for cell 
counting. The remaining cells were diluted to 250,000 cells/ml and 100 μl of the 
diluted cell suspension was transferred (at 25,000 cells/well) to a 96-well plate 
and incubated at 37 °C, 5% CO2. After 24 hrs, the medium was replaced with 
100 μl of fresh medium, with the following conditions: culture medium 
containing amylin at a final concentration of 20 μM in culture medium with or 
without the peptide inhibitors at 20 μM and 5 μM. Furthermore, culture medium 
containing amylin at a final concentration of 10 μM with or without the peptide 
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inhibitors at 10 μM and 2.5 μM. Each condition was plated in 6 wells and 
incubated at 37 °C, 5% CO2. After 24 hrs, 20 μl of CellTiter 96 aqueous one 
solution reagent was directly added to each cell culture well and incubated for 3 
hrs at 37 °C, 5% CO2 and the absorbance at 490 nm recorded using a Wallac 
Victor2 1420 multilabel counter (PerkinElmer).  
 
 
2.6.4 The CytoTox-ONE Homogeneous Membrane Integrity (LDH) Assay  
 
The CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega) is a 
fluorometric technique to determine the amount of non-viable cells present in a 
cell based assay. The number of non-viable cells can be measured by the amount 
of substances release into the cytoplasm following membrane damage.  The 
CytoTox-ONE assay is also known as the of lactate dehydrogenase (LDH) 
assay, as it involves the secretion of LDH into the culture medium  following 
membrane disruption in an enzymatic reaction where resazurin is converted into 
resorufin. In this assay, the membranes of healthy cells remain intact thus LDH 
release can be measured homogeneously in an assay containing both viable and 
damaged cells. The LDH assay is typically used to examine the cytotoxicity of 
various compounds. About 100 assays in a 96-well format or 400 assays in a 
384-well can be performed with each vial of the CytoTox-ONE Homogeneous 
Membrane Integrity Assay (Cat no: G7890; Size: 200–800 assays). 
The assay kit includes: 
 2 vials Substrate Mix 
 24ml Assay Buffer 
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 0.5ml Lysis Solution 
 11ml Stop Solution 
All kit components were stored at –20°C in the dark. The reconstituted 
CytoTox-ONE Reagent was stored for 6–8 weeks at –20°C, in the dark. 
 
2.6.5 Cell Toxicity Protocol for LDH Assay 
 
Reagent Preparation 
 Substrate Mix and Assay Buffer were thawed using a 37°C water bath 
between 30 seconds to 1 minute. 
 CytoTox-ONE Reagent was prepared by adding 11ml of Assay Buffer to 
each vial of Substrate Mix and then mixed gently to dissolve substrate. 
 
The culture medium was removed from cells which had formed a monolayer of 
non-overlapping confluence in a 75 cm3 flask, and replaced with 2 mls of 
trypsin. After 30 secs, the trypsin was removed and replaced with another 2 mls 
of trypsin, and then incubated at 37°C, 5% CO2 for 5 mins. Culture medium (2 
mls) was then added to the flask and the suspended cells were transferred to a 15 
ml tube and centrifuged for 5 mins at 3000 xg. The culture medium was 
removed and cell pellet was resuspended in 2 mls of fresh medium, with mixing. 
A 10 μl sample of this suspension was loaded into a haemocytometer chamber 
for cell counting. The remaining cells were diluted to 250,000 cells/ml and 100 
μl of the diluted cell suspension was transferred (at 25,000 cells/well) to a 96-
well plate and incubated at 37 °C, 5% CO2. After 24 hrs, the medium was 
replaced with 100 μl of fresh medium, with the following conditions: culture 
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medium containing amylin at a final concentration of 20 μM in culture medium 
with or without the peptide inhibitors at concentrations of 80, 40, 20, 10, 5 and 
2.5μM. Each condition was plated in 6 wells and incubated at 37 °C, 5% CO2. 
After 24 hrs, 2 μl of Lysis Solution was added to the positive control wells and 
100 μl of CytoTox-ONE™ Reagent was then added to the 100 μl of medium 
containing cells and incubated at 22°C for 10 mins after which, 50μl of Stop 
Solution was then added to each well. Stop Solution was added using the same 
addition order for CytoTox-ONE Reagent to maintain consistency in incubation 
times. The plate was shaken in the Wallac Victor2 1420 multilabel counter 
(PerkinElmer) plate reader for 10 seconds and fluorescence recorded with an 
excitation wavelength of 560nm and an emission wavelength of 590nm aqueous 
one solution reagent was directly added to each cell culture well and incubated 
for 3 hrs at 37 °C, 5% CO2 and the absorbance at 490 nm recorded using a 
Wallac Victor2 1420 multilabel counter (PerkinElmer). Appropriate controls 
were used for this experiment. To detect background fluorescence, negative 
controls having wells without cells were used. The untreated cells control 
contained cells in culture without the peptides. The LDH release control was 
setup by adding 2 μl of lysis buffer to the positive control wells (Cells with 
treatment). Each experimental condition was set up in triplicates. 
 
 
2.6.6   Cell Penetration Assay 
 
The cell penetration assay was carried out to access the cellular uptake and 
intracellular localization of our peptide inhibitors. Described below is the 
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protocol used for delivery of amylin peptide-based inhibitors to adherent 
cultured human pancreatic PANC-1 cells. 
 
2.6.7    Cell Penetration Assay Protocol 
 
Peptides were fluorescently tagged according to manufacturer’s instructions 
using the protein labelling kit from Thermo Fisher Scientific, Alexa Fluor 488, 
as follows: 
 
1 M sodium bicarbonate solution was prepared by adding 1 ml deionized water 
(dH2O) to the vial of sodium bicarbonate (Component B) and vortexed until the 
reagent was fully dissolved. The bicarbonate solution had a pH of ~8.3 and was 
stored at 4°C for up to two weeks. 50 μl of a 1 mg/ml solution of peptide was 
transferred to a reaction tube (Component C) and 5 μl of 1 M sodium 
bicarbonate added and mixed by pipetting up and down several times. 11.3 nmol 
of the reactive dye was prepared immediately prior to use by adding 10 μl of 
dH2O to one vial of Alexa Fluor® 488 TFP ester (Component A). 1 μl of 
reactive dye was added to the reaction tube containing the pH-adjusted protein 
and mixed thoroughly by pipetting up and down several times. The reaction 
mixture was then incubated for 15 mins at room temperature. The conjugate was 
purified by separating labelled protein from unreacted dye by using purification 
spin filters containing gel resin (Component E). The upper chamber of the spin 
filter was filled with 800 μl of suspended gel resin, and the spin filter 
centrifuged at 16,000 xg in a microcentrifuge for a total of 15 secs. After 
preparation of the spin filter, 50 μl of the conjugate reaction mixture was added 
onto the centre of the resin bed surface. The collection tube now contained 
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purified dye-labelled protein in approximately 60–100 μl of buffer. The 
unreacted dye is retained on the filter and the resin has a yellow-green colour 
 
For cell penetration experiments, 100 μl of the diluted cell suspension  (25,000 
cells/well) were grown on cover slips in a 6 well plate for 24 hours, the 
fluorescein-tagged peptides, at a concentration of 10 µM, was then added to cell 
growth medium on a slide containing cultured PANC-1 cells and incubated for 
10 mins, 30 mins and 1 hr. After incubation, cells were mounted on slides using 
Fluoroshield mounting medium containing DAPI as a nuclei stain. Labelled 
samples where excited using the 488nm laser and emission collected 495 – 
630nm with DAPI visualised using 405 laser and emissions collected 410 – 
490nm wavelengths.Confocal micrographs were taken using the Zeiss LSM880 
laser scanning confocal microscope. 
 
 
2.7     Congo Red Assay 
The Congo Red (CR) spectrophotometric assay was used to examine amylin 
samples in the presence of inhibitors. The CR spectrophotometric assay is 
relatively objective, and can be easily combined with the microscopic analysis 
 
2.7.1 Protocol for Procedures for Congo Red Spectroscopic Assay: 
Amylin peptide (25 μM) with and without inhibitors (at varying concentrations) 
was incubated for 48 hrs at 37 ᵒC prior to the experiment. 
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A 7 mg/mL solution of CR was prepared in buffer (5 mM potassium phosphate, 
150mM NaCl, pH7.4) and filtered through a 0.2 µm syringe filter immediately 
prior to use. 
The UV-Vis Nanodrop 200c   spectrophotometer was first zeroed between 400 
and 700 nm at room temperature with a sample of 1 mL phosphate buffer in a 
disposable cuvette. 
To measure the spectrum for CR, 5µL of the CR solution was added to 1 mL 
phosphate buffer in a disposable cuvette and scanned between 400 and 700 nm. 
10 µL of protein sample was then added to disposable cuvette containing 5 µL  
of CR solution in 1 mL of phosphate buffer and incubated for 30 mins at room 
temperature. At this stage, a red precipitate becomes visible. The contents of the 
cuvette were then mixed by pipetting the solution up and down and then the 
spectrum was recorded, between 400 and 700 nm. 
A maximal spectral difference at 540 nm is indicative of amyloid fibrils. This is 
calculated mathematically by subtracting the CR spectrum from the protein + 
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 2.8  Stability Assay using High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) is a more advanced and 
highly sensitive form of column chromatography where the solvent is forced 
through under high pressures. This permits the passage of smaller sized particles 
as well as giving a finer separation of the components of the mixture. Here, 
reverse-phase HPLC was used to determine the stability of the peptide inhibitors 
in plasma, and in the presence of various proteolytic enzymes. In this form of 
HPLC, the silica column is modified to make it non-polar by linking long 
hydrocarbon chains to its surface. Hydrophobic molecules are adsorbed onto this 
type of column in the presence of a polar solvent, and are eluted by employing 
increasing concentrations of a non-polar organic solvent. The HPLC equipment 
used for these experiments was the Dionex GP50 Gradient pump. The column 
used for these experiments was the C18  x 2.0mm colunm and the solvent 
consisted of a gradient produced from 0.01% trifluoro acetic acid in dH2O 
(Solvent A) versus 0.01% trifluoro acetic acid in acetonitrile (Solvent B). 
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) is 
concerned with the dissociation of molecules by reason of their hydrophobicity. 
This dissociation is influenced by the hydrophobic binding of the solute 
molecule between the mobile phase and the immobilized hydrophobic ligands 
connected to the stationary phase in other words, sorbent. Firstly, the solute 
mixture is added to the sorbent in the presence of aqueous buffers, the presence 
of organic solvent at the mobile phase elutes the solutes, this can be isocratic, 
where there is a constant concentration of organic solvent or it can be by 
gradient conditions where there the amount of organic solvent accumulates over 
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a period of time. The solutes are thus eluted in an increasing succession of 
molecular hydrophobicity. 
 
RP-HPLC is an especially important approach for peptide and protein analysis 
because chromatographs can be altered without difficulty via changes in mobile 
phase attributes. Also, RP-HPLC also possesses high resolution for both similar 
and disimilar molecules attained through its variety of chromatographic 
conditions. In addition, RP-HPLC produces high quality repetitive separations 
as well as high recoveries (Aguilar and Hearn, 1996; Mant and Hodges, 1996).  
RP-HPLC can however result in irreversible denaturing of protein samples thus 
the chances of recovering biologically active materials is greatly diminished. 
 
Human plasma samples were obtained, with ethical approval including informed 
consent (Oldham Ethics Committee), from Prof. David Mann (University of 
Manchester). The frozen plasma sample (stored at −80°C) was thawed in a water 
bath (25°C) for 5 min. To assess the stability of the peptide inhibitors in plasma, 
5µl of peptide was added to 95 µl of thawed plasma in a microfuge tube and 
incubated for 0 hrs, 1hr, 3hrs, 24hrs, 48hrs and 72 hrs at 37°C. To assess the 
stability of peptides in the presence of proteolytic enzymes (table 2.8), 2 µl of 
enzyme was added to 98 µL of peptide. After incubation at 0 hrs, 1hr, 3hrs, 
24hrs, 48hrs and 72 hrs, 100 μl of sample was injected into the HPLC injector 
column and monitored at a flow rate of 1ml/min for a total run time of 40 mins 
at a linear gradient of 0-60% solution B, with the absorbance measured at a 
wavelength of 220nm. 
 











Factor X 1mg/ml 
 




2.9 Transmission Electron Microscopy 
 
Solutions of amylin at 25 μM and amylin in the presence of inhibitors at varying 
concentrations were prepared and incubated in PBS for 48 hrs. After incubation, 
5 μl of the mixture was pipetted onto carbon-coated formvar grids held using 
forceps and left for 3 mins. The edges of the grids were touched with filter paper 
to draw off the liquid, then 5 μl of 2% aqueous phosphotungstic acid (adjust pH 
to 7.3 using 1N NaOH) was applied immediately (before the sample had dried) 
and left for 1 min. The excess liquid was removed as before, the grid was 
allowed to dry overnight (in the grid box) before observation. Five fields for 
each sample were randomly photographed at 5000x magnification, after first 
examining the grid for uniformity. The negatives were enlarged 3.0x to a final 
magnification of 15000x. Five photographs were examined for each sample. 
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2.9.1 Statistical analysis 
The Th-T assays were performed in triplicate, while the cell toxicity assays were 
performed in replicates of six. The data are expressed as mean ± standard error 
of mean (SEM), or representative data are shown. Statistical analysis with SPSS 
was performed using One-way ANOVA, Tukey's post hoc test, and confidence 
interval (CI) analysis (P < 0.05 + 95% CI) was used to compare mean values. 
For the quantitative studies in chapter 3, a one-way between samples ANOVA 
was conducted to compare the effect of peptide inhibitors at varying 
concentrations on amylin aggregation, inhibitor only (no amylin) and the amylin 
only (no inhibitor) conditions. Significance was recorded at *P<0.05, **P<0.01, 
***P<0.001. Post hoc comparisons using the Tukey’s post hoc test indicated the 
significant difference between the mean scores for the peptide conditions at 
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Chapter 3    
 
 
Quantitative analysis of peptide-based inhibitors on 
amylin aggregation 
 
This chapter is focused on the hypothesis that the deposition of amylin in the 
pancreatic islets leads to the development of T2DM and that developing peptide-
based inhibitors which interact with the binding region of human amylin may 
stop amylin from misfolding and/or prevent its subsequent aggregation. Amylin 
exists as monomers in its normal physiological state. However, in T2DM, 
amylin begins to aggregate to form dimers, oligomers and ultimately fibril-like 
structures. The inhibition of amylin aggregation at the initial monomeric state 
may hold considerable potential for the treatment of T2DM. In this Chapter, 
peptide inhibitors developed from the binding region of human amylin were 
tested using Thioflavin-T (Th-T) and Congo Red (CR) assay techniques to 
investigate their effects on the aggregation of human amylin.  
 
 
3.1   Thioflavin T assay 
 
The Th-T assay is a fluorescence-based assay used for the detection of 
misfolded protein aggregates, as described previously (section 2.5.2). This assay 
has been used to assess the extent of amyloid fibril formation in vitro (Khurana 
et al., 2005;  Lindberg et al., 2015) and stains such as Th-T are also used to 
examine histological tissue samples for the presence of amyloids in general 
(LeVine, 1993;  Groenning, 2010). A common feature of all amyloid proteins is 
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the formation of long misfolded β-sheet structures (Sunde et al., 1997) which 
are targets for Th-T binding. Resulting changes in Th-T fluorescence can be 
used to identify and distinguish varying surface characteristics of amyloid fibrils 
(Cohen et al., 2013; Bolognesi et al., 2014). It also appears that Th-T has some 
predisposition for interacting with aromatic side chains (Biancalana et al., 2009; 
Wolfe et al., 2010). Nevertheless, the intensity of Th-T fluorescence varies 
significantly between samples of different amyloid proteins and also differs 
when comparing fibrils formed from normal and mutant forms of the same 
protein (Adler et al., 2014; Walsh et al., 2009). Here, the Th-T assay was used 
to measure changes in fluorescence intensity of Th-T upon binding to amylin 
fibrils in the presence and absence of varying concentrations of the different 
peptide-based inhibitors. 
 
3.1.1 Peptide based inhibitors show inhibitory effects on amylin aggregation 
 
In order to find a suitable inhibitor of amylin aggregation, peptides spanning the 
binding region of human amylin, named IO1, IO2, IO3, IO4, IO5, IO6 and IO7, 
were tested. The aggregation of amylin in the presence of these peptides was 
assessed using the Th-T assay. Amylin was incubated at 25 M in PBS in the 
continuous presence of Th-T for 48 hrs, with shaking, and fluorescence 
measurements were taken every 10 mins in a BioTek Synergy 2 plate reader at 
30°C. The IO1-IO7 peptide inhibitors were incubated at varying concentrations 
of 0 µM, 0.6 M,  2.5 M, 5 M, 12.5 M, 25 M, 50 M and 100 M, while 
the concentration of amylin was kept constant at 25 M. All experiments were 
carried out in triplicate and repeated three times. This is the case for all of the 
Th-T experiments presented in this Chapter, and the results show mean +/- 
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standard error of the mean (SEM) for one representative experiment. Figure 
3.1.1 presents aggregation curves showing a typical sigmoidal shape, with lag, 
sigmoidal and plateau phases of fibril formation. Amylin alone showed a 
characteristic increase in fluorescence, while the presence of inhibitors, at 
varying concentrations, had different effects on amylin aggregation. Figure 
3.1.1.1 shows data for the percentage aggregation of amylin in the presence of 
IO1, IO2, IO3, IO4, IO5, IO6 and IO7 peptide inhibitors at the above 
concentrations, relative to a non-inhibitor control. IO5 significantly inhibited 
amylin aggregation at 12.5 μM, 25 μM, 50 μM and 100 μM. IO4 significantly 
inhibited amylin aggregation at 25 μM and 100 μM. IO2 significantly inhibited 
amylin aggregation at 12.5 μM and 100 μM. IO3 and IO7 only showed 
inhibitory effects on amylin aggregation at 100 μM, the highest concentration 
tested. On the other hand, IO1 and IO6 showed no inhibitory effect on amylin 
aggregation. At lower concentrations, all peptides appeared to stimulate amylin 
aggregation. 
 
IO5 is considered to be the best inhibitor, since it inhibits amylin aggregation at 
12.5 μM, 25 μM, 50 μM and 100 μM. Data from IO1, IO2, IO6 and IO7 showed 
unusual curves quite unlike the others (figure 3.1.1.1), revealing a ‘hump’ along 
the curve and not the characteristic “sigmoidal” shape expected of an inhibition 
curve. However, curves from IO4 and IO5 looked more convincing, with a dose-
dependent effect. In fact the shape of all of the graphs was rather unusual and 
did not show the characteristic “sigmoidal” shape often expected for an 
inhibition curve. Since IO4 and IO5 showed the most promising results, they 
were chosen for further studies. 







Figure 3.1.1: Examples of Th-T fluorescence curves for time-dependent aggregation of human 
amylin in the presence of two representative inhibitors, IO1 (A) and IO4 (B). Amylin alone at 25 
μM displayed a characteristic increase in Th-T fluorescence corresponding to the lag, sigmoidal 
and plateau phases of fibril formation, while the addition of inhibitors, at varying concentrations, 
had clear effects on amylin aggregation. Buffer PBS controls (‘Control’) contained neither 







































































































     
                                     
 
Figure 3.1.1.1: Effects of IO1, IO2, IO3, IO4, IO5, IO6 and IO7 peptides on amylin 
aggregation. Percentage aggregation of amylin, in the presence of (A) IO1, (B) IO2, (C) IO3, 
(D) IO4, (E) IO5, (F) IO6 and (G) IO7 peptides. All peptides were tested at 0.6 M, 2.5 M, 5 
M, 12.5 M, 25 M, 50 M and 100 M, with amylin at 25 μM. The peptides and amylin were 
incubated for 48 hrs in the presence of Th-T. Triplicate readings were taken for each condition 
and results are means +/- SEM. One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, 
***P<0.001, compared to 100% control (amylin alone). [Percentage aggregation = fluorescent 
reading of amylin alone minus (-) fluorescence of amylin in the presence of peptide multiplied 
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3.1.2 Effect of amylin derived peptide inhibitors (IO8 and RI-IO8) on amylin 
aggregation 
 
The IO8 inhibitor was designed using the combined amino acid sequences of 
IO4 and IO5 as they appeared to be more potent inhibitors compared to other 
previously tested inhibitors (see sections 2.2 and 3.1.1). In order to stabilise IO8 
and preserve it from proteolytic degradation, a retro-inverso version of IO8 (RI-
IO8) was made. This was achieved by reversing the peptide sequence and 
replacing the L-amino acids with D-amino acids. The Th-T assay was used to 
monitor the effects of IO8 and RI-IO8 on amylin aggregation, carried out under 
similar experimental conditions to those described above (Section 3.1.1). Figure 
3.1.2 shows data for the percentage aggregation of amylin in the presence of IO8 
and RI-IO8 peptides. IO8 displayed inhibitory effects on amylin aggregation at 
all concentrations ≥1 μM (1:25 molar ratio of inhibitor to amylin). At an 
equimolar concentration of amylin, IO8 reduced the development of Th-T 
fluorescence to 16% of the non-inhibited control (figure 3.1.2). At 50 μM (2:1 
molar ratio of IO8 to amylin) and 100 μM (4:1 molar ratio of IO8 to amylin), 
IO8 significantly decreased the Th-T fluorescence to 11% and 8% respectively 
(p<0.001); levels comparable with buffer control (figure 3.1.2). In complete 
contrast, the addition of RI-IO8 peptide to amylin under the same experimental 
conditions showed no inhibitory effects on amylin aggregation and in fact 
appeared to enhance fibril formation at all concentrations mentioned above, with 
the exception of 100 μM (4:1 molar ratio inhibitor to amylin), where RI-IO8 
(p<0.05) decreased amylin aggregation to 77% of control (figure 3.1.2). 
Therefore, IO8 acts as an inhibitor, whereas RI-IO8 does not and may even 
stimulate aggregation. 

















Figure 3.1.2:   Percentage aggregation of amylin in the presence of IO8 and RI-IO8 peptides.  
The peptides, at 0.1 μM, 0.3 μM, 0.6 μM, 1 μM, 2.5 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 
100 μM, along with amylin at 25 μM, were incubated for 48 hrs in the presence of Th-T. 
Triplicate readings were taken for each condition and results are means +/- SEM. One-way 
ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 100% control 
(amylin alone). [Percentage aggregation = fluorescent reading of amylin alone minus (-) 
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3.1.3 Effect of IO8, NMeG24NMeI26 and ANFLVH  on amylin aggregation 
 
Given that IO8 is the most promising inhibitor of amylin aggregation, compared 
to the other peptides, the effects of this inhibitor on amylin aggregation were 
monitored alongside NMeG24 NMeI26 (Sellin et al., 2010) and ANFLVH 
(Potter et al., 2009), which are inhibitors reported to reduce amylin fibril 
formation in the literature. However, ANFLVH did not dissolve in aqueous 
solution, and so could not be used for this experiment. The Th-T assay was 
carried out under similar experimental conditions to those described above. 
Figure 3.1.3 shows data for the percentage aggregation of amylin in the presence 
of IO8 and NMeG24 NMeI26 peptides, relative to a non-inhibited control. IO8 
displayed strong inhibitory effects on amylin aggregation at all concentrations ≥ 
1 μM, and at 2.5 μM (1:10 molar ratio inhibitor to amylin), IO8 decreased 
amylin aggregation to 35% (p<0.01) of the non-inhibited control (figure 3.1.3). 
On the other hand, the addition of NMeG24 NMeI26 peptide to amylin under 
the same conditions showed no inhibitory effect on amylin and significantly 
accelerated fibril formation at 0.05 μM, 0.1 μM and 0.3 μM. The data confirm 
the inhibitory effects of IO8, but fail to demonstrate any inhibition with 
NMeG24 NMeI26.  
 
  








Figure 3.1.3:    Effects of IO8 and NMeG24 NMeI26 peptides on amylin aggregation. 
Percentage aggregation of amylin (at 25 µM) in the presence of IO8 and NMeG24 NMeI26 
peptides at 0.1 μM, 0.3 μM, 0.6 μM, 1 μM, 2.5 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM. 
The peptides and amylin were incubated for 48 hrs and then monitored by Th-T assay. One-way 
ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 100% control 
(amylin alone). [Percentage aggregation = fluorescent reading of amylin alone minus (-) 
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3.1.4 Effect of H2N-RGNFGAILSGR-NH2 on amylin aggregation 
 
Inhibitor IO8 (directed at the binding region of amylin) was then compared with 
another peptide directed at the amyloidogenic region (H2N-RGNFGAILSGR-
NH2), the latter being the region focused on in most of the other peptide 
inhibitors described the literature (Potter et al., 2009; Sellin et al., 2010; 
Andreasen et al. 2012). Again, the Th-T assay was carried out under similar 
experimental conditions to those described above. Figure 3.1.4 shows data for 
the percentage aggregation of amylin in the presence of the IO8 and H2N-
RGNFGAILSGR-NH2 peptides. IO8 displayed strong inhibitory effects on 
amylin aggregation at all concentrations ≥ 1 μM. At 100 μM (4:1 molar ratio 
inhibitor to amylin), this peptide decreased amylin aggregation to 8% of the 
non-inhibited control, and at 25 μM (1:1 molar ratio inhibitor to amylin), it 
decreased amylin aggregation to 18% (p< 0.001). On the other hand, the 
H2N-RGNFGAILSGR-NH2 peptide accelerated amylin aggregation at 100 μM 
(4:1 molar ratio of inhibitor to amylin), 50 μM (2:1 molar ratio), and 25 μM (1:1 



























Figure 3.1.4:    Effects of IO8 and H2N-RGNFGAILSGR-NH2 peptides on amylin aggregation. 
Data show percentage aggregation of amylin (at 25 µM) in the presence of 0.1 μM, 0.3 μM, 0.6 
μM, 1 μM, 2.5 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM of each peptide inhibitor, by Th-
T assay. The peptides and amylin were incubated for 48 hrs and results show means +/- SEM, 
n=3. One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 
100% control (amylin alone). [Percentage aggregation = fluorescent reading of amylin alone 
minus (-) fluorescence of amylin in the presence of peptide multiplied by (X) 100. Calculated for 
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3.1.5 Effect of HIO8 on amylin aggregation 
 
Given that the retro-inverso peptide RI-IO8 failed to inhibit amylin aggregation, 
but instead stimulated the aggregation of amylin, we devised a new strategy to 
protect IO8 (H2N-RGANFLVHGR-NH2) from proteolytic degradation. Thus 
peptide HIO8, with amino acid sequence H2N-Har-GANFLVHG-Har-NH2, was 
designed. In HIO8, the arginine residues of IO8 (coloured red) were replaced 
with homoarginine (coloured blue), which is an unnatural analogue of arginine. 
This replacement was designed to protect the peptide from proteolytic 
degradation by trypsin as an initial step to protect the peptide, although still 
susceptible to degradation by other proteases like chymotrypsin. The Th-T assay 
was carried out under similar experimental conditions to those described above. 
Figure 3.1.5 shows data for the percentage aggregation of amylin in the presence 
of IO8 and HIO8 peptides. Again, IO8 displayed strong inhibitory effects on 
amylin aggregation at all concentrations ≥ 1 μM.  At 100 μM (4:1 molar ratio 
inhibitor to amylin), it decreased amylin aggregation to 10% of the non-inhibited 
control (p<0.001). At a concentration of 25 μM (1:1 molar ratio), IO8 decreased 
amylin aggregation to 15%. In addition, HIO8 showed similar inhibitory effects 
on amylin aggregation to IO8. At 100 μM (4:1 molar ratio of inhibitor to 
amylin), HIO8 decreased amylin aggregation to 13% (p<0.001). At a 
concentration of 25 μM (1:1 molar ratio), HIO8 decreased amylin aggregation to 













Figure 3.1.5:      Effects of IO8 and HIO8 peptides on amylin aggregation. Percentage 
aggregation of IO8 and HIO8 peptides at  0.1 μM, 0.3 μM, 0.6 μM, 2.5 μM, 1 μM, 5 μM, 12.5 
μM, 25 μM, 50 μM and 100 μM in the presence of amylin at 25 m, with aggregation monitored 
by Th-T assay after 48 hrs incubation. One-way ANOVA, Tukey's post hoc test *P<0.05, 
**P<0.01, ***P<0.001, compared to 100% control (amylin alone). [Percentage aggregation = 
fluorescent reading of amylin alone minus (-) fluorescence of amylin in the presence of peptide 


















































3.1.6 Effect of N1-IO8 and N2-IO8 on amylin aggregation 
 
For peptides to be used as effective drug candidates, it is important to protect 
them from proteolytic degradation. One method to improve the physiochemical 
properties of IO8 is through N-methylation of particular amino acid residues, 
and so the next step was to carry out Th-T assays under similar experimental 
conditions to those described above with two different N-methylated peptides. 
Figure 3.1.6 shows data for the percentage aggregation of amylin in the presence 
of these N1-IO8 (H2N-R G Am N Fm L Vm H G R-NH2) and N2-IO8 (H2N-R 
G A Nm F Lm V Hm G R-NH2) peptides. Both N1-IO8 and N2-IO8 showed 
clear dose-dependent inhibition of amylin aggregation, with very similar 
inhibition curves. Both inhibitors showed highly significant inhibition of 
aggregation (p<0.001) at concentrations of ≥ 25 μM. At 100 μM (4:1 molar ratio 
of inhibitor to inhibitor), N1-IO8 decreased amylin aggregation to 15% of the 
non-inhibited control. At a concentration of 25 μM (1:1 molar ratio), N1-IO8 
inhibited amylin aggregation to 34%. At 100 μM (4:1 molar ratio of inhibitor to 
amylin), N2-IO8 decreased amylin aggregation to 12%. At a concentration of 
25 μM (1:1 molar ratio), N2-IO8 inhibited amylin aggregation to 36%. Thus N1-
IO8 and N2-IO8 inhibited amylin aggregation in a similar way and they are both 
















Figure 3.1.6:      Effects of N1-IO8 and N2-IO8 peptides on amylin aggregation. Percentage 
aggregation of amylin (at 25 m) in the presence of N1-IO8 and N2-IO8 peptides at 0.1 μM, 0.3 
μM, 0.6 μM, 2.5 μM, 1 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM, relative to a control 
without inhibitor. The peptides and amylin were incubated for 48 hrs and aggregation was 
monitored by Th-T assay. One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, 
***P<0.001, compared to 100% control (amylin alone). [Percentage aggregation = fluorescent 
reading of amylin alone minus (-) fluorescence of amylin in the presence of peptide multiplied 
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3.2   Quantifying amylin aggregation using the Congo Red Spectrophotometric   
        Assay 
 
Congo Red (CR) is a dye which binds to the β-pleated sheet of all amyloid 
fibrils and gives a characteristic green/red birefringence when a histology tissue 
sample is examined by polarisation microscopy. This study was aimed at 
confirming the effects of peptide-based inhibitors on amylin aggregation by 
quantifying this process using CR stain and measuring the characteristic change 
in colour absorbance on binding to amyloid fibrils. Amylin at 25 μM was 
incubated in the absence and presence of peptides at varying concentrations for 
48 hrs as described in the Methods section 2.7.1. UV-VIS measurements were 
carried out using the NANODROP 2000C spectrophotometer. These sets of 
experiments were focused on the most promising peptides, IO8, N1-IO8 and 
N2-IO8, as well as the retroinverso peptide RI-IO8 which appeared to stimulate 
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3.2.1   Congo red binding studies of amylin aggregation in the presence of IO8   
           inhibitor 
 
The effect of IO8 on amylin fibril formation was monitored by using the CR 
binding assay. IO8 was incubated with amylin (25 μM) at inhibitor 
concentrations of 0 µM, 0.1 μM, 0.3 μM, 0.6 μM, 1 μM, 2.5 μM, 5 μM, 12.5 
μM, 25 μM, 50 μM and 100 μM, for 48 hrs at 37ᵒC with continuous shaking and 
then addition of CR solution. The absorbance spectrum was read between 400 to 
700 nm using the UV-VIS Spectrophotometer. The spectrum obtained with CR 
alone was subtracted from the ‘protein plus CR’ spectrum, with spectral 
difference at the optimal wavelength of 540 nm indicating the presence of 
amyloid fibrils. Figure 3.2.1 shows the effects of IO8 on amylin fibril formation. 
Similar to the Th-T results, the data suggest that IO8 at concentrations of 100 
μM (4:1 molar ratio of inhibitor to amylin) and 50 μM (2:1 molar ratio of 
inhibitor to amylin) inhibits amylin fibril formation to around 13% of a non-
inhibited control, which is comparable with a buffer alone control. IO8 on its 
own did not alter the absorbance of CR. These data also confirm that the 




















Figure 3.2.1: Effect of IO8 on human amylin fibril formation as monitored by Congo red assay.  
Relative fibril formation of 25 M amylin in the presence IO8 at 0.1 μM, 0.3 μM, 0.6 μM, 2.5 
μM, 1 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM. The peptides and amylin were incubated 
for 48 hrs at 37 ᵒC and then analysed by Congo red assay. The results show means +/- SEM, n 
=3. One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 
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3.2.2   Congo red binding studies of amylin aggregation in the presence of RI-IO8  
 
The effect of RI-IO8 on amylin fibril formation was also monitored by using the 
CR binding assay, with similar experimental conditions to those described 
above. Figure 3.2.2 shows the percentage fibril formation of amylin in the 
presence of different concentrations of RI-IO8. Similar to the Th-T fluorescence 
results, the data suggest that RI-IO8 significantly stimulated the formation of 
amylin fibrils. However, at a concentration of 100 μM (4:1 molar ratio of 
inhibitor to amylin), a decreased CR spectrum at 540 nm was observed, with 
RI-IO8 decreasing fibril formation to 74%. RI-IO8 on its own did not alter the 
binding absorbance of CR. These data confirm that RI-IO8, at all but the highest 


























Figure 3.2.2: Effect of RI-IO8 on human amylin fibril formation as monitored by Congo red 
assay. Relative fibril formation of 25 M amylin in the presence RI-IO8 at 0.1 μM, 0.3 μM, 0.6 
μM, 2.5 μM, 1 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM. The peptides and amylin were 
incubated for 48 hrs at 37 ᵒC and analysed by Congo red assay. The results are means +/- SEM, 
n =3. One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 
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3.2.3   Congo red binding studies of amylin aggregation in the presence of N1-IO8   
           inhibitor 
 
The effect of N1-IO8 on amylin fibril formation was monitored by using the CR 
binding assay, with similar experimental conditions to those described above. 
Figure 3.2.3 shows the relative fibril formation of amylin in the presence of 
different concentrations of N1-IO8. Similar to Th-T fluorescence results, the 
data suggest that N1-IO8 at concentrations of 100 μM (4:1 molar ratio of 
inhibitor to inhibitor) and 50 μM (2:1 molar ratio of amylin to inhibitor), 
decreased CR spectra at 540 nm, confirming their inhibitory effect on amylin  
fibril formation. At these concentrations, amylin fibril formation was decreased 
to 17% and 29%, respectively, levels comparable with buffer control. N1-IO8 on 
its own did not alter the binding absorbance of CR. These data also confirm that 






















Figure 3.2.3:  Effect of N1-IO8 on human amylin fibril formation, as monitored by Congo red 
assay.  Relative fibril formation of 25 M amylin in the presence N1-IO8 at 0.1 μM, 0.3 μM, 0.6 
μM, 2.5 μM, 1 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM. The peptides and amylin were 
incubated for 48 hrs at 37 ᵒC and analysed by Congo red assay. Results are means +/- SEM, n=3. 
One-way ANOVA, Tukey's post hoc test *P<0.05, **P<0.01, ***P<0.001, compared to 100% 
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3.2.4   Congo red binding studies of amylin aggregation in the presence of N2-IO8  
           inhibitor 
 
The effect of N2-IO8 on amylin fibril formation was also monitored using the 
CR binding assay, as before. Figure 3.2.4 shows the relative fibril formation of 
amylin in the presence of different concentrations of N2-IO8. Similar to Th-T 
fluorescence results, the data show that N2-IO8 at concentrations of 100 μM 
(4:1 molar ratio of inhibitor to amylin) and 50 μM (2:1 molar ratio of inhibitor 
to amylin), decreased CR spectra at 540 nm,  confirming their inhibitory effect 
on amylin  fibril formation. At these concentrations, amylin fibril formation was 
decreased to 23% and 35% respectively, levels comparable with buffer control. 
N2-IO8 on its own did not alter the binding absorbance of CR. These data also 




















































Figure 3.2.4:  Effect of N2-IO8 on human amylin fibril formation as monitored by Congo red 
assay. Relative fibril formation of 25 M amylin in the presence N2-IO8 at 0.1 μM, 0.3 μM, 0.6 
μM, 2.5 μM, 1 μM, 5 μM, 12.5 μM, 25 μM, 50 μM and 100 μM in the presence of amylin at 25 
M. The peptides and amylin were incubated for 48 hrs at 37 ᵒC and analysed using the Congo 
red assay. The results are means +/- SEM, n =3. One-way ANOVA, Tukey's post hoc test 
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Most patients with T2DM have amyloid deposits in their pancreatic islets 
(Westermark, 1972). This leads to a reduction of β cell mass and function (Hull 
et al., 2004; Jurgens et al., 2011). Although many different peptide-based 
inhibitors have been designed for the inhibition of amyloid beta (Aβ) 
aggregation, less work has been done on the inhibition of amylin aggregation. 
Research has shown that the highly amyloidogenic region of human amylin 
(NFGAIL) resides in residues 22-27 (Westermark et al., 1990); whereas in 
rodent amylin, proline substitutions impede β-sheet formation (Moriarty and 
Raleigh, 1999). This has led to the design of ‘β-sheet breaker’ peptide inhibitors 
based on this amyloidogenic region. In contrast, the study reported here was 
focused instead on investigating potential inhibitors of human amylin derived 
from the binding region corresponding to residues 11-20 of the molecule 
(RLANFLVHSS), and determining their effects on the fibrillogenesis of full-
length human amylin. A series of overlapping small peptides was designed to 
target this binding region, and the ability of each of these peptides to prevent 
amylin aggregation was investigated. The rationale here is that prevention of the 
interaction between two amylin monomers, even if they are already misfolded, 
should impede their further aggregation. The ability of these peptide inhibitors 
to interfere with the formation of β-sheet amylin fibrils was examined using 
both Th-T and CR assay methods. Firstly, the inhibitory effects of IO1, IO2, 
IO3, IO4, IO5, IO6 and IO7 peptides on 25 µM amylin were determined at a 
wide range of different inhibitory peptide concentrations (figure 3.1.1.1). Th-T 
analysis revealed that IO2, IO3 IO4, IO5 and IO7 showed some inhibitory 
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effects on amylin aggregation, but even at 100 μM, the highest concentration 
tested, amylin aggregation was only inhibited by around 50% relative to non-
inhibited controls. Peptides IO1 and IO6 showed no inhibitory effect on amylin 
aggregation, and at lower concentrations, all of the peptides appeared to 
stimulate amylin aggregation. The most convincing inhibition was achieved with 
peptides IO4 and IO5, and so their amino acid sequences were combined to 
make IO8, with the aim of enhancing their inhibitory effects. Th-T analysis 
showed that the IO8 peptide had a strong inhibitory effect on human amylin 
aggregation (figure 3.1.2). Incubating human amylin with IO8 at concentrations 
of 100 μM (4:1 molar ratio of inhibitor to amylin), 50 μM (1:2 molar) and 25 
μM (1:1 molar ratio) had a highly significant inhibitory effect on amylin 
aggregation, and the Th-T assay showed that IO8 inhibits the formation of 
amylin aggregates with an IC50 of around 1 μM, which is very encouraging. 
Moreover, the inhibitory action of IO8 was clearly concentration dependent and 
almost complete inhibition (down to levels comparable with buffer only 
controls) was now achievable. However, the retro-inverso version of IO8 (RI-
IO8) showed no inhibitory effect on human amylin aggregation, rather, an 
increase in the aggregation of human amylin was observed. CR experiments 
confirmed the results obtained for both IO8 and RI-IO8 (figure 3.2.1; figure 
3.2.2). Although the mechanism of inhibition of IO8 has not been investigated, it 
is likely that this is due to binding of IO8 to monomeric amylin. Also, it is not 
clear why RI-IO8 actually enhanced amylin aggregation, as all of the peptides 
on their own at 100 μM did not appear to form β sheets as assessed by Th-T 
assay (Appendix D). This result was surprising since previous studies at 
Lancaster have shown that a retro-inverso peptide (RI-OR2) can successfully 
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inhibit the aggregation of Aβ associated with Alzheimer’s disease (Taylor et al., 
2010). Most inhibitors of amylin aggregation are designed to target the 
aggregation prone region of amylin. However our peptides were designed to 
target the binding region of the human amylin peptide. The residues on the N- 
and C- termini are designed to act to facilitate aggregation inhibition and impede 
the binding of additional amylin-peptide complex. The N- and C- termini of all 
our peptides are capped with the GR-NH2 side chains to improve solubility of 
the peptides. Solubility is important when choosing side chains and Ramírez-
Alvarado et al., 1999 have previously used the Ac-RG- and -GR NH2 Side 
chains to improve solubility of peptides. Our results add to previous research 
which has elucidated the effects of peptides and small molecule inhibitors on 
amylin aggregation. Small molecule inhibitors such as resveratrol have been 
shown to inhibit membrane bound human amylin at a ratio of 1:2 
amylin:resveratrol complex /membrane interphase (Lolicato et al., 2015). 
Molecular dynamics simulations for human amylin pentamer with resveratrol 
also showed that resveratrol binding with human amylin resulted in significant 
conformational changes of human amylin pentamer (Wang et al., 2015). 
Another molecule, acid fuchsin (Meng et al., 2010) have been previously used 
to impede amylin amyloid formation.  Also, small molecules comprising of 
polyphenols and aromatic groups have been shown to impede amylin amyloid 
formation, but this was only achieved by using molar excess of the inhibitory 
compounds (Cheng et al., 2011; Sinha et al., 2011; Mishra et al., 2009). In 
addition, tetracycline showed little inhibitory effect on human amylin, with 
some inhibition being achieved only at a molar ratio of 20 fold excess of the 
inhibitory molecules (Aitken et al., 2003). Other small molecules such as 
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Acridine Orange and Methylene Blue were able to bind to oligomeric forms of 
human amylin but showed no inhibitory effect on human amylin aggregation 
even at 20-fold molar excess concentrations of the inhibitory compounds 
(Aitken et al., 2003). Although small molecule inhibitors have potential 
advantages including easy penetration into a large population of cells, they are 
not good candidates as amyloid aggregation inhibitors because inhibiting amylin 
aggregation requires impeding interactions between relatively large amylin 
monomers. Due to the size and geometry of the protein interaction surface, the 
small molecule would need to be the size of a peptide to work as an aggregation 
inhibitor. Protein-protein interaction regions are generally of the size 1500–3000 
Å (Keskin et al., 2008), while protein–small molecule interaction regions are 
approximately 300–1000 Å (Cheng et al., 2007; Smith et al., 2006). Therefore, 
small molecules are mostly incapable of generating sufficient steric hindrance to 
impede amylin aggregation. Thus peptide-based inhibitors are a better choice for 
aggregation inhibitor drugs. Full-length amylin with a single proline substitution 
in the 20–29 region has been shown to inhibit amylin fibril formation and 
toxicity, so converting amylin into a potent amyloid inhibitor (Abedini et al., 
2007; Meng et al., 2010); furthermore, a double N-methylated variant of human 
amylin effectively inhibited the formation and cytotoxicity of amylin amyloid 
formation (Yan et al., 2006). Although the mechanism of action of these 
compounds is yet to be understood, they may carry out their activity through 
interaction with helical oligomers (Stefani and Rigacci, 2013). However, full 
length amylin is expensive and difficult to synthesize. There could also be a risk 
for immunogenic responses. Thus full length amylin may not be the best peptide 
for amylin aggregation inhibitors.   
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Next, we compared the effects of IO8 with a previously reported inhibitor of 
amylin aggregation in literature, NMeG24 NMeI26 (Sellin et al., 2010) which is 
a modified form of amylin 22-27 amyloidogenic fragment (NFGAIL), with N-
methylation at the amide bonds G24 and I26. Although IO8 showed significant 
inhibition of amylin aggregation, NMeG24 NMeI26 was found to have no 
inhibitory effect on amylin aggregation, and actually showed the capacity to 
enhance amylin aggregation (figure 3.1.3). We also attempted to test the peptide 
ANFLVH (Potter et al., 2009) which has been reported in literature to show 
inhibitory effects on amylin aggregation. However, this peptide was found to be 
insoluble in aqueous solution, and therefore could not be used in this study. A 
possible explanation for this could be the absence of arginine and glycine (RG) 
residues at both ends of the ANFLVH peptide, which are present in IO8. In 
search of other inhibitory peptides of amylin aggregation, we designed peptides 
with longer sequences spanning through the binding region; namely H2N-
RGANFLVHSSNNFGR-NH2 and its retro inverso form Ac-rGfnnsshvlfnaGr-
NH2. The inhibitory effects of these peptides could also not be assessed as they 
were insoluble in aqueous and non-aqueous solutions, and so no data is shown. 
It should be noted that as peptide length increases, generally the purity of the 
peptide becomes lower (Milton et al., 1990). Probably shortening the sequence 
to eliminate some hydrophobic residues could help increase peptide polarity, as 
the greater the polarity, the more likely it is that the peptide will be soluble in 
aqueous solution.  
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Given that IO8 was the best inhibitor, efforts were made to stabilise IO8 from 
proteolytic degradation by replacing the arginines in IO8 
(H2N-RGANFLVHGR-NH2) with homoarginine, to give HIO8 (H2N-Har-
GANFLVHG-Har-NH2). This was to protect IO8 from degradation by trypsin. 
HIO8 showed inhibition of amylin aggregation comparable to that seen with 
IO8, and at a concentration of 100 μM (4:1 molar ratio of inhibitor to amylin), 
amylin aggregation was decreased to 13 % (figure 3.1.5). However, to 
completely stabilise IO8, it must be protected from proteolytic degradation by 
other proteolytic enzymes, and not just trypsin.  
 
In the search for a more potent peptide than IO8, and to compare two different 
strategies (i.e. targeting of amyloidogenic versus binding regions of amylin), we 
designed another peptide, H2N-RGNFGAILSGR-NH2 containing the ‘core’ of 
the 20-29 amyloidogenic region (NFGAIL). Our rational was to investigate if 
the addition of positively charged RG (arginine-glycine) groups on either side of 
this peptide could confer inhibitory properties on the peptide, as they have been 
reported to improve peptide solubility and upon binding with the amyloid 
protein, prevents other molecules from binding to the amyloidogenic protein 
(Taylor et al., 2010). However, the H2N-RGNFGAILSGR-NH2 peptide showed 
no inhibitory effect on human amylin aggregation and even seemed to enhance 
aggregation (figure 3.1.4). Previous studies have shown that the peptide 
NFGAIL forms β-sheet containing amyloid fibrils (Tenidis et al., 2000). It could 
thus be suggested that the presence of the amyloidogenic sequence NFGAIL 
could account for the increase in amylin aggregation as detected by Th-T assay 
in the presence of NMeG24 NMeI26 and NH2-RGNFGAILSGR-NH2 peptides. 
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Another study showed that the addition of N-methyl groups to the peptide 
NFGAIL (NF(N-Me)GA(N-Me)IL) resulted in its conversion to a non-
amyloidogenic and non-cytotoxic peptide (Tatarek-Nossol  et. al., 2005) and 
reasonably impeded amylin amyloid formation, suggesting that N-methylation 
of peptides could be a beneficial approach in the design of amyloid therapeutics 
for T2DM. N-methylated peptides are designed to repress the H-bonding 
capacity of a NH group, to control the peptide backbone, and to assemble 
cylindrical β-sheet dimers (Vitoux et al., 1986; Manavalan and Mormany, 1980; 
Clark et al., 1998; Sun and Lorenzi. 1994). Considering the fact that our IO8 
peptide was our most potent inhibitor of amylin aggregation, we thought to 
stabilize IO8 to proteolytic degradation and possibly improve its inhibitory 
properties through the selective N-methylation of alternate amino acid residues 
within the IO8 primary sequence. These N-methylated peptides, N1-IO8 (H2N-
RGAmNFmLVmHGR-NH2) and N2-IO8 (H2N-RGANmFLmVHm R-NH2), 
gave significant inhibition of amylin aggregation, and at a concentration of 100 
μM (4:1 molar ratio of inhibitor to amylin), N1-IO8 decreased amylin 
aggregation to 15 % (figure 3.1.6). At a similar concentration, N2-IO8 decreased 
amylin aggregation to 12 % (figure 3.1.6). The Th-T assay showed that N1-IO8 
and N2-IO8 inhibited the formation of amylin aggregates with IC50 values of 
around 1.6 μM and 1.5 μM, respectively. They are, therefore, no more potent 
than IO8, which gave an IC50 of 1 µM.  The inhibitory action of both N1-IO8 
and N2-IO8 was very similar and showed clear concentration dependence. 
These results were also confirmed by CR experiments (figure 3.2.3; figure 
3.2.4). These N- methylated peptides show better inhibitory properties than 
those described in literature as they inhibit amylin aggregation even at very low 
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concentrations. N1-IO8 and N2-IO8 are presumably capable of interacting with 
the full length human amylin, leading to inhibition of β-sheet formation and/or 
amyloidogenesis.  N-Methylation has been thought to enhance β-sheet formation 
by converting the residue to a β conformation thereby producing soluble 
monomeric β-sheet peptides. N-methylation of the amide NH groups may 
impede intermolecular hydrogen bonding and possibly amyloid aggregation 
(Hughes et al., 2000). These results suggest that there are definite structural 
rules that dictate protein self-assembly into amyloid (Dobson et al., 1999), and 
illustrate the significance of adopting a rational approach to inhibitor design, and 
specific structural models of the amyloid core, when using native sequences as 
scaffolds to design amyloid inhibitors. For example, it is likely that the 
insolubility of the ANFLVH peptide is due to the predominance of hydrophobic 
residues which can sometimes lead to assembly problems (Fauchere and Pliska, 
1983). This suggests that adding a polar residue like Arginine as seen in our IO8 
peptide (H2N-RGANFLVHGR-NH2), could help to alter regular peptide 
structure thereby increasing polarity and solubility. Although the IO8 peptide 
has a similar sequence with the peptide in literature ANFLVH, it showed high 
solubility in aqueous solution, along with a greater inhibitory ability on amylin 
aggregation, thus making IO8 the better drug candidate. 
 
Fluorescent dye-binding assays, like Congo red and Th-T are generally used to 
probe the aggregation of amyloidogenic proteins and for assessing inhibitors of 
amyloid aggregation and fibrillization (Hawe et al., 2008; Buell et al., 2010). 
This plays a key role in the understanding of numerous human diseases linked 
with protein aggregation.  Following binding to protein aggregates, these dyes 
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show distinct spectral shifts when compared to their unbound state and thus can 
be used as good reporters of protein aggregation states (Nilsson, 2004; Eisert et 
al., 2006). It is generally assumed that emission at 490 nm is directly 
proportional to the amount of amyloid fibrils present, and thus, the kinetics of 
fibril formation can be assessed by measuring the time dependent increase in 
fluorescence. On the other hand, a decrease in Th-T fluorescence generally 
denotes an inhibition of the amyloid self-assembly process (Buell et al., 2010; 
Hawe et al., 2008). It has however been shown that Th-T fluorescence may 
sometimes not give accurate assessment of the kinetics of the amyloid 
aggregation (Middleton et al., 2012). For example, Middleton et al. (2012), 
reported that after 8 hours of amyloid aggregation, Th-T fluorescence attained a 
plateau state and continued in that state for up to 30 hours, which indicates the 
presence of a stable β-sheet content. However, 2D IR measurements showed that 
β-sheet structural and content changes occurred throughout a 24 hour period 
(Middleton et al., 2012). Also, Th-T does not detect soluble amyloid oligomers, 
as observed from a characteristic lag phase in the time-dependent studies (figure 
3.1), but predominantly detects the insoluble fibrillar aggregates in the β-sheet 
conformation (Bartolini et al., 2011; Amaro et al., 2011). Some studies have 
however reported that Th-T can differentiate between oligomeric and fibrillar 
Aβ species (Maezawa et al., 2008; Ryan et al., 2010). These differences in 
reports can be attributed to variations in preparation methods for the Aβ 
oligomers (Reinke and Gestwicki, 2011). 
 
Another draw-back with dye-binding assays is, competitive binding of the dye 
and the inhibitors to the amyloidogenic proteins (Klunk et al., 1999). If the 
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binding site of the inhibitor to the aggregating protein is the same as the binding 
site of the dye to the aggregating protein, the inhibitor and dye would have to 
compete for the binding site, which may result in inadequate binding of the dye 
to the aggregating protein. This may cause changes in signal intensity resulting 
in artifacts or false positives (Klunk et al., 1999). Thus, when assessing the 
inhibitory effect of inhibitors on amylin aggregation and fibril formation, it is 
important to examine the impact of the inhibitors on the fluorescence of the dye 
in the absence of the aggregating peptide. In this study, inhibitors alone, in the 
presence of the dye indicated the absence of aggregation, with results similar to 
PBS buffer controls. 
Considering the ease of manipulation and high throughput screening of potential 
inhibitors, dye-binding assays are usually used as the fundamental test of 
aggregation inhibiting peptides. Compounds that show inhibitory effects on 
amylin aggregation are considered for further testing, while compounds that do 
not show any inhibitory effect are not considered for further testing. Further 
testing of inhibitory molecules using biophysical methods like atomic force 
microscopy (AFM) and Transmission Electron Microscopy (TEM) are therefore 











Previous studies have focused on developing inhibitors of amylin amyloid 
aggregation by targeting the amyloidogenic region (Scrocchi et al., 2002; Porat 
et al., 2004; Kapurniotu et al., 2002; Tatarek-Nossol et al., 2005), which on its 
own can form fibrillar structures exhibiting a β-sheet conformation (Glenner et 
al., 1988; Westermark et al., 1990). However, in general these inhibitors were 
only found to work when they were in high molar excess compared to the 
amylin peptide (Scrocchi et al., 2002; Porat et al., 2004). Here, the effects on 
fibrillogenesis of full-length human amylin of a series of overlapping human 
amylin peptides derived from the binding region of amylin was examined, the 
objective being to determine if these fragments are capable of interacting with 
human amylin and altering the aggregation pathway. IO8, HIO8, N1-IO8 and 
N2-IO8 peptides were the most potent inhibitors and were shown to be 
significantly better than the peptide-based and small molecule inhibitors 
reported in literature. Even at a molar ratio of 1:10 inhibitor to amylin, these 
peptides are still potent inhibitors of amylin aggregation. It is important to note 
that for a peptide to be a good drug candidate, it must not only inhibit amyloid 
aggregation, but must also be stable to proteolytic degradation and be non-toxic. 
Applying this approach could lead to the development of new therapeutics 
capable of affecting amylin aggregation and further contribute information on 











Qualitative analysis of the effects of peptide-based 
inhibitors on amylin aggregation 
 
 
Transmission Electron Microscopy (TEM) has been used extensively for 
monitoring the formation of amyloid fibrils from proteins in vitro. TEM can be 
used qualitatively to assess characteristics such as fibril curvature and surface 
smoothness as well as bends and twists in the ribbon-like fibrils (Thorn et al., 
2008). Also, quantitative data such as the length of seeds and early aggregates, 
the amount of protofilaments, as well as the diameter of fibrils, can be obtained 
using TEM (Goldsbury et al., 2000). Human amylin has been shown previously 
by TEM to assemble into amyloid fibrils from its initial monomeric stage, 
through to oligomers (Lee et al., 2016). In order to confirm the effects of the 
peptide inhibitors on amylin aggregation, the aggregation of human amylin with 
and without inhibitors was examined, focussing specifically on IO8, N1-IO8, 
N2-IO8 and RIO8. The ultrastructural morphology of amylin aggregates was 
determined by using TEM to compare the effects of IO8 with its stable forms, 
N1-IO8, N2-IO8, as well as with RI-IO8 which appeared to stimulate amylin 
aggregation as observed in the Th-T assay. Although the Th-T assay has the 
advantage of showing the kinetics of amylin amyloid formation, it can give 
misleading results since it is dependent on the binding of an extrinsic probe 
(Meng et al., 2008), and can lead to false positives result since a range of factors 
can result in the loss of Th-T fluorescence in addition to inhibition of amyloid 
formation (Jaikaran et al., 2004). Therefore it was important to validate the Th-T 
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data by use of TEM to compare the ultrastructural morphology of human amylin 





4.1  IO8 inhibits amylin aggregation 
 
TEM was used to monitor the effects of IO8 on human amylin aggregation, with 
samples being negatively stained with 2% phosphotungstic acid (PTA). The 
effect of IO8 on the aggregation of 25 μM amylin was examined at varying IO8 
concentrations of 100 μM, 50 μM, 25 μM, 5 μM and 0 µM (non-inhibited 
control). All experiments were repeated three times with similar results. Figure 
4.1 shows the ultrastructural morphology of human amylin in the presence and 
absence of IO8 inhibitor. Figure 4.1A shows clearly that amyloid fibrils were 
formed after 48 hrs incubation of human amylin alone. With addition of 100 
μM, 50 μM, or 25 µM IO8 (4:1, 2:1 and 1:1 molar ratios of IO8 to amylin), no 
fibrils were observed after 48 hrs incubation (Figure 4.1B, 4.1C and 4.1D). It 
should be noted that at 100 μM, an altered crystal-like morphology was 
observed. At a concentration of 5 μM IO8 (1:5 molar ratio of IO8 to amylin), the 
presence of relatively less dense fibrils with a morphology similar to that of 
amylin fibrils was observed (Figure 4.1E). IO8 alone at 100 μM showed no 
tendency to aggregate (Figure 4.1F). These results confirm that IO8 is an 




















Figure 4.1: TEM examination of the effects of IO8 on amylin fibril formation. Samples of 25 
μM amylin  in the presence and absence of IO8 at varying concentrations were incubated with 
continuous shaking for 48 hrs at 37ᵒC in distilled water, negatively stained with phosphotungstic 
acid (2% w/v) and visualized using TEM. (A) Amylin alone; (B) Amylin + IO8 (100 μM); (C) 
Amylin + IO8 (50 μM); (D) Amylin + IO8 (25 μM); (E) Amylin + IO8 (5 μM); (F) IO8 peptide 
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4.2   RI-IO8 stimulates amylin aggregation 
 
Studies from the Th-T assays showed that RI-IO8 appeared to stimulate amylin 
aggregation. To confirm these results, TEM was used to monitor the effects of 
RI-IO8 on amylin aggregation. The samples were negatively stained with 2% 
PTA. The effect of RI-IO8 on amylin aggregation was examined at varying 
concentrations of 100 μM, 50 μM, 25 μM and 5 μM, with amylin at a constant 
concentration of 25 μM. All experiments were repeated three times with similar 
results. Figure 4.2 shows the ultrastructural morphology of human amylin in the 
presence and absence of RI-IO8. Figure 4.2A shows clearly that amyloid fibrils 
were formed after 48 hrs incubation of human amylin alone. These electron 
micrographs confirm the presence of amyloid fibrils/aggregated species in all 
samples of amylin. As can be seen in Figure 4.2A-F, there was a slight 
morphological variation among the aggregates/fibrillar species seen in these 
samples. On addition of 100 μM RI-IO8 (4:1 molar ratio of RI-IO8 to amylin), 
relatively dense fibrillar aggregates with a similar morphology those seen with 
amylin alone were observed (Figure 4.2B). At 50 μM RI-IO8 (2:1 molar ratio of 
RI-IO8 to amylin), dense fibrils with a more ‘rigid’ morphology than amylin 
fibrils were observed (Figure 4.2C). These rigid fibrils were denser and more 
numerous at 25 μM and 5 µM of RI-IO8 (1:1 and 1:5 molar ratios of RI-IO8 to 
amylin) (Figure 4.2D, 4.2E). RI-IO8 alone showed no tendency to aggregate 
(Figure 4.2F). These results support the Th-T data and confirm that RI-IO8 has 
no inhibitory effect on amylin aggregation, but rather stimulates the amylin 
aggregation process. 
 


















Figure 4.2: TEM examination of the effects of RI-IO8 on amylin fibril formation. Samples of 25 
μM of amylin in the presence and absence of RI-IO8 at varying concentrations were incubated 
with continuous shaking for 48 hrs at 37ᵒC in distilled water, negatively stained with 
phosphotungstic acid (2% w/v) and visualized using TEM. (A) Amylin alone; (B) Amylin + RI-
IO8 (100 μM); (C) Amylin + RI-IO8 (50 μM); (D) Amylin + RI-IO8 (25 μM); (E) Amylin + RI-
IO8 (5 μM); (F) RI-IO8 alone (100 μM). n=3 (3 replicates for each sample) Magnification = 
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4.3   N1-IO8 inhibits amylin aggregation 
 
Following examination of the effects of N1-IO8 on amylin aggregation using the 
Th-T assay, we used the TEM to monitor its effects on amylin aggregation. The 
samples were negatively stained with 2% PTA, with the same conditions as 
before. The data shown are representative of at least two different experiments 
with similar results. Figure 4.3 shows the ultrastructural morphology of human 
amylin in the presence of N1-IO8 inhibitor. Figure 4.3A shows clearly the 
formation of amyloid fibrils following 48 hrs incubation of human amylin alone. 
In the presence of 100 μM, 50 μM and 25 μM of N1-IO8 (4:1, 2:1 and 1:1 molar 
ratios of N1-IO8 to amylin), no fibrils were seen after 48 hrs incubation (Figure 
4.3B, C and D). At 5 μM of N1-IO8 (1:5 molar ratio of N1-IO8 to amylin), the 
presence of relatively less dense fibrils with a morphology similar to that of 
amylin fibrils was observed (Figure 4.3E). N1-IO8 showed no tendency to 
aggregate (Figure 4.3F). These results confirm that N1-IO8 is an effective 































Figure 4.3: TEM examination of the effect of  N1-IO8 on amylin fibril formation. Samples of 
25 μM of amylin in the presence and absence of RI-IO8 at varying concentrations were 
incubated with continuous shaking for 48 hrs at 37ᵒC in distilled water, negatively stained with 
phosphotungstic acid (2% w/v) and visualized using TEM. (A) Amylin alone; (B) Amylin + RI-
IO8 (100 μM); (C) Amylin + N1-IO8 (50 μM); (D) Amylin + N1-IO8 (25 μM); (E) Amylin + 
N1-IO8 (5 μM); (F) N1-IO8 peptide alone (100 μM). n=3 (3 replicates for each sample) 
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4.4   N2-IO8 inhibits amylin aggregation 
 
Following examination of the effects of N2-IO8 on amylin aggregation using the 
Th-T assay, TEM was used to monitor its effects on amylin aggregation, with 
the same experimental conditions as those described above. The data shown are 
representative of at least two different experiments with similar results. Figure 
4.4 shows the ultrastructural morphology of human amylin in the presence of 
N2-IO8 inhibitor. Figure 4.4A shows clearly the formation of amyloid fibrils 
following 48 hrs incubation of human amylin. In the presence of 100 μM, 50 
µM, 25 µM or 5 µM N2-IO8 (4:1, 2:1, 1:1, 1:5 molar ratios of N2-IO8 to 
amylin), no fibrils were seen after 48 hrs incubation (Figure 4.4B, 4.4C, 4.4D, 
4.4E). N2-IO8 on its own at 100 μM failed to aggregate (Figure 4.4F). These 










































        
 
 
Figure 4.4: TEM examination of the effects of N2-IO8 on amylin fibril formation. Samples of 
25 μM of amylin in the presence and absence of N2-IO8 at varying concentrations were 
incubated with continuous shaking for 48 hrs at 37ᵒC in distilled water, negatively stained with 
phosphotungstic acid (2% w/v) and visualized using TEM. (A) Amylin alone; (B) Amylin + N2-
IO8 (100 μM); (C) Amylin + N2-IO8 (50 μM); (D) Amylin + N2-IO8 (25 μM); (E) Amylin + 
N2-IO8 (5 μM); (F) N2-IO8 peptide alone (100 μM). n=3 (3 replicates for each sample) 
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4.5 Disaggregation of pre-formed amyloid fibrils 
 
The ability of IO8, RI-IO8, N1-IO8 and N2-IO8 to disaggregate pre-formed 
amylin amyloid fibrils was then monitored using the TEM. Human amylin was 
pre-aggregated at 25 μM for 48 hrs and a sample was prepared immediately for 
TEM after which 100 μM or 50 μM (final concentration) of IO8, RI-IO8, N1-
IO8 or N2-IO8 peptides were added to the pre-formed fibrils and incubated for a 
further 48 hrs with continuous shaking at 37ᵒC and another TEM sample was 
prepared. The samples were negatively stained with 2% PTA. Figure 4.5.1 to 
4.5.4 illustrate the effects of IO8, RI-IO8, N1-IO8 and N2-IO8, respectively, on 
pre-aggregated amylin. All amylin controls clearly showed the formation of 
amyloid fibrils, following incubation of 25 μM human amylin for 48 hrs (e.g. 
Figure 4.5.1A; 4.5.1C). After 48 hrs incubation of fibrils in the presence IO8 at 
100 μM or 50 µM, less amylin fibrils fibrils were observed (Figure 4.5.1B; 
4.5.1D) compared to the amylin control samples (Figure 4.5.1A; 4.5.1C).  
 
Upon addition of 100 μM or 50 µM RI-IO8 to pre-aggregated amylin, no 
disaggregation was observed (Figure 4.5.2 B; 4.5.2 D) as compared to the 
amylin control samples (Figure 4.5.2A; 4.5.2C). In fact, the number of fibrils 
after 48 hrs post-incubation seemed to be increased after the addition of RI-IO8 
(Figure 4.5.2B; Figure 4.5.2D) when compared to the amylin control samples 
(Figure 4.5.2A; Figure 4.5C). The addition of 100 μM of N1-IO8 to pre-
aggregated amylin resulted in the disaggregation of pre-formed fibrils (Figure 
4.5.3B), as compared to the amylin control samples (Figure 4.5.3A). Also, the 
addition of 50 μM of N1-IO8 to pre-aggregated amylin resulted in the 
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disaggregation of pre-formed fibrils (Figure 4.5.3D) leaving a less dense fibril 
mass when compared to the amylin control samples (Figure 4.5.3C). The 
addition of N1-IO8 noticeably gave rise to fragmented fibrils with a shorter 
length. N2-IO8 also showed significant disaggregation of pre-formed amylin 
fibrils upon incubation of pre-aggregated amylin with 100 μM of N2-IO8 
(Figure 4.5.4B), as compared to the amylin control samples (Figure 4.5.4A). A 
similar result was also obtained with 50 μM of N2-IO8 (compare Figure 4.5.4D 






























Figure 4.5.1: Experiment to monitor possible disaggregation of pre-formed amylin fibrils by 
IO8. (A) 25 μM amylin incubated for 48 hrs, negatively stained with 2% (w/v) phosphotungstic 
acid and immediately taken for TEM imaging. (B) 100 μM of IO8 added to the pre-aggregated 
amylin in “A” and sample incubated for 48 hrs at 37°C before TEM imaging. (C) 25 μM amylin 
incubated for 48 hrs and immediately taken for TEM imaging (D) 50 μM of IO8 added to the 
pre-aggregated amylin in “C” and sample incubated for 48hrs at 37 °C before TEM imaging . 






























Figure 4.5.2: Experiment to monitor possible disaggregation of pre-formed amylin fibrils by RI-
IO8. (A) 25 μM amylin incubated for 48 hrs, negatively stained with 2% (w/v) phosphotungstic 
acid and immediately taken for TEM imaging. (B) 100 μM of RI-IO8 added to the pre-
aggregated amylin in “A” and sample incubated for 48 hrs at 37°C before TEM imaging. (C) 25 
μM amylin incubated for 48 hrs and immediately taken for TEM imaging (D) 50 μM of RI-IO8 
added to the pre-aggregated amylin  “C” and sample incubated for 48hrs at 37 °C before TEM 





























Figure 4.5.3: Experiment to monitor possible disaggregation of pre-formed amylin fibrils by 
N1-IO8. (A) 25 μM amylin incubated for 48 hrs, negatively stained with 2% (w/v) 
phosphotungstic acid and immediately taken for TEM imaging. (B) 100 μM of N1-IO8 added to 
the pre-aggregated amylin in “A” and sample incubated for 48hrs at 37 °C before TEM imaging. 
(C) 25 μM amylin incubated for 48 hrs and immediately taken for TEM imaging (D) 50 μM of 
N1-IO8 added to the pre-aggregated amylin in “C” and sample incubated for 48hrs at 37 °C 


























Figure 4.5.4: Experiment to monitor possible disaggregation of pre-formed amylin fibrils by 
N2-IO8 (A) 25 μM amylin incubated for 48 hrs, negatively stained with 2% phosphotungstic 
acid (w/v) and immediately taken for TEM imaging. (B) 100 μM of N2-IO8 added to the pre-
aggregated amylin in “A” and sample incubated for 48 hrs at 37°C before TEM imaging. (C) 25 
μM amylin incubated for 48 hrs and immediately taken for TEM imaging (D) 50 μM of N2-IO8 
added to the pre-aggregated amylin in “C” and sample incubated for 48hrs at 37 °C before TEM 
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4.6     Discussion 
 
There have been numerous reports concerning the development of inhibitors of 
β-amyloid polypeptide (Aβ) and prion protein amyloid formation and 
cytotoxicity (Findeis, 2000; Reixach et al., 2000; Soto et al., 1998). There have, 
however, been very few reports on inhibitors of amylin amyloid formation. A 
reason for this could be because amylin is one of the most insoluble and 
amyloidogenic polypeptides known (Jarrett and Lansbury, 1993). Developing 
inhibitors of amyloid formation is of therapeutic importance as well as holding 
potential for understanding the mechanism of amyloid fibril formation. The 
main objective of this study was to devise a method of impeding the aggregation 
of amylin into β-sheet oligomers and fibrils. Further to our Th-T and CR 
experiments, we carried out confirmatory TEM experiments were carried out to 
examine the ability of the various peptides to influence the aggregation of 
human amylin. Full-length human amylin assembles into fibrillar structures 
made up of numerous protofilaments, which are typical of those seen with 
various forms of amyloid (Serpell et al., 2000), and are characterised by a dense 
mass of fibrils possessing a mesh-like morphology. The data confirm that IO8, 
at concentrations of 25, 50 and 100 μM, impedes the formation of fibrils derived 
by incubating amylin at 25 µM concentration. At 5 μM IO8, thin less compact 
fibril structures were found. These results are consistent with the Th-T and CR 
data. Although the Th-T and CR results did not show complete inhibition of 
fibril formation, TEM analysis revealed an almost complete inhibition of amylin 
fibril formation by IO8 at 100 μM, 50 μM and 25 μM concentrations. Although 
IO8 was able to inhibit amylin fibril formation when added to freshly dissolved 
amylin, it did not completely degrade pre-aggregated amylin fibrils (figure 
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4.5.1). Inhibiting amylin aggregation has been dependent on using compounds 
which can bind to amylin (Abedini et al., 2007; Yan et al., 2006; Tatarek-Nossol 
et al., 2005). The study reported here is consistent with a previous study which 
showed that two peptides, Ser-Asn-Asn-Phe-Gly-Ala and Gly-Ala-Ile-Leu-Ser-
Ser-Thr, moderately inhibit amylin amyloid aggregation at an equimolar ratio 
with associated protection from amylin cytotoxicity to RIN-1056 cells (Scrocchi 
et al., 2002). Previous study has also shown the effect of rat amylin as well as 
mutant forms of rat amylin on human amylin inhibition. Although rat amylin 
moderately inhibited human amylin aggregation by 85% at a ratio of 10:1 rat 
amylin to human amylin, the mutant forms of rat amylin were less effective 
inhibitors (Cao et al., 2010). Even at a molar ratio of 10:1 rat amylin to human 
amylin, TEM images revealed the presence of fibrils although they were 
significantly thinner than that observed in the control (Cao et al., 2010). 
However, the IO8 peptide inhibits amylin aggregation even at low 
concentrations of the peptide and is thus a considerably better inhibitor than 
those described above. 
On the other hand, the retro-inverso peptide, RI-IO8 had no inhibitory effect on 
amylin aggregation and in fact increased fibril formation at all concentrations 
tested. RI-IO8 appeared to enhance amylin aggregation resulting in a denser and 
more complex amylin fibril mesh (figure 4.2). Although this came as a surprise, 
previous studies have shown that small peptides can sometimes increase fibril 
formation, for example the addition of the NFGAIL fragment to amylin greatly 
enhanced amylin aggregation and fibril formation (Scrocchi et al., 2002). It is 
likely that the NFGAIL peptide enhances amyloid aggregation because it 
originates from the amyloidogenic sequence of human amylin and can act as a 
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seed to promote aggregation, however the mechanism of action by which RI-
IO8 enhances amyloid aggregation is currently not known. In addition, RI-IO8 
did not degrade already formed fibrils (figure 4.5.2), although a less-defined 
dense fibril mesh was observed. RI-IO8 on its own did not form any fibrillary 
structure or aggregates. 
 
The N1-IO8 peptide had a strong effect on β sheet and fibril formation. 
Incubating 25 µM amylin with either 100 μM, 50 μM or 25 μM of N1-IO8 was 
sufficient to prevent fibril formation (figure 4.3). However at a concentration of 
5 μM, amylin fibril formation was not completely inhibited, although the fibrils 
present did seem to have an altered morphology with loosely linked ribbon-like 
structures. This is consistent with a previous study where the peptide fragment 
AILSST showed inhibitory properties when it was in 5 fold molar excess, but no 
inhibitory effect at a 1:1 molar ratio (Scrocchi et al., 2002).  However, N1-IO8 
proved to be the better inhibitor, as it inhibits fibril formation even at a 1:1 
molar ratio. N1-IO8 also had a strong effect on β sheet and fibril formation of 
pre-formed amylin amyloid fibrils. Incubating N1-IO8, at either 100 μM or 50 
μM with already formed amylin fibrils was sufficient to degrade pre-formed 
fibrils (figure 4.5.3). While N1-IO8 could not completely degrade pre-formed 
fibrils at 50 μM, the aggregates appeared to have an altered morphology and 
appeared as short thread-like, less compact fibril structures. This suggests that 
the interaction of human amylin with N1-IO8 peptide altered normal fibril 
assembly. Furthermore, incubating amylin in the presence of N2-IO8 altered the 
morphology of the fibrils; no fibril was formed unlike the densely packed fibril 
clusters observed when amylin was incubated alone (figure 4.4). N2-IO8 also 
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completely degraded preformed amylin fibrils at both 100μM and 50 μM 
concentrations (figure 4.5.4). N2-IO8 was the only peptide here which 
completely inhibited amylin fibril formation even at a 1:5 molar ratio of peptide 
to amylin. These results are consistent with a previous study which showed that 
incubating amylin in the presence of GAILSS or SNNFGA peptide fragments 
significantly decreased the density of amylin fibrils formed, but did not 
completely inhibit the formation of fibrils. This reduced effect was also only 
observed when the peptides were in to- or 20- fold excess of amylin (Scrocchi et 
al., 2002). Double N-methylated peptides derived from the partial human amylin 
amyloidogenic  sequence SNNFGAILSS,  including F(N-Me)GA(N-Me)IL, 
NF(N-Me)GA(N-Me)IL, SNNF(N-Me)GA(N-Me)IL, and SNNF(N-Me)GA(N-
Me)ILSS were the first reported to inhibit the short partial human amylin 
amyloidogenic  sequence SNNFGAILSS. Contrary to the parent peptide 
sequence, the N-methylated derivatives were very soluble and did not aggregate 
into amyloid fibrils. This suggests that strategies like N-methylation are capable 
of changing the amyloidogenic amylin into a non-amyloidogenic state. More 
work is, however, required to study the binding affinity of the peptides reported 
here to amylin. To completely disaggregate amylin fibrils, these peptides would 
have to bind to amylin at very high affinity to break the hydrogen bonding 
between amylin monomers. 
 
Although studies have shown that amyloid deposition is linked with decreased 
β-cell mass (Clark et al., 1988; Westermark  and Grimelius, 1973), controversies 
have arisen as to whether amylin is a cause or consequence of β-cell 
dysfunction/hyperglycemia in T2DM as amylin deposits have also been found in 
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non-diabetic individuals (Bell, 1959; Westermark, 1976).  However, it is likely 
that amylin does plays a key role in the β-cell dysfunction/apoptosis seen in 
T2DM, as previous studies have clearly shown an association between amylin 
and T2DM. Although the reduction in β-cell mass is not sufficient to explain the 
defects in insulin dysfunction found in T2DM, it is still likely that these cell 
functions will be altered, since previous study has shown the presence of 
amyloid fibrils within cells (Cooper et al., 1987) and these have been shown to 
be cytotoxic. Amylin is synthesized (in vivo) in the pancreatic β cells and 
secreted from the secretory granules in soluble form (Serpell et al., 2000). 
However, certain environmental circumstances such as amylin concentration, 
pH and molecular binding could alter the conformation of amylin from a random 
coil to a β- sheet, which stimulates amyloid fibril formation (Janson et al., 1999; 
Kayed et al., 1999; Hoopener et al., 1999). Studies have suggested that a build-
up of insoluble amylin fibrils plays a key role in β cell failure in T2DM 
(Janciauskiene et al., 1997; de Koning et al., 1993). This is supported by a 
previous studies which has shown that non-clearance of amylin after secretion as 
well as a partial pro-amylin processing  (Clodi et al., 1998) in patients with 
T2DM could promote increased fibrillogenesis and aggregation (Park and 
Verchere, 2001; Higham et al., 2000). It could be thought that IO8, N1-IO8 and 
N2-IO8 are capable of keeping amylin in soluble form for an extended period of 
time, and thus impair fibril aggregate formation typical of insoluble amylin. The 
sudden increase in fibril formation observed when amylin was incubated with 
RI-IO8 proves the ability of some peptides to increase fibrillogenesis. The 
results displayed in this present study confirm that peptide sequences found 
within the human amylin molecule impede β sheet formation and fibrillary 
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assembly. The data presented here demonstrate that IO8, N1-IO8 and N2-IO8 
inhibit amyloid formation by human amylin in a dose-dependent manner and 
alter the morphology of the fibrils formed. These peptides suggest a potential 
therapeutic approach for treating already formed amyloid deposition in patients 
with T2DM. 
 
4.7   Conclusion 
 
This study investigated the inhibitory effects of IO8, RI-IO8, N1-IO8 and N2-
IO8 on in vitro human amylin fibrillogenesis via TEM experiments. The 
findings demonstrate that IO8, N1-IO8 and N2-IO8 impede amylin amyloid 
formation and aggregation in a concentration-dependent manner. On the other 
hand, RI-IO8 enhanced amylin fibril formation. Further investigation on the 
exact mechanism of action of amylin-inhibitor interactions is required. However 
the results from this study will promote our understanding of the mechanisms of 
amyloid self-assembly and design of potential targets for therapeutics designed 
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Chapter 5 
Peptide Stability Studies  
Peptide stability is an important consideration when developing peptide-based 
molecules as potential drug candidates. Reversed-Phase High-Performance 
Liquid Chromatography (RP-HPLC) is an especially important approach for 
peptide and protein analysis because chromatographs can be tailored to specific 
requirements via changes in mobile phase attributes. Also, RP-HPLC possesses 
high resolution for both similar and dissimilar molecules, attained through its 
variety of chromatographic conditions. In addition, RP-HPLC produces high 
quality repetitive separations as well as high recoveries (Aguilar and Hearn, 
1996; Mant and Hodges, 1996).  RP-HPLC can, however, result in irreversible 
denaturing of protein samples, thus the chances of recovering biologically active 
materials is greatly diminished, although this is not a consideration in the 
present study. The presence of eluted peptides or proteins is most often detected 
by absorbance of ultraviolet (UV) light (typically at 210–220nm) which is 
strongly absorbed by peptide bonds. Some amino acid residues, however, absorb 
light at a different wavelength, for example, the aromatic residues 
phenylalanine, tyrosine and tryptophan absorb UV light between 250–290 nm. 
RP-HPLC is the main mode of HPLC used for separating peptides because it is 
typically more excellent in efficiency and speed compared to other HPLC modes 
(Richards et al., 1994; Oroszlan et al. 1992; Unger, 1990; Henry, 1991; Zhou 
and Hathaway, 2003; Rusnak and Hathaway, 2002; Masaki et al., 1994). In this 
study, RP-HPLC was used to assess the stability of peptides in plasma, and after 
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incubation with various proteolytic enzymes. The chromatographic performance 
of peptides is impacted by the presence of different counter ions, and the pH 
value will also affect peptide charge. Anionic counter-ions such as 
trifluoroacetic acid (TFA) will combine with the positively charged residues of 
the peptide, while cationic counter-ions, such as triethylammonium, have a 
tendency to combine with negatively charged residues of the peptide. The 
solvents employed here all contained 0.01% TFA, which is a commonly used 
condition for RP-HPLC peptide separations. The resolution of the peptides was 
optimized by using an appropriate gradient of increasing concentrations of the 
organic solvent acetonitrile.  
Previous chapters have elucidated the effects of RI-IO8 on amylin aggregation; 
this retro-inverso peptide was designed for the purpose of protecting it from 
proteolytic degradation. Although RI-IO8 showed no inhibitory effect on amylin 
aggregation, its stability was examined in order to verify the effect of retro-
inversion on the susceptibility of this peptide to proteolytic enzyme attack. The 
stability of RI-IO8 was assessed in the presence of different proteolytic 
enzymes, including chymotrypsin and trypsin. RP-HPLC chromatographs (see 
Appendix A) show that RI-IO8 was stable for at least 24 hrs in human plasma, 
and in the presence of these proteolytic enzymes. RP-HPLC was also used to 
examine the stability of HIO8 peptide, derived by substitution of the N-terminal 
and C-terminal arginines of IO8 with homoarginine. As elucidated in Chapter 3, 
HIO8 was designed by replacing these arginine residues in IO8 (N2H-
RGANFLVHGR-NH2) with homoarginine (N2H-Har-GANFLVHG-Har-
NH2) to protect the peptide from trypsin digestion. Chromatographs of HIO8 
(see Appendix A) show that HIO8 is indeed stable to proteolytic degradation by 
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trypsin, but is, however, degraded by other proteases, in particular 
chymotrypsin. Due to this instability, it is not suitable for therapeutic purposes. 
On the other hand, although RI-IO8 is stable towards proteases, it is also 
unsuitable as an amyloid therapeutic, as it appeared to actually stimulate amylin 
aggregation. 
This Chapter is mainly aimed at assessing the stability of the most promising 
inhibitory peptides (IO8, N1-IO8 and N2-IO8) towards proteases, and in plasma. 
The peptides were incubated with each proteolytic enzyme and with plasma at 
37ᵒC at varying time points, as described in the Methods section (2.3.4), and run 
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5.1 The stability of IO8 in the presence of proteolytic enzymes. 
The stability of IO8 peptide was assessed in the presence of various proteolytic 
enzymes, namely chymotrypsin, cathepsin G, trypsin, elastase, thrombin, 
kallikrein, plasmin and factor X. IO8 peptide (100 μl of 100 μM) was incubated 
at 37ᵒC with 1 μl of a 1 mg/ml solution of each enzyme at varying time points of 
0 hr, 1 hr and 3 hrs. The stability of IO8 was examined by injecting 100 μl of 
this peptide solution onto a RP-HPLC system (Dionex GP50 Gradient pump, 
C18 column), followed by elution with a linear gradient of 0–60% acetonitrile 
containing 0.01% TFA over 40 min, at a flow rate of 1 mL/min. IO8, as detected 
by a peak corresponding to intact peptide, was found to be degraded in the 
presence of trypsin and chymotrypsin, as compared to the standard IO8 alone, 
even after an incubation time with enzyme of zero. No new peaks were seen in 
the chromatograms of degraded samples of IO8 (figure 5.1.1 – figure 5.1.8). 
Cathepsin G, elastase, thrombin, kallikrein, plasmin, and factor X, also degraded 
IO8, but not to the same extent as trypsin and chymotrypsin. Thus, IO8 was 
unstable in the presence of proteolytic enzymes. Appendix A shows RP-HPLC 
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Figure 5.1.1:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by trypsin. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with trypsin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were eluted 
with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow rate of 





































































































































Figure 5.1.2:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by chymotrypsin. (A) 
RP-HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of IO8 after incubation with chymotrypsin (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA 









































































































































Figure 5.1.3:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by cathepsin G. (A) 
RP-HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of IO8 after incubation with cathepsin G (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. 
Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 





































































































































Figure 5.1.4:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by Elastase. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with Elastase (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were 
eluted with a linear gradient from 0–60% acetonitrile containing 0.01% TFA over 40 min, at a 






































































































































Figure 5.1.5:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by Thrombin. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with Thrombin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were 
eluted with a linear gradient from 0–60% acetonitrile containing 0.01% TFA over 40 min, at a 




































































































































Figure 5.1.6:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by Kallikrein. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with Kallikrein (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were 
eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow 

































































































































Figure 5.1.7:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by Plasmin. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with Plasmin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were 
eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow 




































































































































Figure 5.1.8:  RP-HPLC profile of 100 μM IO8 and effects of proteolysis by Factor X. (A) RP-
HPLC chromatographs of IO8 in the absence of proteolytic enzymes. RP-HPLC chromatographs 
of IO8 after incubation with Factor X (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs. Peptides were 
eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow 


























































































































 138 | P a g e  
 
5.2 The stability of N1-IO8 in the presence of proteolytic enzymes. 
N1-IO8 was N-methylated at alternate amino acid residues, with the aim of 
protecting it from proteolytic degradation. The positive inhibitory effects of N1-
IO8 on amylin aggregation have been presented previously and here its stability 
to proteolytic degradation was determined, in the presence of various proteolytic 
enzymes, namely chymotrypsin, cathepsin G, trypsin, elastase, thrombin, 
kallikrein, plasmin and factor X. The N1-IO8 peptide was incubated with each 
enzyme, at varying time points, and examined by RP-HPLC, as before. In the 
presence of trypsin and chymotrypsin, no apparent degradation of N1-IO8 was 
observed at up to 3 hrs incubation (figure 5.2.1 B-D; figure 5.2.2 B-D). 
However, after 24 hrs of incubation, the chromatographic peak area of N1-IO8 
was slightly decreased (figure 5.2.1 E; figure 5.2.2 E). Thus, N1-IO8 was 
considerably more stable than IO8 to the effects of these proteolytic enzymes. 
Also, cathepsin G, elastase, thrombin, kallikrein, plasmin and factor X had no 
effect on the chromatographic peak of N1-IO8 (figure 5.2.3-figure 5.2.8), 
suggesting that these proteolytic enzymes had no effect on N1-IO8. Appendix A 




























































                      
Figure 5.2.1:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Trypsin. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Trypsin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min Graphs show absorbance at 220 nm and 



















































































































































                          
Figure 5.2.2:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Chymotrypsin. 
(A) RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Chymotrypsin (B) for 0 hr, (C) for 1 hr, (D) for 
3 hrs (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Graphs show absorbance at 220 nm 
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Figure 5.2.3:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Cathepsin G. 
(A) RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Cathepsin G (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 



























































































































































                                      
Figure 5.2.4:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Elastase. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Elastase (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 


































































































































































Figure 5.2.5:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Thrombin. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Thrombin (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 
































































































































































             
 
Figure 5.2.6:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Kallikrein. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Kallikrein (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 




































































































































































Figure 5.2.7:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Plasmin. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Plasmin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient from 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 

































































































































































Figure 5.2.8:  RP-HPLC profile of 100 μM N1-IO8 and effects of proteolysis by Factor X. (A) 
RP-HPLC chromatographs of N1-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N1-IO8 after incubation with Factor X (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient from 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Graphs show absorbance at 220 nm 
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5.3 The stability of N2-IO8 in the presence of proteolytic enzymes. 
N2-IO8 has been shown to significantly inhibit amylin aggregation. We thus 
assessed the stability of N2-IO8 peptide in the presence of the same proteolytic 
enzymes and under the same conditions as before. No apparent degradation of 
N2-IO8 was observed even after 24 hrs in the presence of trypsin and 
chymotrypsin (figure 5.3.1 B-D; figure 5.3.2 B-D). However, following 24 hrs 
of incubation, the chromatographic peak area of N2-IO8 was slightly decreased 
(figure 5.3.1 E; figure 5.3.2 E). Therefore, N2-IO8 was stable for at least for 24 
hours after incubation in proteolytic enzymes.  Also, cathepsin G, elastase, 
thrombin, kallikrein, plasmin and factor X had no effect on the chromatographic 
peak of N2-IO8 (figure 5.3.3- figure 5.3.8), suggesting that these enzymes did 







































































                                            
Figure 5.3.1:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Trypsin. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Trypsin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 

































































































































































Figure 5.3.2:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Chymotrypsin. 
(A) RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Chymotrypsin (B) for 0 hr, (C) for 1 hr, (D) for 
3 hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 































































































































































Figure 5.3.3:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Cathepsin G. 
(A) RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Cathepsin G (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 























































































































































































            
Figure 5.3.4:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Elastase. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Elastase (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 









































































































































































                            
                                       
Figure 5.3.5:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Thrombin. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Thrombin (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 










































































































































































                                          
Figure 5.3.6:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Kallikrein. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Kallikrein (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 












































































































































































Figure 5.3.7:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Plasmin. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Plasmin (B) for 0 hr, (C) for 1 hr, (D) for 3 hrs, 
(E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 










































































































































































                               
 
Figure 5.3.8:  RP-HPLC profile of 100 μM N2-IO8 and effects of proteolysis by Factor X. (A) 
RP-HPLC chromatographs of N2-IO8 in the absence of proteolytic enzymes. RP-HPLC 
chromatographs of N2-IO8 after incubation with Factor X (B) for 0 hr, (C) for 1 hr, (D) for 3 
hrs, (E) for 24 hrs. Peptides were eluted with a linear gradient of 0–60% acetonitrile containing 
0.01% TFA over 40 min, at a flow rate of 1 mL/min. Graphs show absorbance at 220 nm and 
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5.4   The stability of peptide inhibitors in plasma. 
After examining the effects of proteolytic enzymes on these peptides, we 
assessed the stability of these peptides in the presence of plasma. The stability of 
IO8, N1-IO8 and N2-IO8 peptides were assessed in the presence of 50% human 
plasma. 100 μM of peptides in 50% plasma was incubated at varying time points 
of 0, 3, 24, 48 and 72 hrs at 37ᵒC. The stability of peptides was examined by 
injecting 100μl of peptide solution onto the RP-HPLC system, with the same 
column and elution conditions as before. The IO8 peptide was found to be 
degraded in plasma, even at zero incubation time, while N1-IO8 and N2-IO8 
showed negligible degradation for up to 48 hrs incubation in plasma. However, 
after 72 hrs of incubation, the areas of the chromatographic peaks for N1-IO8 
and N2-IO8 were decreased with percentage recoveries of 7% and 19% 
respectively. This shows that the stability of these peptides was greatly 
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Figure 5.4.1:  RP-HPLC profile of 100 μM IO8 in plasma. (A) RP-HPLC chromatograph of IO8 
in the absence of plasma. RP-HPLC chromatographs of IO8 after incubation with plasma (B) for 
0 hr, (C) for 1 hr, (D) for 24 hrs, (E) for 48 hrs, (F) for 72 hrs. Peptides were eluted with a linear 
gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow rate of 1 mL/min. 

































































































































































































Figure 5.4.2:  RP-HPLC profile of 100 μM N1-IO8 in plasma. (A) RP-HPLC chromatograph of 
N1-IO8 in the absence of plasma. RP-HPLC chromatographs of N1-IO8 after incubation with 
plasma (B) for 0 hr, (C) for 1 hr, (D) for 24 hrs, (E) for 48 hrs, (F) for 72 hrs. Peptides were 
eluted with a linear gradient of 0-60% acetonitrile containing 0.01%TFA over 40 min, at a flow 




























































































































































































Figure 5.4.3:  RP-HPLC profile of 100 μM N2-IO8 in plasma. (A) RP-HPLC chromatograph of 
N2-IO8 in the absence of plasma. RP-HPLC chromatographs of N2-IO8 after incubation with 
plasma (B) for 0 hr, (C) for 1 hr, (D) for 24 hrs, (E) for 48 hrs, (F) for 72 hrs. Peptides were 
eluted with a linear gradient of 0–60% acetonitrile containing 0.01% TFA over 40 min, at a flow 
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5.5  Discussion 
 
Peptides are excellent drug candidates as they have many therapeutic advantages 
over small molecules with respect to target specificity and affinity. However, 
due to poor bioavailability, low solubility, poor membrane permeability and 
most commonly poor proteolytic stability, peptides are not readily used as drugs 
(Giannis and Kolter 1993; McGregor 2008). The degradation of peptides and 
proteins by proteases is a major factor to be considered in the development of 
peptide-based drugs. Peptide-based drugs are easily degraded by proteolytic 
enzymes in vivo resulting in decreased pharmacokinetic properties. Previous 
studies have elucidated strategies for protecting peptides or proteins from 
proteolytic degradation. For example peptide cyclization (Hummel et al.2006; 
Ferrie et al. 2013), PEGylation of peptides (Dasgupta et al. 2002; Werle and 
Bernkop-Schnurch 2006;  Vlieghe et al., 2010), addition of noncanonical amino 
acids like D-amino acids, β-amino acids and N-methylated amino acids (March 
et al., 2012; Sani et al., 2006). These approaches help in enhancing the kinetic 
and thermodynamic properties of peptides and proteins by rendering them 
proteolytically and structurally stable (Dougherty 2000; Frackenpohl et al. 
2001). Other strategies developed to overcome proteolytic cleavage include the 
use of retro-inverso peptides (Fletche and Campbell, 1998), introducing peptide 
bond isosters (Goodman et al., 2002), peptidomimetics (Giannis, 1993) and 
peptoids (Kessler, 1993). Although these approaches have many advantages, 
they can require careful configuration, which can involve difficult syntheses.  
For this study, the N-methylation approach was used to counter the challenges 
of using peptides as a basis for drug development. In some previous studies, 
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mono-N-methylation has been applied to modify the pharmacokinetic properties 
of peptides (Gilon et al., 2002). Multiple N-methylation has sometimes been 
used due to the challenges with synthesis and risk of losing activity associated 
with mono-N-methylation (Holladay et al., 1994; Teixido et al., 2005). Here, the 
N-methylated peptides (N1-IO8 and N2-IO8) were assessed for their stability in 
the presence of proteolytic enzymes and in plasma through analytical RP-HPLC 
compared to the unmodified peptide IO8. HPLC is a well-recognized, efficient, 
sensitive and reproducible approach for analyzing peptide cleavage products and 
reactions (Ferrie et al., 2013; Hua and Huang, 2010). The degradation behaviour 
of IO8 was assessed in the presence of various proteolytic enzymes (table 5.1). 
IO8 was found to be very unstable in the presence of trypsin and chymotrypsin, 
and was completely degraded by these enzymes after 3 hrs of incubation. In the 
presence of cathepsin G, elastase, kallikrein, plasmin and thrombin, IO8 was not 
completely degraded after 3 hrs, although the peak area was decreased. The 
results obtained on the stability of IO8 suggest that this peptide-based drug must 
be protected from proteolytic degradation. No new peaks were seen in the 
chromatograms of degraded samples of IO8 (figure 5.1.1 – figure 5.1.8) 
suggesting that the proteolytic fragments are not resolved by this RP-HPLC 
system. IO8 was also completely degraded in plasma, which is not surprising 
since this would contain trypsin and chymotrypsin activity (Suzuki et al., 1990). 
Upon subjecting IO8 (H2N-RGANFLVHGR-NH2) to an ExPasy program, 
PeptideCutter; IO8 was cleaved at positon 5 (F) by high specificity 
chymotrypsin and positions 5, 6, 8 (F, L, H) by low specificity chymotrypsin, 
while trypsin cleaves IO8 at positions 1 and 9. Other enzymes that cleave IO8 
not used in this study are Arg-C proteinase, clostripain, proteinase K, pepsin and 
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thermolysin. These results are consistent with our RP-HPLC data and suggest 
that these enzymes do not have high activity for the amino acid sequence present 
in IO8, with the exception of trypsin and chymotrypsin. Also for confirmatory 
purposes, RI-IO8 (Ac-rGhvlfnaGr-NH2) and HIO8 (H2N-Har-GANFLVHG-
Har-NH2) were also analysed for stability using RP-HPLC. The results confirm 
that retro-inversion blocks recognition of this peptide by proteolytic enzymes, 
thus protecting it from proteolytic degradation (see data in Appendix A). The 
RP-HPLC results show that RI-IO8 was stable in the presence of chymotrypsin 
and trypsin, unlike IO8 (Appendix A). However, it should be noted that 
although we successfully protected IO8 from proteolytic degradation by the 
retro-inverso method, our retro-inverso peptide was ineffective at inhibiting the 
aggregation of human amylin, as described in previous chapters. Thus another 
approach for stabilizing IO8 was considered. RI-IO8 (Ac-rGhvlfnaGr-NH2) 
could not be analyzed using the ExPasy PeptideCutter as this peptide is retro-
inverted, with L-amino acids replaced by D- amino acids. The next step in 
stabilising IO8 was by targeting individual residues in the sequence and 
protecting them from proteolytic degradation by substituting with other amino 
acid analogues. Integrating non-natural amino acids to peptides is a key strategy 
in increasing the bioavailability of pharmacologically active peptides. Firstly, 
we replaced the two arginines in IO8 with Homoarginine. Our data showed that 
the replacement of these arginines (in IO8; H2N-RGANFLVHGR-NH2) with 
Homoarginine (in HIO8; H2N-HarGANFLVHGHaR-NH2) rendered HIO8 
resistant to proteolytic degradation by trypsin (Appendix A). Homoarginine is 
an unnatural analogue of arginine, and is not recognised by trypsin (Atkinson et 
al., 1999). The HIO8 peptide was, however, still susceptible to cleavage by 
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chymotrypsin (Appendix A), which selectively causes hydrolysis of peptide 
bonds on the C-terminal side of tyrosine, phenylalanine, tryptophan and leucine. 
Protection of the ‘FL’ residues in HIO8 would therefore be required to further 
develop this peptide inhibitor as a drug. A more suitable approach to protecting 
IO8 from proteolytic degradation was thought to be N-methylation of alternate 
amino acid residues, leading to the development of N1-IO8 (H2N-R-G-Am-N-
Fm-L-Vm-H-G-R-NH2) which was methylated at residues A, F and V; and N2-
IO8 (H2N-R-G-A-Nm-F-Lm-V-Hm-G-R-NH2), which was methylated at 
residues N, L and H. N-methylation, which is the methylation of nitrogen atoms, 
is one of the most significant chemical modifications to control biological 
functions. N1-IO8 (figure 5.2.1 - 5.2.8) and N2-IO8 (figure 5.3.1 - 5.3.8) were 
protected from proteolytic degradation by trypsin, chymotrypsin and other 
enzymes including cathepsin G, elastase, thrombin, kallikrein, plasmin and 
factor X. This confirms that N-methylation of this peptide renders it resistant to 
proteolytic degradation. N1-IO8 (figure 5.4.2) and N2- IO8 (figure 5.4.3) were 
also found to be stable in plasma for at least 48 hrs (Appendix B). The 
chromatographic peaks for these peptides, however, did decrease after 72 hrs. 
Previous studies have elucidated the impact of N-methylation on the activity, 
stability and structure of biologically active peptides. Research has shown that 
multiple N-methylation significantly improves the oral bioavailability and 
receptor subtype selectivity of some peptides (Biron et al., 2008; Chatterjee et 
al., 2007). Recent research has also proved that N-methylation remarkably 
improves the pharmacokinetic profile of drugs (Di Gioia et al., 2016). This is 
supported by research which showed that N-methylation of a cyclopeptidic 
somatostatin analog cyclo (-PFwKTF-) peptide, improved the metabolic 
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stability, intestinal permeability and bioavailability of the peptide (Chatterjee et 
al., 2008).  Many peptides are metabolically unstable due to their short plasma 
half-life. The results presented here show that N- methylation can remarkably 




This present study presents a systematic investigation of the stability of the 
different peptides under investigation against degradation by proteolytic 
enzymes and in plasma. The main aim was to develop proteolytically stable 
peptides which have therapeutic relevance. Five peptides were systematically 
characterised for their stability towards nine different proteolytic enzymes, as 
well as in plasma.  The IO8 peptide was immediately degraded by proteases and 
was not stable in plasma. The substitution of the arginines with homoarginine in 
HIO8 led to its protection from degradation by trypsin, although HIO8 was still 
degraded by other proteolytic enzymes. RI-IO8, with reversal of the sequence 
and replacement of L-amino acids with D-amino acids, greatly improved 
stability towards proteases, confirming that retro-inversion of peptides can 
completely alter their proteolytic stability. Further investigation demonstrated 
that N-methylation also enhances the resistance of these peptides to degradation 
by proteases. NI-IO8 and N2-IO8 showed excellent stability in plasma and in 
the presence of proteolytic enzymes. N-methylation is an important approach for 
the development of peptide-based drugs, with marked improvement in their 
pharmacokinetic properties. 
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Chapter 6   
 
Cell based Studies 
 
 
Proteins are able to form a variety of insoluble amorphous or fibrillar 
aggregates. Amylin forms β sheet fibres (Serpell et al., 2000; Luca et al., 2007). 
A number of studies have linked the cytotoxicity of amylin with the oligomers 
that form during the early stages of the aggregation process, rather than the 
mature amyloid fibrils (Lin et al., 2007; Haataja et al., 2008). Therefore, the 
inhibition of amylin aggregation at the early stage of amyloid formation could 
be a promising approach to decrease islet cell disruption in T2DM as well as in 
other amyloidogenic diseases (Necula et al., 2007). The latter would include 
Alzheimer’s disease, where aggregated proteins of Tau and Amyloid beta (Aβ) 
play key roles in disease pathogenesis; and Parkinson’s disease, where 
aggregated α-synuclein plays a key role in disease pathogenesis (Glenner et al., 
1984; Iwai et al., 1995). This approach seems to have considerable potential as 
some inhibitors of Aβ and Tau aggregation have already reached clinical trials 
(Abian et al., 2013; Lopez et al., 2012; Conesa et al., 2012). On the other hand, 
the majority of peptide-based drugs are not adequately taken up by cells and this 
is a major draw-back in therapeutic development. Previous Chapters of this 
thesis have described peptide-based inhibitors of amylin aggregation. Here, the 
CellTiter 96 aqueous one solution cell proliferation (MTS) and the CytoTox-
ONE Homogeneous Membrane Integrity Assay also known as lactate 
dehydrogenase (LDH) assay (described in Methods sections 2.5.3 and 2.5.5) 
were used to determine the ability of these peptides to protect PANC-1 Human 
pancreatic 1.4E7 (ECACC 10070102) insulin-secreting cells from the toxicity of 
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human amylin in culture. MTS is a colorimetric technique that determines the 
number of viable cells by measuring NAD(P)H-dependent cellular 
oxidoreductase enzyme activity. The LDH enzyme is said to be stable and is 
found in all cell types and is quickly discharged into the cell culture medium 
following disruption of the plasma membrane on cell damage. The LDH 
released into the culture medium results in a higher fluorescent signal, indicating 
a greater number of nonviable cells. The ability of the inhibitory peptides to 
penetrate across the cell membrane was also determined by attaching the 
peptides to a fluorescent dye (Alexa fluor 488) and examining cells following 
exposure to fluorescent peptides by using confocal microscopy.  
 
A one-way between samples ANOVA was conducted to compare the viability of 
human pancreatic PANC-1 β cells in the presence of human amylin, human 
amylin plus (+) peptide inhibitors, no amylin, cells only and peptide only 
conditions. Significance was recorded at *P<0.05, **P<0.01, ***P<0.001. Post 
hoc comparisons using the Tukey’s post hoc test indicated the significant 
difference between the mean cell viability between human pancreatic PANC-1 β 
cells in the presence of human amylin, human amylin plus (+)  peptide 
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First of all, the toxic effect of freshly prepared human amylin peptide on PANC-
1 human cells was determined. The ability of IO8 peptide to inhibit amylin 
cytotoxicity was then assessed using the MTS assay, with replicates of n = 6. 
Three different experiments were performed with similar results, and the data 
presented in figure 6.1 are from a single experiment, where results show mean 
+/- SEM (n = 6). The effect of amylin alone was investigated by the addition of 
20 μM and 10 μM of freshly prepared amylin to 96 well plates containing 
PANC-1 cells in media. Amylin at 20 μM was significantly cytotoxic to 
untreated PANC-1 cells and reduced cell viability to 41% (figure 6.1). At 10 
μM, amylin reduced cell viability to 90 %. IO8 significantly rescued the cells 
from the toxic effects of amylin when present at both equimolar and 1:4 molar 
ratio of IO8 to amylin as compared to cells treated with amylin alone. The effect 
of inhibitor alone on the cells was also tested. IO8 alone at 20 μM and 5 μM had 
no significant effect on the cells. The total volume of solution in the wells was 



















Figure 6.1:  Cytotoxic effect of amylin in the presence or absence of IO8 peptide on PANC-1 
cells. PANC-1 cells were incubated for 24 hrs with 20 μM and 10 μM human amylin in RPMI-
1640 medium with or without the IO8 peptide, and viability was measured using the MTS cell 
proliferation assay. The results are means +/- SEM, n = 6. One-way ANOVA, Tukey's post hoc 
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6.2 Effect of N1-IO8 on amylin-induced toxicity PANC-1 human pancreatic  
             cells 
 
 
The effect of freshly prepared human amylin peptide on PANC-1 human cells 
was investigated, along with the ability of N1-IO8 peptide to inhibit amylin 
cytotoxicity, using the MTS cell proliferation assay, with the same conditions as 
those described previously. Three different experiments were performed with 
similar results, and the data presented in figure 6.2 (mean +/- SEM, n = 6) are 
from a single experiment. The effect of amylin alone was investigated by the 
addition of 20 μM and 10 μM of freshly prepared amylin to 96 well plates 
containing PANC-1 cells in media. Amylin alone at 20 μM and 10 μM was 
significantly cytotoxic to untreated PANC-1 cells and reduced cell viability to 
35% (figure 6.2) and 63 % respectively. At a molar ratio of 1:1 and 1:4 of N1-
IO8 peptide to amylin, N1-IO8 significantly rescued the cells from the toxic 
effects of amylin when compared to cells treated with amylin alone. In addition, 


















Figure 6.2:  Cytotoxic effect of amylin in the presence or absence of N1-IO8 peptide on PANC-
1 cells. PANC-1 cells were incubated for 24 hrs with 20 μM and 10 μM human amylin in RPMI-
1640 medium with or without the IO8 peptide, and viability was measured using the MTS cell 
proliferation assay. The results are means +/- SEM, n = 6. One-way ANOVA, Tukey's post hoc 
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The ability of N2-IO8 peptide to inhibit amylin cytotoxicity was also assessed 
using the MTS cell proliferation assay, with the same cells and conditions as 
those described previously. The experiment was performed in replicates of n = 
6.  The data presented in figure 6.3 are mean +/- SEM from a single experiment 
(where n = 6) and are representative of 3 different experiments. Amylin at 20 
μM and 10 μM was significantly cytotoxic to untreated PANC-1 cells and 
reduced cell viability to 40% and 61 % respectively. However, at a 1:1 and a 1:4 
molar ratio of N2-IO8 peptide to amylin, N2-IO8 significantly rescued the cells 
from the toxic effects of amylin. In addition, N2-IO8 alone at 20 μM and 5μM 

























Figure 6.3:  Cytotoxic effect of amylin in the presence or absence of N2-IO8 peptide on PANC-
1 cells. PANC-1 cells were incubated for 24 hrs with 20 μM and 10 μM human amylin in RPMI-
1640 medium, with or without the IO8 peptide, and viability was measured using the MTS cell 
proliferation assay. The results are means +/- SEM, n = 6. One-way ANOVA, Tukey's post hoc 







































6.4 LDH analysis of IO8 on amylin-induced toxicity PANC-1 human   
             pancreatic cells 
 
 
The ability of IO8 peptide to inhibit amylin cytotoxicity was also assessed using 
the LDH cytotoxicity assay. Two different experiments were carried out in 
replicates of n = 6. The data presented in figure 6.4 are from a single 
experiment, where results show mean +/- SEM (n = 6). The data show the 
viability of PANC1 human pancreatic cells as measured by LDH assay, after 
exposure to 80, 40, 20, 10, 5 and 2.5 μM of IO8 in the presence of 20 μM 
amylin. The ‘negative control’ bar is the background absorbance without cells. 
The ‘untreated cells control’ bar is the absorbance of cells without any 
intervention. The ‘LDH control’ bar indicates the absorbance of lysed cells. 
Amylin at 20 μM was significantly cytotoxic to untreated PANC-1 cells and 
reduced cell viability as shown by a substantial increase in absorbance (figure 
6.4). At concentrations of 80 μM (4:1 molar ratio peptide to amylin to peptide), 
40 μM (2:1 molar ratio peptide to amylin), 20 μM (1:1 molar ratio peptide to 
amylin), 10 μM (1:2 molar ratio peptide to amylin), 5 μM (1:4 molar ratio 













Figure 6.4:  IO8 inhibits the toxic effects of human amylin on pancreatic islet β cells, as 
measured by LDH assay.  Human amylin at 20 μM was cytotoxic to cells.  IO8 at concentrations 
of 80, 40, 20, 10, 5 and 2.5 μM protected cells from amylin cytotoxicity. The “negative control” 
bar is the background absorbance without cells. The “untreated cells control” bar represents cell 
absorbance without any intervention. The “LDH control” bar represents the absorbance of lysed 
cells. IO8 control is 100 μM of IO8 in cell culture. The results are means+/- SEM, n =6. One-
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6.5  LDH analysis of N1-IO8 on amylin-induced toxicity PANC-1 human   
             pancreatic cells 
 
 
The ability of N1-IO8 peptide to inhibit amylin cytotoxicity was also assessed 
using the LDH assay, using the same cells and conditions as described 
previously. The data presented in figure 6.5 are from a single experiment carried 
out in replicates of n=6 and are representative of two different sets of 
experiments. Results show means +/- SEM (n = 6). The ‘negative control’ bar is 
the background absorbance without cells. The ‘untreated cells control’ bar 
shows the absorbance of cells without treatment. The ‘LDH control’ bar 
indicates the absorbance of lysed cells. Amylin at 20 μM was significantly 
cytotoxic to untreated PANC-1 cells and reduced cell viability as shown by a 
substantial increase in absorbance (figure 6.5). At concentrations of 80 μM (4:1 
molar ratio peptide to amylin to peptide), 40 μM (2:1 molar ratio peptide to 
amylin), 20 μM (1:1 molar ratio peptide to amylin), 10 μM (1:2 molar ratio 
peptide to amylin), 5 μM (1:4 molar ratio peptide to amylin) and 2.5 μM, N1-














Figure 6.5:  N1-IO8 inhibits the toxic effects of human amylin on pancreatic islet β cells, as 
measured by LDH assay.  Human amylin at 20 μM was cytotoxic to cells.  N1-IO8 at 
concentrations of 80, 40, 20, 10, 5 and 2.5 μM protected cells from amylin cytotoxicity. The 
“negative control” bar is the background absorbance without cells. The “untreated cells control” 
bar represents cell absorbance without any intervention. The “LDH control” bar represents the 
absorbance of lysed cells. N1-IO8 control is 100 μM of IO8 in cell culture. The results are 
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6.6  LDH analysis of N2-IO8 on amylin-induced toxicity PANC-1 human    
              pancreatic cells 
 
 
The ability of N2-IO8 peptide to inhibit amylin cytotoxicity was also assessed 
using the LDH assay, with the same conditions as above. The data presented in 
figure 6.6 are from a single experiment being carried out in replicates of n = 6 
and are representative of two separate experiments with similar results. Results 
show mean +/- SEM (n = 6). The ‘negative control’ bar is the background 
absorbance without cells. The ‘untreated cells’ control bar is the absorbance of 
cells without any intervention. The ‘LDH control’ bar indicates the absorbance 
of lysed cells. Amylin at 20 μM was significantly cytotoxic to PANC-1 cells and 
reduced cell viability (figure 6.6). At concentrations of 80 μM (4:1 molar ratio 
peptide to amylin to peptide), 40 μM (2:1 molar ratio peptide to amylin), 20 μM 
(1:1 molar ratio peptide to amylin), 10 μM (1:2 molar ratio peptide to amylin), 5 
μM (1:4 molar ratio peptide to amylin) and 2.5 μM, N2-IO8 significantly 
















Figure 6.6:  N2-IO8 inhibits the toxic effects of human amylin on pancreatic islet β cells, as 
measured by lactate dehydrogenase (LDH) assay.  Human amylin at 20 μM was cytotoxic to 
cells.  N2-IO8 at concentrations of 80, 40, 20, 10, 5 and 2.5 μM protected cells from amylin 
cytotoxicity. The “negative control” bar is the background absorbance without cells.  The 
“untreated cells control” bar represents cell absorbance without any intervention. The “LDH 
control” bar represents the absorbance of lysed cells. N2-IO8 control is 100 μM of IO8 in cell 
culture. The results are means +/- SEM, n = 6. One-way ANOVA, Tukey's post hoc test 
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6.7 Peptide Cell Uptake Experiment 
 
 
In the studies above, it was shown that the introduction of IO8, N1-IO8 and N2-
IO8 was able to reverse the cytotoxic effects of human amylin. In this study, the 
ability of the most potent inhibitory peptides, IO8, N1-IO8 and N2-IO8, to 
penetrate into cultured cells was assessed. 10 μM of Alexa-Fluor 488 
Fluorescein-labelled versions of IO8 (Flu-IO8), N1-IO8 (Flu-N1-IO8) and N2-
IO8 (Flu-N2-IO8) peptides in media were incubated with cells for 10 mins and 
1 hr to assess their ability to penetrate the cell membrane. Flu-IO8, Flu-N1-IO8 
and Flu-N2-IO8 all penetrated the cell membrane in as little as 10 mins, 
although in each case a further increase in green fluorescence was observed after 
incubation for 1 hr. Some auto-fluorescence was observed in all control samples. 
The blue stain seen in all samples is the nucleus counter-stained with DAPI. The 
data below are representative of three different experiments carried out under 
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Figure 6.7:  Confocal microscope images of PANC-1 cells exposed to fluorescently tagged 
peptides. (A) Media only, (B) 10 µM Flu-IO8 for 10 mins, (C) 10 µM Flu-IO8 for 1 hr, (D) 10 
µM Flu-N1-IO8 for 10 mins, (E) 10 µM Flu-N1-IO8 for 10 mins, (F) 10 µM Flu-N2-IO8 for 10 











Given that pro-insulin and pro-amylin are processed together in the same islet 
secretory vesicles, an impaired processing and further hypersecretion of 
immature pro-amylin are likely to occur (Park and Verchere, 2001; Clark et al., 
1993). Elevated levels of secreted amylin and pro-amylin result in the 
accumulation of  islet amyloid deposits which are toxic to pancreatic β cells 
leading to a decrease in β cell mass and subsequently β cell failure (Kogire et 
al., 1991; Westermark and Grimelius, 1973).  β cell depletion, loss of function 
and death are the main features of T2DM (Halban  et al., 2014; Ashcroft and 
Rorsman, 2012) and are associated with the formation of islet amyloid as well as  
inflammation, glucolipotoxicity and cholesterol accumulation (Poitout and 
Robertson, 2002; Halban  et al., 2014; Donath and Shoelson,  2011). The 
deposition of islet amyloid has also been proved to play a part in the failure of 
islet cell transplantation. Studies have revealed the presence of amyloid deposits 
in the transplanted human islets of patients with islet graft failure, and these 
deposits have also been shown to form quickly following islet transplantation 
from humans into nude mice (Westermark  et al., 2012; Westermark et al., 
2011; Udayasankar et al., 2009). These findings are related to a study on mice 
which showed that the formation of islet amyloid precedes hyperglycaemia and 
is linked with the loss of β islet cells.  Further studies have also elucidated that 
amylin aggregation and hyperglycaemia are contributing factors in the 
development of diabetes-associated cardiovascular disease (Despa et al., 2014; 
Gilead and Gazit, 2008). 
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Our results are consistent with previous data and have demonstrated that amylin 
is cytotoxic to pancreatic β cells in both MTS and LDH assays. The IO8 peptide 
inhibited amylin cytotoxicity. In addition, N1-IO8 and N2-IO8 also impeded the 
cytotoxic effects of amylin on human pancreatic islet β cells in culture. It is 
possible that these peptides could be used as part of a therapeutic approach for 
the treatment of amyloid islet cytotoxicity in type 2 diabetic patients.  The 
mechanism by which these peptides interact with amylin in culture is not yet 
known. Our results confirm the association between amylin aggregation and β 
cell death and support a previous study where human amylin decreased β cell 
viability by about 25 - 40 % (Scrocchi et al., 2002), while the incubation of the 
peptide SNNFGA with amylin impeded amylin cell toxicity by 25 – 50 %. 
Although a number of protein based inhibitors have been designed for the 
inhibition of amyloid beta (Aβ), less work has been done on the inhibition of 
amylin amyloid aggregation. In a previous study, segments of amylin sequence 
were inserted into the loop area of a stable IgG variable domain, leading to the 
inhibition of amylin amyloid formation and cytotoxicity (Ladiwala et al., 2012). 
Studies have also shown that the calcium binding protein Nucleobindin 1 
(NUCB1) inhibited amylin fibril formation and cytotoxicity (Gupta et al., 2012). 
Progress has been made with designing inhibitors of amylin aggregation; 
however, more work still needs to be done to develop inhibitors of amylin 
amyloid formation which will also be effective in protecting cells from the 
cytotoxic effects of human amylin. 
 
It has been proposed that amyloid deposition may lead to damage of β cell 
function a long time before β cell death (Porte and Kahn, 2001). Studies have 
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shown that amylin-mediated cell death is through the interaction of amylin 
fibrils with the cell membrane (Lorenzo et al., 1994; Janson et al., 1999). 
Another study proposed that amylin-mediated cell death is through the 
biochemical, morphological and structural alterations associated with apoptosis 
(Saafi et al., 2001). Oxidative stress also plays a key role in cell degeneration 
upon exposure to amyloid toxic aggregates (Sochocka et al., 2013; Butterfield et 
al., 2013) and antioxidant treatments have been found to have protective 
properties against amylin toxicity (Zampagni et al., 2012; Choi et al., 2012). 
Studies on nerve tissue showed that ageing and oxidative stress impacts on cell 
viability and decrease proteasome action and expression levels (Rogers et al., 
2012; Keller et al., 2002) leading to build-up of misfolded protein and 
subsequent damage by reactive oxygen species (ROS) (Fratta et al., 2005). The 
reason behind the production of ROS following protein aggregation, for 
example in Aβ42 (Brunelle and Rauk, 2002), is not fully understood, although 
certain processes are involved. The production of hydrogen peroxide from metal 
ions such as Cu (1) and Fe (II) also lead to oxidative stress (Tabner, 2002; 
Turnbull et al., 2001). Intracellular oxidative stress is typically linked to cell 
membrane disruptions by toxic species alongside a loss of plasma membrane 
protein regulation (Mattson et al., 1999) and/or damage to mitochondrial 
function. The mitochondria play a key role in oxidative stress and apoptosis. The 
neurotoxicity of Aβ is thought to occur through the introduction of Ca2+ to the 
mitochondria of the neurons, resulting in increased membrane permeability (Du 
and Yan, 2010) and subsequent discharge of apoptotic inducers like cytochrome 
c. Both intracellular and extracellular amyloid toxic aggregates damages cell 
functions including cell signalling, synaptic communication with cell membrane 
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mitochondria function, which ultimately leads to apoptotic cell death and 
sometimes to necrosis (Bucciantini et al., 2005; Ross, 2002; Morishima, 2001). 
Although amylin toxicity has been suggested to arise from the disruption of 
membrane integrity (Janson et al., 1999; Trikha and Jeremic, 2011), the main 
cause of cell death associated with amyloid toxicity is not clear. The degree of 
membrane permeabilization by amylin is influenced by several factors including 
pH, lipid to peptide ratio, and ionic strength and increased levels of anionic 
lipids significantly induce amylin membrane interactions (Trikha and Jeremic, 
2011). Studies are currently being carried out on amylin-induced model 
membrane damage. Previous studies have shown that membrane damage occurs 
by a detergent process; however other studies have shown that these membrane 
disruptions occur by pore-like mechanisms (Janson et al., 1999; Bucciantini et 
al., 2005). Further studies have indicated that the process involving fibril growth 
can impact on membrane damage, contrarily; some other studies suggest that β 
sheet formation do not play a role in membrane disruption (Cao et al., 2013; 
Last et al., 2011; Engel et al., 2008; Anguiano et al., 2002). It is likely that a 
combination of processes are involved and the exact mechanism involved is 
determined by the membrane system used (Schlamadinger and Miranker, 2014; 
Brender et al., 2012). It is important to note that the introduction of amylin 
induces a number of toxic effects on a variety of related cells proposing that 
there are other mechanisms of cytotoxicity other than nonspecific membrane 
damage (Law et al., 2010).  
 
The main cause of cell death associated with amyloid toxicity is not clear, 
however, a number of overlapping cellular mechanisms and triggered 
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downstream signalling pathways result in amyloid toxicity.  These comprises of 
both receptor-mediated and non-receptor-mediated mechanisms. Cell membrane 
permeabilization, oxidative stress, membrane damage, Endoplasmic reticulum 
(ER) stress, triggering of cell death signalling pathways and  increased secretion 
of pro-inflammatory cytokines all play a part in amylin toxicity (Bram et al., 
2014;  Gupta and Leahy, 2014; . Park et al., 2012; Saafi et al., 2001; Cooper et 
al., 2010; Zhang et al., 2003). Disputes have however arisen on the role of ER 
stress on amylin-induced toxicity in vivo. Studies on transgenic mice show that 
overexpressing amylin revealed the role of ER stress in mediating amylin-
induced β cell defect. Also, inducing amylin exogenously has been shown to 
trigger ER stress (Gurlo et al., 2010; Casas et al., 2007). Further research has 
also proved that ER defects and ER related protein degradation induce amylin 
toxicity associated with β cell death (Westermark et al., 2011). On the contrary, 
a study on cultured islet cells suggested that increased physiological levels of 
human amylin did not trigger ER stress (Hull et al., 2009). Autophagy disorders 
have been thought to contribute to amyloid protein toxicity. Studies have shown 
that the overexpression of human amylin in islet β cells leads to defects in 
autophagy (Rivera et al., 2011; Gupta et al., 2014). Impeding autophagy 
promotes amylin induced β cell apoptosis while triggering autophagy prevents 
amylin induced cytotoxicity (Rivera et al., 2011; Gupta et al., 2014). Another 
cause of amyloid toxicity could be chronic inflammation as seen in local and 
systemic amyloidosis. Aggregated human amylin stimulate localized 
inflammatory response through the activation of inflammasomes leading to β 
cell defects (Masters et al., 2010; Sheedy et al., 2013). Inflammasomes consist 
of multiproteins that dictate a wide variety of proinflammatory stimuli and 
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release active caspase-1, which triggers cytokines IL-1𝛽 and IL-18. IL-1𝛽 is 
believed to directly impact on amylin-induced β cell death and defects (Masters 
et al., 2010;  Sheedy et al., 2013). The development of an effective therapeutic 
against the toxicity of amyloid will therefore involve more insight into the main 
characteristics of cell/tissue degeneration when they come in contact with toxic 
amyloid.  
 
Regardless of the great potential of using proteins or peptides as treatments for 
various diseases, it is important that these molecules are capable of penetrating 
the cell membrane into their target cells. The results presented here show that 
the peptides under study were taken up by live human pancreatic PANC-1 cells 
when added exogenously. Fluorescently-labelled IO8, N1-IO8 and N2-IO8 were 
used for these experiments. Confocal images of PANC-1 cells exposed to 1 μM 
of Flu-IO8, N1-Flu-IO8 or N2-Flu-IO8 for 10 mins revealed an accumulation of 
fluorescence inside the cells (figure 6. 3.1). Our peptides demonstrated rapid 
entry into cultured cells, suggesting that they possess transducing properties. 
The mechanism by which these cells absorb the peptide is not fully understood 
but it is probably by protein transduction. Cellular uptake is regulated by 
protein-transduction domains. Although our peptides were not attached to a 
peptide delivery system also known as cell-penetrating peptides (CPPs), they 
still transverse the cell membrane. However, an effective peptide delivery 
system could be necessary to enhance cellular uptake and give high cell 
specificity. It is pharmacologically important that efficient delivery systems are 
developed to allow effective uptake and accurate drug targeting (Veldhoen et 
al., 2008; Torchilin, 2008). While great progress has been made, there is still an 
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apparent need for effective protein delivery systems which protect proteins from 
degradation, show excellent biological activity, possess excellent biosafety 
profile for in vivo therapeutic use, efficiently internalize in individual target 
cells, tissues and organs, and are non-cytotoxic (Heitz et al., 2009). Despite the 
fact that the mechanism of cellular uptake by CPPs is highly disputed, they are 
still widely used to convey the delivery of pharmacological molecules 
intracellularly (Dietz et al., 2004; Temsamani and Vidal, 2004) since they are 
non-cytotoxic and possess excellent cell specificity (Patel et al., 2007). Most 
biomolecules including antisense oligonucleotides (Astriab-Fischer et al., 2002), 
liposomes (Torchilin et al., 2001), peptide nucleic acids (Pooga et al., 1998) and 
nanoparticles (Lewin et al., 2000) have been delivered by the protein 
transduction process. In addition, various proteins like HIV-1 Tat and HSV-1 
VP22 have been proven to cross the cell membrane through the process of 
protein transduction with their biological activity conserved as they reach the 
nucleus (Prochiantz, 2000, Green and Loewenstein, 1998). Thus, conjugation 
therapeutic molecules with CPPs may be an important approach to enhance the 













Major advancement has been made in amylin amyloid formation research, 
however a lot of work is still required to understand the nature of toxic species, 
verify amyloid initiation sites in vivo, unravel the mechanism of amylin amyloid 
formation and β cell death in vivo and in vitro, which play a vital role in amylin 
toxicity. There are currently no clinically approved inhibitors of amylin 
cytotoxicity and only a few drug-like inhibitors of amylin aggregation have been 
published, and so more work in this area is required. The peptides under 
development here have been shown to penetrate into human pancreatic islet 
cells, and also to protect islet cells from the toxicity of human amylin; the 
peptides on their own were not toxic to the cells. These findings hold huge 
potential for the development of these inhibitors as peptide-based therapeutics 
and will play a key role in the development of new peptide sequences for the 
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Chapter 7 




T2DM is the most widespread endocrine disorder (Hossain et al., 2007), 
characterised by a reduction in β cell mass, insulin resistance , and the presence 
of amyloid deposits in the pancreas, the main component being human islet 
amyloid polypeptide otherwise called amylin (Westermark et al., 1987). 
Amyloid is a particular type of protein aggregate described by characteristic 
fibrillar morphology, initiated by structure-specific molecular interactions in an 
ordered pattern (Cornwell et al., 1995). Studies have shown that amyloid 
formation occurs through a nucleation-dependent aggregation process (Harper 
and Lansbury, 1997). Nucleation-dependent aggregation is different from 
disordered aggregation as it is initiated from the production of a defined 
intermediate, the aggregation nucleus, through the addition of monomeric 
species (Harper and Lansbury, 1997). The monomers are the smallest stable 
species. However, the smaller dimers and oligomers have been shown to be 
extremely unstable. The molecular basis of protein amyloidogenicity is not fully 
understood and the classification of the mechanisms that initiate the 
development of these pathological deposits in tissues which are the hallmark of 
numerous life threatening diseases are presently being investigated. A number of 
factors influence protein fibrillation including, electrostatic charge, protein 
hydrophobicity and the pedisposition to form secondary structures for example, 
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α-helix and β-sheet (DuBay et al., 2004; Chiti et al., 2003), as well as pH and 
ionic strength (Chiti et al., 2003; Tartaglia, et al., 2008).  In addition, 
fluctuations in glycosylation levels may increase the tendency of peptide 
aggregation (Makimattila et al., 2000). Also, in vivo alterations in pH, changes 
in amylin concentration and changes in molecular binding stimulate formation 
of amyloid fibrils by changing the configuration of amylin from a random coil to 
a β sheet structure (Hoopener et al., 1999). Partial enzymatic processing of 
amylin from its precursor pro-amylin have been observed in type 2 diabetes, and 
may possibly stimulate the “seeding” of amyloid fibrils (Higham et al., 2000). 
Studies have shown that the overproduction of amylin in transgenic mice as well 
as other factors, including increased fat in mouse chow (Verchere et al., 1996) 
or genetic traits that promote obesity and insulin resistance in mice (Soeller et 
al., 1998; Hoppener et al., 1999), increase amyloid formation. Further studies 
have shown that homozygous transgenic mice resulted in increased production 
of amylin enough for the formation of amyloid (Janson et al., 1996; Hoppener et 
al., 1999). However, other studies have shown that overproduction of amylin is 
not necessary for the development of amyloid in mouse models (Hoppener et al., 
1993; Verchere et al., 1997). These studies suggest that there is a complex 
association between the overproduction of amylin, amyloid formation and the 
pathology of T2DM.  
 
The 20-29 segment of amylin is regarded as the amyloidogenic region of the 
peptide and has been associated with the formation of fibrils (Moriarty and 
Raleigh, 1999; Westermark et al., 1990). Although residues 20-29 of amylin 
play a crucial role in the formation of fibrils, other residues may also be 
 194 | P a g e  
 
involved in fibril formation. A study suggested that the amylin 14-20 fragment 
forms amyloid fibrils (Sawaya et al., 2007). Another study reported the role of 
aromatic-aromatic interactions in fibril formation (Azriel and Gazit, 2001). 
However, a study on 3 human amylin aromatic residues at positions 15, 23, and 
37 suggested that aromatic residues are not important in the formation of amylin 
fibrils, as triple mutants lacking aromatic residues were seen to form fibrils in 
vitro. Moreover, this substitution reduced the rate of fibril formation and 
modified the propensity of amylin to aggregate. Further research reported that 
amylin amyloidogenic regions spans the 30-37 residues of the C-terminal region 
and in aqueous media, both human and rodent amylin 30-37 are likely to form 
amyloid fibrils (Nilsson and Raleigh, 1999). Another amyloidogenic region 
spanning residues 8-20 has also been reported to form β sheet fibrils which are 
structurally identical to in vivo amyloid (Jaikaran et al., 2001). The reason for 
these differences is not fully understood. This is, however, likely to result from 
the use of dissimilar techniques in studying amyloid fibrillization.  
 
Although several amyloidogenic regions of human amylin have been identified, 
this study was concerned with developing peptide inhibitors from the binding 
region of human amylin corresponding to amino acids 11-20 (with sequence 
RLANFLVHSS), and their impact on fibrillogenesis of the full-length human 
amylin 1–37 peptide were assessed. It has been suggested that this region is 
responsible for the binding of two misfolded amylin molecules, after which they 
begin to aggregate (Mazor et al., 2002). Thus, if we are able to prevent two 
amylin molecules from binding, we may be able to prevent their aggregation. 
We initially generated 7 peptide inhibitors to target the binding region of human 
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amylin 1–37, and investigated the ability of each of these peptides to influence 
fibril formation. The peptide fragments were derived from human amylin 11-20 
(IO1), as well as pentapeptides derived from human amylin 11-15 (IO2), 12-16 
(IO3), 13-17 (IO4), 14-18 (IO5), 15-19 (IO6) and 16-20 (IO7). These peptides 
were assessed using the Th-T assay. The Th-T fluorescence assay is a key 
indicator of the presence of amyloid fibrils, as it interacts with the β-pleated 
sheet-containing amyloid fibrils leading to increase in Th-T fluorescence 
(Biancalana and Koide, 2010). IO2, IO3, IO4, IO5 and IO7 peptides showed 
some inhibitory effects on the aggregation of full length human amylin 1-37; 
however, IO1 and IO6 showed no significant effect. In addition, IO1, IO3, IO4, 
IO5 and IO7 significantly stimulated amylin aggregation at low concentrations 
(figure 3.1.1). Data from IO1, IO2, IO6 and IO7 showed unusual curves quite 
unlike the others, revealing a strange hump along the curve. It is likely that these 
peptides are not properly bound to the full length amylin sequence at the 
concentrations where the hump appears. It is also possible that the peptides 
could be insoluble to some extent at these higher concentrations (figure 3.1.1). 
While these peptides did not appear to completely inhibit fibril formation, it is 
likely that the amyloid fibrils has been inhibited but the aggregates present have 
been converted into another form, such as amorphous aggregates, which are still 
Th-T positive, but not fibrillar in nature, giving rise to the Th-T signal still 
observed. IO4 and IO5 showed more promising results compared to other 
peptides (figure 3.1.1), but they failed to reduce aggregation to less than 50%. 
IO4 and IO5 were thus considered for further investigation. These results are 
consistent with those of other studies and suggest that peptide fragments as well 
as human amylin derivatives are able to inhibit fibril formation in vitro. 
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However, new inhibitors are desired as many of the reported inhibitors only 
work when they are in molar excess (Kapoor et al., 2010; Yan et al., 2006; 
Meng, et al., 2010; Saraogi et al., 2010). A study on peptide fragments 
corresponding to human amylin residues 20-25 (SNNFGA) and human amylin 
residues 24-29 (GAILSS) showed strong inhibitory effect on β-sheet transition 
and amyloid aggregation. However, this inhibition was achieved at 10:1 and 
20:1 molar ratios of peptide to amylin, where the peptide is in molar excess 
compared to amylin, and although SNNFGA significantly improved cell 
viability by 25%, GAILSS had no significant effect on amylin-induced 
cytotoxicity (Scrocchi et al., 2002). Another study showed that engineered, 
soluble forms of the human Ca2+ binding protein nucleobindin 1 (NUCB1) 
impedes the aggregation of amylin at substoichiometric levels and  
disaggregates preformed fibrils, however, this anti-amyloidogenic  effect was 
only seen in the absence of Ca2+ (Gupta et al., 2012).  
Given the encouraging results from this study, further experiments were carried 
out on the IO4 and IO5 peptides. The IO4 and IO5 peptides had their amino acid 
sequences combined to give IO8 (amino acid sequence: -2HN-RGANFLVHGR-
NH2). Considering that retro-inverted peptides are more stable to proteolysis, the 
retro-inverso form of IO8 (RI-IO8: Ac-rGhvlfnaGr-NH2) was derived by 
sequence reversal and substitution of L- with D- amino acids. The Th-T assay 
was used to monitor the effects of IO8 and RI-IO8 on amylin aggregation. The 
IO8 peptide showed a strong inhibitory effect on amylin aggregation (figure 
3.1.2). Also, IO8 did not appear to stimulate amylin aggregation at low 
concentrations. Congo red experiments also confirmed the inhibitory effect of 
IO8 on amylin aggregation (figure 3.2.1). The relative density and morphology 
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of fibrils in the presence of IO8 were also visualized using negative stain TEM. 
No fibrils were observed at concentrations of 100 μM, 50 μM and 25 μM of IO8 
(figure 4.1), relative to 25 µM amylin. However, at a lower concentration of 5 
μM IO8, fibrils were formed but had an altered morphology; they were less 
compact. IO8 also disaggregated pre-existing amylin fibrils (figure 4.5.1), with a 
characteristic less dense fibril mesh being observed. These results support the 
Th-T and Congo red data, and suggest that IO8 is a strong inhibitor of amylin 
fibril formation. However, RP-HPLC stability analysis proved that IO8 was 
unstable to proteolytic degradation and in plasma (figure 5.1.1). It comes with 
no surprise that IO8 was completely degraded both in plasma and in the 
presence of proteolytic enzymes as L-analogs of peptides are quickly 
metabolized (Kellock et al., 2016). On the other hand, RI-IO8 had no inhibitory 
effect on amylin aggregation, except at 100 μM (4:1 molar ratio RI-IO8 to 
amylin), where the peptide reduced amylin aggregation to 77% of a non-
inhibited control. At lower concentrations (figure 3.1.2) RI-IO8 significantly 
stimulated amylin aggregation. This finding was unexpected and suggests that 
RI-IO8 does not bind in the same way to human amylin as IO8, resulting in its 
non-inhibitory effect and facilitation of aggregation at low concentrations. The 
Congo red experiments also confirmed the non-inhibitory effect of RI-IO8 on 
amylin aggregation (figure 3.2.2). This was further supported by TEM studies 
where RI-IO8 greatly increased amylin fibril formation (figure 4.2). A 
characteristic denser fibril mesh was observed in the presence of RI-IO8. Unlike 
IO8, RI-IO8 did not disaggregate pre-existing amylin fibrils (figure 4.5.2). This 
result with RI-IO8 is contrary to a previous study, where the retro-inverso 
peptide RI-OR2 developed against amyloid beta (Aβ) oligomers in Alzheimer’s 
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disease was shown to significantly inhibit fibril formation and rescue cells from 
the toxic effects of Aβ, and was also shown to be highly resistant to proteolysis 
(Taylor et al., 2010). Since the retro-inverso peptide RI-IO8 did not inhibit 
amylin aggregation, other methods for making peptides resistant to proteolysis, 
such as N-methylation, were considered.  
The results presented here indicate that IO8 is the most potent inhibitor of 
human amylin aggregation tested so far, and this is highlighted by comparison 
of the effects of IO8 on amylin aggregation with ANFLVH (Potter et al., 2009) 
and NMeG24 NMeI26 (Sellin et al., 2010) peptides, which have been reported 
to inhibit amylin fibril formation in the literature. NMeG24 NMeI26 is a 
modified form of amylin 22-27 fragment (NFGAIL), with N-methylation at the 
amide bonds G24 and I26 (Sellin et al., 2010). ANFLVH could not be dissolved 
in aqueous solution and thus could not be used for the experiment. It is 
interesting to note that the peptide ANFLVH reported in the literature has a 
similar amino acid sequence to our IO8 peptide inhibitor (RGANFLVHGR-NH2, 
the similar sequence is underlined). However, our peptide possess a cationic 
Arginine (Arg) added at both N- and C-termini via a Glycine (Gly) spacer. The 
insolubility observed with the ANFLVH peptide provides further support for the 
rationale of placing a cationic Arg at the N- and C-termini of the peptides under 
study here, via a Gly spacer. The Arg and Gly residues help to facilitate the 
interaction between amylin and the peptide inhibitors, as well as promote the 
solubility of the peptides, while preventing them from self-assembly. This 
finding is consistent with that of Taylor et al. (2010) who found that Arg and 
Gly residues facilitate peptide solubility and prevent self-assembly. Although 
the ANFLVH peptide has been reported to inhibit amylin fibril formation in 
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vitro and to significantly increase cell viability in human islet cultures (Potter et 
al., 2009), it should be noted that these effects were observed at equimolar and 
20 fold molar excess concentrations of the peptide. In addition, at even higher 
concentrations of ANFLVH, incomplete inhibition of islet amyloid formation 
was observed, as some deposits were still seen in islets at high microscopic 
magnification. Furthermore, ANFLVH was reported to disaggregate pre-existing 
amyloid fibres and reduced amyloid load to ~33% compared to untreated 
cultures only when the peptide was in 10 and 20 fold molar excess of amylin 
(Potter et al., 2009). The IO8 peptide inhibits amylin aggregation and 
disaggregates pre-existing amylin fibrils (figure 4.5.1) at much lower 
concentrations than the ANFLVH peptide. It should be noted that, for an 
inhibitor to be an effective drug it should be able to work at low concentrations, 
as high concentrations may not be biologically tolerable and may also be toxic 
to cells. The IO8 peptide was also assessed alongside NMeG24 NMeI26. IO8 
showed strong inhibitory effects on amylin aggregation. In contrast to the study 
reported in the literature (Sellin et al., 2010), no evidence of inhibition of amylin 
aggregation was observed upon addition of NMeG24 NMeI26. NMeG24 
NMeI26 was also seen to significantly promote fibril formation at lower 
concentrations (figure 3.1.3). It is possible that NMeG24 NMeI26 was unable to 
bind to full length amylin and was thus incapable of exerting inhibitory effects 
on amylin, as it is derived from the amyloidogenic region (NFGAIL) of human 
amylin and not the binding region. To confirm this, we designed another peptide 
from the amyloidogenic region of human amylin (amyloidogenic sequence 
underlined: H2N-RGNFGAILSGR-NH2). ThT studies showed that this peptide 
did not inhibit amylin aggregation, but rather stimulated aggregation (figure 
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3.1.4) at higher concentrations. This finding is in agreement with Andreasen et 
al. (2012) who showed that two human amylin derived peptides with sequence 
NFGAIL and SNNFGAILSS were unable to inhibit the fibrillation of human 
amylin, suggesting their inability to bind to existing fibril surfaces. Another 
finding showed that NFGAIL causes an immediate conformational alteration to 
β-sheet of amylin, suggesting that NFGAIL, rather than having inhibitory 
properties, promotes fibril formation (Scrocchi et al., 2002). With IO8 being the 
most promising peptide inhibitor, it was stabilised from proteolytic degradation 
through N-methylation of alternate amino acid residues, to give N1-IO8 (H2N-
R-G-Am-N-Fm-L-Vm-H-G-R-NH2) and N2-IO8 (H2N-R-G-A-Nm-F-Lm-V-
Hm-G-R-NH2). Th-T and Congo red results showed that both NI-IO8 and N2-
IO8 significantly inhibited amylin aggregation (figure 3.1.6, figure 3.2.2, figure 
3.2.3). At 100 μM, N1-IO8 and N2-IO8 decreased amylin aggregation to 15% 
and 12%, respectively, compared to amylin alone. TEM studies also confirmed 
that NI-IO8 at 100 μM, 50 μM and 25 μM, completely impeded the formation of 
amylin fibrils, but thread-like amyloid fibrils were observed in the presence of 5 
μM N1-IO8 (figure 4.3). In addition, N2-IO8 showed completed inhibition of 
amylin fibrils at concentrations of 100 μM, 50 μM, 25 μM, and 5 μM (figure 
4.4). N1-IO8 at 100 μM completely disaggregated pre-existing amylin fibres and 
at 50 μM (figure 4.5.3), partially disaggregated pre-existing amylin fibres, while 
N2-IO8 completely disaggregated pre-existing amylin fibres at both 100 μM and 
50 μM (figure 4.5.4). N1-IO8 (figure 5.2.1- figure 5.2.8) and N2-IO8 (figure 
5.3.1- figure 5.3.8) were also stable against proteolytic degradation, and in 
plasma, for at least 48 hrs. N-methylated (NMe) derivatives of Aβ (25–35) have 
been reported to impede the aggregation of fibrils and prevent cytotoxicity, and 
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studies have suggested that analogues of amylin with amide bonds methylation 
do not form fibrils (Yan et al., 2007; Yan et al., 2006). Another peptide inhibitor 
designed to target the amyloidogenic region of human amylin showed ~50% 
decrease in amylin-induced toxicity (Scrocchi et al., 2002).  
Given the significant inhibitory effect of IO8 on amylin fibril formation, we 
investigated the effect of amylin on PANC-1 human pancreatic islet β cells and 
the ability of the IO8 peptide to inhibit amylin-induced cytotoxicity using the 
CellTiter 96 aqueous one solution cell proliferation (MTS) and the CytoTox-
ONE Homogeneous Membrane Integrity (LDH) assays. In both experiments, 
externally adding human amylin to PANC-1 cells was significantly cytotoxic to 
the cells, resulting in decreased cell viability. However, the addition of IO8 
(figure 6.1, figure 6.4), N1-IO8 (figure 6.2, figure 6.5) and N2-IO8 (figure 6.3, 
figure 6.6) significantly protected PANC-1 cells from the cytotoxic effects of 
human amylin. The toxic effect of amylin was also shown to be concentration 
dependent, with increased toxicity observed at a higher concentration. These 
findings support the idea that amylin and insulin protein levels are maintained at 
a molar ratio of ~1:100 of amylin to insulin in normal pancreatic β cells. 
However, in diseases, it is maintained at a molar ratio of ~1:20 of amylin to 
insulin (Knight et al., 2008; Hull et al., 2004). The increase in amylin secretion 
in diseased conditions may result in increases in cytotoxicity. Deposition of 
amyloid plaques in pancreatic β cells have been observed in humans with 
T2DM. (Chiti and Dobson, 2006). Amyloid deposits in the pancreas have been 
shown to result in the apoptosis of pancreatic β cells (Hoppener et al., 2000) and 
the interaction of amylin with lipid membranes promote fibril formation (Engel 
et al., 2006).  Studies have shown that human amylin forms channel like pores 
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which penetrate the membrane and alter barrier properties (Quist et al., 2005), 
but the non-amyloidogenic mouse amylin does not form pores in membrane 
(Mirzabekov et al., 1996). However, studies on human neuroblastoma cells 
showed that the addition of oligomeric amylin to cells loaded with a fluorescent 
dye resulted in the cellular permeability of the dye (Demuro et al., 2005). This 
suggests that when amylin is added to the extracellular environment, it is 
cytotoxic through general disruption events and not by a given ion pore. Since 
human amylin is situated at cellular membranes in the pancreatic islets, and is 
associated with alteration of the membrane structure, it is likely that the 
membrane may be a target for cytotoxic amylin, resulting in the death of insulin 
producing β cells (Janson et al., 1999; Saafi et al., 2001).  This is supported by 
Huang et al. (2007) who reported that the main targets for cytotoxic amylin are 
the Endoplasmic Reticulum (ER) and mitochondrial membranes leading to ER 
stress and β-cell apoptosis. In addition, small human amylin aggregates have 
been proven to be cytotoxic in cell cultures, and these aggregates have been 
shown to alter the membrane structure (Janson et al., 1999). Studies have shown 
that amylin oligomers form pores in membrane, permitting small sized 
molecules to pass through the membrane; however, upon maturation of the 
fibrils, the pores disappeared and membrane damage was minimized (Anguiano 
et al., 2002; Porat et al., 2003). Mature fibrils have been found to be less toxic to 
cells and they produced less membrane interruption than oligomeric amylin 
(Demuro et al., 2005; Konarkowska et al., 2006). Studies have however 
hypothesized that amylin-induced membrane disruption is not triggered by a 
given amylin specie, for example oligomers, but through the process of fibril 
development at the cell membrane (Knight et al., 2006; Lopes et al., 2007). 
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Research has also suggested that amylin fibril growth at cell membranes gives 
rise to membrane impairment. Monomeric amylin is likely to interact with 
membrane, as it has a high propensity to attach to phospholipid monolayers 
(Engel et al., 2006; Knight et al., 2006; Lopes et al., 2007). This is supported by 
another study on Alzheimer’s disease-related Aβ, which suggest that the process 
of amyloid fibrillogenesis is accountable for membrane impairment and not 
specifically given species (Wogulis et al., 2005). The exact mechanism of action 
by which amylin oligomers disrupts membranes is however not fully 
understood. 
 
Studies are being carried out to develop molecules that inhibit amylin-induced 
β-cell death through the inhibition of amylin fibril formation. A number of these 
inhibitors are synthetically modified human amylin fragments which do not 
form fibrils, but are capable of binding to the full length human amylin and 
impede its fibril formation (Abedini et al., 2007; Porat, et al., 2004; Yan et al., 
2006). In our study, IO8, N1-IO8 and N2-IO8 were seen to significantly rescue 
PANC-1 cells from the toxic effects of human amylin both at 1:1 and 1:4 molar 
ratios of peptides to amylin. In addition, IO8, N1-IO8 and N2-IO8 were not 
toxic to normal PANC-1 cells, as no significant difference was observed 
between cells treated with peptides and control untreated cells. These findings 
are in agreement with Potter et al. (2009), where the addition of full length 
amylin resulted in 25% of cell death, but the presence of human amylin 13-18 
peptide fragments appeared to reverse the toxicity formed by 12.5%, while 
human amylin 20-25 residues decrease amylin cytotoxicity by 25%. 
Furthermore, the amylin modified peptide, NF(N-Me)GA(N-Me)IL was 
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reported to significantly decrease amylin-induced cell damage in RIN-5fm cells 
(Tatarek-Nossol et al., 2005). Modified full length amylin with N-methylation at 
positions 24 and 26 has been shown to impede amylin-induced cytotoxicity in 
RIN-5fm cells (Yan et al., 2006). This is supported by another study which 
showed that human amylin derived peptides containing residues 20-25 
decreased amylin toxicity by 25%, while the peptide containing residues 24-29 
did not (Scrocchi et al., 2002). A study reported that dehydrophenylalanine 
containing peptides inhibit human amylin fibrillization and protects β cells from 
amylin-induced toxicity (Mishra et al., 2009). Another recent study also showed 
that the polyphenol, 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) is a potent 
inhibitor of amylin aggregation and was found to inhibit amylin aggregation in a 
1:1 molar ratio, it was also shown to protect PC12 rat cells from the  toxic 
effects  of human amylin, and has been shown to have anti-cancer and anti-
diabetic properties (Bruno et al., 2013). Also, a study on two salen derivatives 
with established antioxidants properties, EUK-8 and EUK-134, significantly 
impeded amyloid formation at 1:1 and 5:1 drug to protein molar ratios 
(Bahramikia and Yazdanparast, 2013), with greater inhibitory effect at the 5:1 
drug to protein molar ratio. In a recent study, benzbromarone, quercetin, and 
folic acid exerted inhibitory effects on amylin aggregation. However, 
benzbromarone and folic acid were cytotoxic to RIN-m5F cells, while quercetin  
partially protected the cells from the cytotoxic effects of human amylin (López 
et al., 2016). However, another study reported that quercetin did not inhibit 
amylin aggregation, whereas Morin, a closely linked flavonoid to quercetin, was 
reported to inhibit amylin aggregation and also disintegrate preformed 
aggregates (Noor et al., 2012). These contradictions could be a result of the 
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varied experimental conditions used. In addition, a human amylin derived 
peptide marketed as pramlintide, with proline substitutions at positions 25, 28 
and 29, has been reported to have undergone clinical trials (Kong et al., 1998; 
Maggs et al., 2004; Thompson et al., 1998) and administered alongside insulin 
for management of T2DM. It is important to note that this peptide has not been 
assessed as an inhibitor of human amylin aggregation or its associated 
cytotoxicity. Furthermore, the effects of Metformin and Rosiglitazone on amylin 
aggregation have been studied in vivo (Hull et al., 2005). These therapeutic 
agents of diabetes significantly decreased amyloid deposit formation in the 
pancreas of amylin transgenic mice (Hull et al., 2005). However, these 
interventions are only able to manage the disease and not cure the disease. This 
emphasises the need for developing inhibitors of amylin aggregation, 
particularly short peptides, as the full length human amylin sequence is hard to 
synthesize.  
 
Due to the fact that the interaction of amylin and membranes in non-diabetic 
individuals do not usually cause β cell death (Jaikaran et al., 2001), it is 
interesting to consider that certain conditions associated with T2DM trigger 
amylin-induced membrane damage. In insulin resistance, the level of amylin 
which is co-secreted with insulin is increased; this increase could set off amylin 
fibril formation. Changes in the ratio of insulin to amylin secretion, as seen in 
diabetic individuals, may possibly result in a reduced inhibitory effect of insulin 
on amylin amyloid fibril formation (Jaikaran et al., 2001). Our peptides IO8, 
N1-IO8 and N2-IO8 significantly decreases amylin aggregation even at a very 
low molar concentrations of 1:10 (peptide to amylin), suggesting that they are 
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highly potent in inhibiting amylin-related fibrillogenesis. IO8, N1-IO8 and N2-
IO8 also showed significant inhibition of amylin aggregation as observed under 
the TEM, with N2-IO8 showing even greater inhibitory effect and the only one 
of the three most potent peptides that completely disaggregates pre-formed 
amylin fibrils. IO8, N1-IO8 and N2-IO8 also protected PANC-1 cells from the 
toxic effects of human amylin. The mechanism by which these peptides prevents 
aggregation of full length human amylin is probably by direct binding of the 
peptides to full-length amylin to prevent its self-assembly. It is likely that this 
interaction occurs at the initial stage of protein folding, by making contact with 
the random coil conformation which would impede amyloidogenic β-sheet 
formation. Interactions at this stage would prevent amylin aggregation as 




Despite the therapeutic agents of T2DM available in the market, there is still a 
huge unmet medical need, as the current therapeutics are not able to treat or cure 
diabetes, but are only able manage the disease. These therapeutics are also not 
able to prevent diabetes associated complications. Studies to find inhibitors of 
amylin aggregation and associated cytotoxicity are currently advancing. 
However, for these peptides to be developed as therapeutics, novel techniques 
that provide affordable and quick screening of potential drugs for T2DM are 
required. The data presented here clearly demonstrate that IO8, and the N-
methylated peptides, N1-IO8 and N2-IO8, are effective inhibitors of amylin 
amyloid formation and also protect cells from the toxic effects of human amylin 
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in cell culture. N1-IO8 and N2-IO8 were found to be stable to proteolytic 
degradation and in plasma and while N1-IO8 partially disaggregated pre-
existing fibrils, N2-IO8 completely disaggregated already-formed amylin fibrils. 
N2-IO8 demonstrates inhibitory effects on amylin aggregation even at 
substoichiometric ratios, and possibly binds to amylin oligomeric species, and 
has been shown to completely disaggregate amyloid formation when added to 
the lag phase of the amyloid formation pathway. It thus holds huge potential for 
treating individuals already presented with amyloid formation in their pancreas. 
N-methylation has been shown to improve the pharmacokinetic properties of 
peptides, protecting them from proteolysis (Chatterjee et al., 2008), thus 
increasing their potential to be used as drugs. The inhibition of amylin amyloid 
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7.2 Limitations of study and future experimental plans 
 
7.2.1  Limitations of study 
This study was limited to the use of Th-T and Congo red assays to monitor 
amylin fibril formation as well as the CellTiter 96 aqueous one solution (MTS) 
cell proliferation assay (Promega) and the CytoTox-ONE homogeneous 
membrane integrity (LDH) assay (Promega). This study is also limited to the use 
of Reverse Phase High Performance Liquid Chromatography (RP-HPLC) to 
assess the stability of our peptides in plasma and proteolytic enzymes. The Th-T 
and Congo red assays are excellent techniques that are often used to measure the 
formation and inhibition of amyloid fibrils in the presence of anti-amyloidogenic 
agents (Hudson et al., 2009; Klunk et al., 1999). However, biases can arise 
when using the Th-T assay, as there can be a direct interaction between Th-T 
and other agents as well as a competitive binding for amyloid fibrils with Th-T 
(Hudson et al., 2009). In addition, studies have reported that Congo red is an 
inhibitor of amyloid aggregation (Bartolini et al., 2007; Podlisny et al., 1998; 
Hong et al., 2009) and this inhibitory effect is sometimes equivalent to that 
observed with small molecule inhibitors (Yang, et al., 2005; Podlisny et al., 
1998), and so this raises concerns when using Congo red as a reporter dye in 
amyloid inhibition studies. Thus, transmission electron microscopy (TEM) was 
used to monitor amylin amyloid fibril assembly as a confirmatory test for the 
results obtained from the Th-T and Congo red studies. Although these dye-
binding assays have been used to indicate potential interactions between peptide 
inhibitors and amylin, these techniques do not reveal the binding affinity of 
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these peptides for exact conformations. In order to test direct binding of the 
peptides to amylin, other techniques such as NMR studies or surface plasmon 
resonance (SPR) are needed and these can also determine the affinity of the 
peptide inhibitors for amylin.  
 
7.2.2 Future Research 
 
Further research is required to verify the interactions and binding affinity of the 
peptide inhibitors to amylin, for example using solid-state NMR spectroscopy, 
which is a nuclear magnetic resonance (NMR) spectroscopy to characterize and 
study molecular interactions. Magic angle spinning recoupling 1H-1H NMR 
experiments can be used to examine atomic-level characterization of the non-
fibrillar aggregation products of the amylin peptide and the detection of specific 
oligomers which are believed to play a key role in amyloid pathology. This 
provides especially useful structural details not observed by other biophysical 
measurements. Another technique known as NMR relaxation enhancement by 
paramagnetic metals gives excellent information on the three-dimensional 
structures of proteins in solution, and can be used alongside cross-polarization 
magic-angle spinning (CP-MAS) solid-state NMR to study the interaction of 
amylin with peptide-based inhibitors. Also, considering the fact that medical 
history and blood sugar tests do not take into account the long preclinical 
features of the disease, and pancreatic islet damage precedes disease symptoms, 
a biomarker for improved diagnosis of T2DM is therefore highly required. A 
future study would be to use Dynamic light scattering (DLS) as a laser scattering 
 210 | P a g e  
 
technique to provide objective quantitative analysis of amyloid aggregation. 
DLS can be used in addition to Th-T assay because not only can it detect fibrils, 
it can also detect non-fibrilar intermediates which the Th-T fluorescence assay 
cannot (Hill et al., 2009; Lomakin et al., 1996). An additional study would be 
the use of Circular dichroism (CD) spectroscopy. CD provides extensive 
information on the conformation and secondary structure of proteins/peptides 
and can be used to study how protein conformation and secondary structure 
changes when they interact with other macromolecules. Also, to improve 
selectivity and specificity of our peptide for target cells/organ, a future approach 
will be conjugating our peptide with a cell penetrating homing peptide and with 
liposomes. This is a useful approach to improve intracellular drug delivery. 
Furthermore, a future study would be to carry out in vivo experiments on the 
impact of our peptides on the levels of soluble amylin oligomers and on glucose 
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Reversed-Phase High-Performance Liquid Chromatography of IO8, N1-IO8 and N2-IO8 
 
This appendix shows the stability of data of IO8, N1-IO8 and N2-IO8 peptides 
in the presence of varying proteolytic enzymes and plasma performed using 
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). 
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Figure  A1.1:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Trypsin (B) 0 hr   
(C) 1 hr  (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 














Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.6271 - .76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm









Marks test sequence #43 Trypsin in IO8 100um 0 HR UV_VIS_2
mAU
min








15 - 18.42016 - 19.98417 - 20.2358 - 1.51819 - 22.073
20 - 23.46421 - 23.73322 - 24.00123 - 2 . 0224 - 26.27325 - 26.651
26 - 27.57927 - 27.73828 - 27.91529 - 28.2 530 - 29.732
31 - 30.77932 - 31.392
33 - 33.47334 - 34.51935 - 35.52136 - 35.93937 - 36.5358 - 37.17239 - 37.36740 - 37. 63
41 - 38.28342 - 38.81343 - 39.106
WVL:220 nm




















14 - 17.57915 - 17.80316 - 18.496
17 - 19.53818 - 20.3209 - .442
20 - 24.05721 - 24. 2
22 - 30.781
23 - 37.01524 - 37.563
25 - 38.08726 - 39.184
WVL:220 nm








Marks test sequence #45 Trypsin in IO8 100um 3 HR UV_VIS_2
mAU
min




11 - 6.97412 - 9.91713 - 11.737






24 - 18.52725 - 18.83426 - 19.099
27 - 19.56328 - 19.90829 - 20.153
30 - 20.364
31 - 22.75332 - 24.03533 - 24.66834 - 26.451
35 - 27.60036 - 28.25037 - 30.551
38 - 30.81039 - 31.510









Figure A.1.2:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Chymotrypsin (B) 
0 hr   (C) 1 hr (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 
40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and elution time in minutes 
 
 







Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.62711 - 4.76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 20.09830 - 20.28131 - 20.6 13  - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm








Marks test sequence #48 Chymotrpsin in IO8 100um 0 HR UV_VIS_2
mAU
min
1 - 0.1022 - 1.2283 - 1.859
4 - 3.237
5 - 3.4956 - 3.548
7 - 11.590





16 - 17.31017 - 17.50418 - 17.77319 - 18.241
20 - 18.409
21 - 19.02222 - 19.507
23 - 20.276
24 - 22.81725 - 23.98526 - 25.659
27 - 2 .35728 - 26.86929 - 27.463
30 - 28.82831 - 29.33432 - 29.76133 - 30.460
34 - 30.72335 - 31.34136 - 31.953
37 - 33.377
38 - 34.74139 - 35.41440 - 36.99741 - 37.555
42 - 38.05943 - 38.86944 - 39.222
WVL:220 nm


























21 - 16.56722 - 17.561
23 - 17.867
24 - 18.410




33 - 33.42434 - 34.93135 - 35.19836 - 35.698
37 - 37.09938 - 37.759
39 - 38.197
WVL:220 nm






















1  - 14.501
13 - 14.788
14 - 15.325







23 - 19.51724 - 19.84025 - 20.09326 - 20.30827 - 2 .67228 - 21.622
29 - 22.92630 - 24.03131 - 24.522
32 - 26.942
33 - 28.78234 - 28.974
35 - 30.778
36 - 33.779












Figure A1.3:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Cathepsin G (B) 0 
hr   (C) 1 hr (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 












Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.6271 - .76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm


















16 - 17.58317 - 17.7918 - .918
19 - 19.54120 - 20.128
21 - 24.00622 - 24.607
23 - 30.772
24 - 33.460
25 - 35.35626 - 35.75727 - 6.63928 - 37.21029 - 37.685
30 - 38.262
WVL:220 nm














14 - 14.90715 - 15.35616 - 15.748
17 - 15.986
18 - 16.482
19 - 17.27920 - 17.56821 - 18.497
22 - 20.143




29 - 33.43430 - 35.79531 - 36. 81
32 - 37.12033 - 38.258
WVL:220 nm















5 - 8.0126 - 8.3577 - 9.909
8 - 14.2879 - 14.861
10 - 15.3391  - 15.692
12 - 15.983
13 - 16.480
14 - 17.55715 - 18.49616 - 18.888
17 - 19.50718 - 19.86119 - 20.08720 - 20.29421 - 21.22622 - 23.711
23 - 24.0234 - 24.26425 - 26.326
26 - 29.144
27 - 30.77128 - 31.3 1
29 - 33.42330 - 34.34431 - 34.83332 - 35.459











Figure A1.4: Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Elastase (B) 0 hr   
(C) 1 hr (D) 3 hrs.  Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 











Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.62711 - 4.76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 20.09830 - 20.28131 - 20.6 13  - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm

















12 - 14.89613 - 15.22814 - 15.348
15 - 15.974
16 - 16.492
17 - 17.55818 - 18.47619 - 19.52420 - 20.12321 - 20.30722 - 21.1332  - 22.505
24 - 23.98625 - 26.021
26 - 27.56827 - 28.27328 - 29.677
29 - 30.722
30 - 33.38031 - 34.73032 - 35.8923 - 6.48234 - 37.05135 - 37.694
36 - 38.145 - 39.194
WVL:220 nm








Marks test sequence #42 Elastase in IO8 100um 1 HR UV_VIS_2
mAU
min




6 - 11.6667 - 14.514





14 - 18.84415 - 19.04816 - 19.55817 - 20.136
18 - 23.20819 - 23.99720 - 25.52021 - 26.954
22 - 27.5233 - 27.919
24 - 30.73025 - 31.319
26 - 33.36127 - 34.70428 - 35.85529 - 36.61330 - 37.0671 - 37.431
32 - 38.19533 - 39.2194  .302
WVL:220 nm












2 - 0.1803 - 0.2664 - 0.4615 - .56 - 0.7 17 - 1.2618 - 1.4599 - 2.752
10 - 3.251
11 - 3.499
12 - 5.92213 - 6.57414 - 6.9 515 - 7.3241  - 8.14117 - 10.115
18 - 14.33619 - 14.58420 - 14.949










32 - 20.16133 - 20.35534 - 21.13335 - 21.57636 - 22.249
37 - 24.08638 - 24.51339 - 25.05240 - 25.69141 - 26.163
42 - 27.33343 - 27.65444 - 27.8845 - 28.2 6
46 - 29.52547 - 29.88348 - 30.794
49 - 31.471
50 - 33.45451 - 34.27152 - 34.80353 - 35.4805  - 36.478










Figure A1.5:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Thrombin, (B) 0 
hr   (C) 1 hr (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 
min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution time in minutes 
 
 







Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.6271 - .76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm








Marks test sequence #28 Thrombin in IO8 100um 0 HR UV_VIS_2
mAU
min
1 - 0.0542 - 1.6453 - 1.986
4 - 3.2335 - 3.489
6 - 3.772
7 - 4.394
8 - 6.1189 - 6.74510 - 7.44311 - 8.50412 - 10.103
13 - 11.73014 - 13.853
15 - 14.94516 - 15.18217 - 15.34018 - 15.673
19 - 15.958
20 - 16.428
21 - 17.52922 - 18.45023 - 20.09224 - 20.41925 - 21.083
26 - 22.87027 - 23.06028 - 24.00329 - 25.16330 - 26.41231 - 27.334
32 - 28.03233 - 28. 694 - .48
35 - 30.69136 - 31.161
37 - 33.66238 - 35.43839 - 36.48340 - 36. 04
41 - 37.52942 - 38.03643 - 38.677
WVL:220 nm








Marks test sequence #30 Thrombin in IO8 100um 1 HR UV_VIS_2
mAU
min





7 - 5.2448 - 5.5349 - 5.72410 - 6.11911 - 7.409
12 - 8.472
13 - 9.51814 - 9.90515 - 11.794
16 - 13.05717 - 13.67718 - 13.83919 - 14.94020 - 15.236




26 - 17.55227 - 18.45928 - 19.65429 - 19.90430 - 20.07831 - 20.40732 - 22.095
33 - 23.29734 - 24.03435 - 25.22336 - 25.84737 - 26.037
38 - 27.72139 - 28.14340 - 28.550
41 - 30.74342 - 31.410
43 - 33.49044 - 3. 105 - 4.4 146 - 34.86647 - 35.8388 - 36. 609 - 37.05750 - 7.4391 - 37.85652 - 38.461
WVL:220 nm

















10 - 5.49711 - 6.20712 - 7.57113 - 8.13514 - 8.607
15 - 11.80616 - 13.506
17 - 14.49218 - 14.8 019 - 14.959
20 - 15.39321 - 15.7172 - .858
23 - 16.019
24 - 16.475
25 - 17.54626 - 18.463
27 - 19.61228 - 19.89429 - 20.13430 - 22.19331 - 22.948
32 - 24.018
33 - 26.91534 - 27.8615 - 8.00236 - 28.222
37 - 30.72738 - 31.439
39 - 33.46940 - 35.803










Figure A.1.6:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Kallikrein, (B) 0 
hr   (C) 1 hr (D) 3 hrs.  Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 
min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and elution time in minutes 
 







Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.62711 - 4.76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm






Marks test sequence #54 Kallikrein in IO8 100um 0 HR UV_VIS_2
mAU
min
1 - 0.0542 - 0.7033 - 0.9034 - 1.1015 - 1.3576 - 2.3327 - 2.769
8 - 3.319
9 - 3.58310 - 3.656
11 - 3.927
12 - 11.72313 - 14.20814 - 14.49015 - 14.7126  . 9417 - 14.897
18 - 15.26019 - 15.43220 - 15.653
21 - 15.900
22 - 17.17723 - 17.475
24 - 18.387
25 - 19.06226 - 19.66727 - 19.96028 - 20.15329 - 20.46730 - 21.12031 - 21.323
32 - 24.02333 - 24.29034 - 25.687
35 - 27.72936 - 30.38537 - 30.671
38 - 33.13039 - 33.51240 - 36.403
41 - 37.60342 - 38.57443 - 39.023
WVL:220 nm








Marks test sequence #55 Kallikrein in IO8 100um 1 HR UV_VIS_2
mAU
min






10 - 11.70911 - 12.28612 - 14.17313 - 14.44914 - 14.702
15 - 14.916
16 - 15.290
17 - 15.4 418 - 15.686
19 - 15.934
20 - 16.418
21 - 17.17222 - 17.4113 - .50224 - 18.233
25 - 18.379
26 - 19.67527 - 19.96528 - 20.12729 - 20.44530 - 21.52031 - 1.86332 - 22.21633 - 24.026
34 - 27.33335 - 27.741
36 - 30.70137 - 33.50738 - 34.44739 - 36.11340 - 37.075
41 - 37.87442 - 38.5423 - .629
WVL:220 nm









Marks test sequence #56 Kallikrein in IO8 100um 3 HR UV_VIS_2
mAU
min
1 - 0.0542 - 0.127






15 - 5.13616 - 5.68917 - 6.1708 - 8.56219 - 9.07520 - 9.51821 - 10.526
22 - 11.72123 - 12.33224 - 14.20725 - 14.716
26 - 14.94227 - 15.31828 - 15.48729 - 15.707
30 - 15.956
31 - 16.421
32 - 17.18033 - 17.51934 - 17.91635 - 18.251
36 - 18.397
37 - 19.65538 - 20.16339 - 20.453
40 - 25.683
41 - 27.749
42 - 30.70643 - 31.163












Figure A1.7:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in peoteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Plasmin (B) 0 hr   
(C) 1 hr (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 40 











Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.6271 - .76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm








Marks test sequence #27 Plasmin in IO8 100um 0 HR UV_VIS_2
mAU
min
1 - 0.0462 - 0.6073 - 1.130
4 - 3.232
5 - 3.484
6 - 4.3917 - 6.7398 - .5149 - 8.571
10 - 11.75111 - 13.85712 - 14.458





20 - 17.77821 - 18.394
22 - 19.57923 - 19.88424 - 20.08425 - 20.37126 - 23.16627 - 23.97128 - 24.63029 - 24.933
30 - 26.68531 - 27.08332 - 27.67833 - 28.01834 - 29.24835 - 29.480
36 - 30.65337 - 31.593
38 - 33.42339 - .00540 - 35.35941 - 35.781
42 - 37.38343 - 37.78544 - 38.420
WVL:220 nm








Marks test sequence #24 Plasmin in IO8 100um 1HR UV_VIS_2
mAU
min
1 - 0.0462 - 1.4163 - 2.112
4 - 3.2395 - 3.511
6 - 6.1697 - 7.3038 - 8.8889 - 9.27210 - 9.58311 - 10.364
12 - 11.76013 - 11.996
14 - 14.80515 - 14.95616 - 15.340
17 - 15.965
18 - 16.472
9 - 17.04520 - .171
21 - 17.523
22 - 18. 1123 - 18.462
24 - 20.12925 - 20.75826 - 21.00327 - 21.90628 - 22.63829 - 2.99930 - 23.25431 - 3.45932 - 23.6 633 - 2 .025
34 - 25.81435 - 26.46936 - 26.72237 - 26.95638 - 27.197
39 - 28.057
40 - 28.85241 - 29.1104  - 30.30343 - 3 .772
44 - 33.61045 - 34.07546 - 34.60047 - 35.14348 - 35.61249 - 35.95250 - 37.0155  - 37.4062 - 37.8845  - 38.470
WVL:220 nm








Marks test sequence #23 Plasmin in IO8 200um 3HRS UV_VIS_2
mAU
min
1 - 0.0372 - 1.7123 - 2.265
4 - 3.307
5 - 3.568
6 - 6.2537 - 8.6548 - 9. 80
9 - 11.82010 - 12.037




7 - 17.04718 - 17.55119 - 17.83820 - 1 .4622  - 19.09522 - 9.631
23 - 20.14524 - 20.39525 - 22.21126 - 22.66027 - .99628 - 3.24729 - 3.44930 - 23.83431 - 2 .03032 - 25.47033 - 25.81334 - 26.9733  - 27.352
36 - 28.073
37 - 28.86038 - 29.12239 - 30.49340 - 30. 3









Figure A1.8: Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 
before incubation in peoteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in 
Factor X (B) 0 hr   (C) 1 hr (D) 3 hrs. Conditions, linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and elution 
time in minutes 
 
 







Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1. 434 - 1. 62
5 - 3.1476 - 3.3087 - 3.453
8 - 3.7309 - 4.19510 - 4.6271 - .76812 - 6.62013 - 7.43314 - 7.58215 - 9.101




23 - 17.4034 - .545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 0.28131 - 20.6 132 - 21.20233 - 2 .93834 - 2 .74035 - 2 .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.56041 - 25.7962 - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm






Marks test sequence #34 Factor x in IO8 100um 0 HR UV_VIS_2
mAU
min






9 - 17.51410 - 17.76411 - 18.421




19 - 33.38320 - 3.78221 - 34.926
22 - 36.03923 - 37.17624 - 37.686
25 - 38.23326 - 39.178
WVL:220 nm








Marks test sequence #31 Factor X in IO8 100um 1 HR UV_VIS_2
mAU
min
1 - 0.0712 - 0.3993 - 0. 054 - 1.1815 - 1.5 26 - 2.718
7 - 3.281
8 - 3.533
9 - 3.81010 - 4.43211 - 5.6182 - .20913 - 6.53814 - 7.429
15 - 8.47016 - 8.97917 - .12618 - 9.8761  - 10.24520 - 11.7571 93
22 - 13.83923 - 14.82224 - 14.95625 - 15.35226 - 15.657
27 - 15.953
28 - 16.440
29 - 17.20430 - 17.418
31 - 17.539
32 - 18.27633 - 18.45034 - 18. 7535 - 19.02736 - 19.60237 - 19.90338 - 20.101
39 - 20.38040 - 21. 0541 - 21.56342 - 22.11943 - 23.19844 - 24.01245 - 25.014
46 - 27.657
47 - 30.43548 - 30.743
49 - 33.79150 - 35.5061 - 37.453
52 - 38.533
WVL:220 nm









Marks test sequence #37 Factor x in IO8 100um 3 HR UV_VIS_2
mAU
min
1 - 0.0372 - 1.2273 - .447
4 - 3.229
5 - 3.487
6 - 7.1067 - 7.5598 - .6949 - 8.29210 - 9.43011 - 11.628
12 - 13.87713 - 14.27214 - 14.869




20 - 17.54821 - 18.47722 - 19.07823 - 19.52924 - 19. 59
25 - 20.315
26 - 23.05727 - 24.0138 - 24.7709 - 25.68730 - 25.965
31 - 27.51532 - 29.32933 - 29.61934 - 30.383
35 - 30.77336 - 31.365
37 - 33.388









   
Figure A2.1:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in Trypsin 
(B) 0 hr   (C) 1 hr  (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution 
time in minutes 

















10 - 37.62711 - 39.142
WVL:220 nm











3 - 8.1274 - 9.252




10 - 19.61011 - 20.12412 - 20.4063 - 20.610
















3 - 7.9894 - 9.817




10 - 20.20611 - 20.9411  - 1.25013 - 1.46814 - 21.74015 - 21.949
16 - 24.292
17 - 26.082
18 - 34.47419 - 35.29020 - 35.858
21 - 36.6252  - 37.7463 - 38.04024 - 38.37625 - 38.838
WVL:220 nm











3 - 7.0524 - 7.524
5 - 8.1236 - 9.721
7 - 13.2148 - 13.6109 - 13.93210 - 14.247
11 - 15.4382 - 15.76313 - 16.254
14 - 16.86815 - 17.0306 - .157







25 - 20.67426 - 20.88227 - 21.00228 - 21.255
29 - 21.47130 - 21.71931 - 21.9 8
3  - 22.42833 - 24.248
34 - 26.097
35 - 31.715
36 - 33.76537 - 35.35038 - 6.634
39 - 38.11140 - 39. 56
WVL:220 nm









Marks test sequence #172 Trypsin NP1 100um 24 Hr UV_VIS_2
mAU
min
1 - 0.1782 - 0.360
3 - 3.390
4 - 8.0095 - 9.904








15 - 21.22116 - 21.44217 - 22.073
18 - 26.093










        
 
Figure A2.2:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Chymotrypsin (B) 0 hr   (C) 1 hr  (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 
nm and elution time in minutes 
 

















10 - 37.62711 - 39.142
WVL:220 nm






Marks test sequence #169 Chymotrypsin NP1 100 um 0Hr UV_VIS_2
mAU
min
1 - 0.0462 - 1.7803 - 2.018
4 - 3.379
5 - 7.9346 - 8.8067 - .945
8 - 17.8709 - 18.157
10 - 18.520
11 - 18.774
12 - 20.60513 - 20.98214 - 21.277




21 - 37.60322 - 38.1883 - 38.645
WVL:220 nm






Marks test sequence #174 Chymotrypsin NP1 100um 1 Hr UV_VIS_2
mAU
min
1 - 0.0462 - 1.125
3 - 3.383
4 - 7.9345 - 8.8936 - 9.6707 - 9.8558 - 10.2859 - 10.484
10 - 18.456
11 - 18.705
12 - 19.39313 - 19.66314 - 20.194
15 - 20.94616 - 21.218
17 - 23.363
18 - 26.10519 - 26.609
20 - 31.364
21 - 32.98122 - 33.49923 - 35.00024 - 35.831
25 - 36.53226 - 37.74327 - 38.712
WVL:220 nm











3 - 8.0524 - 9.810
5 - 18.609
6 - 18.863
7 - 19.5078 - 19.7589 - 20.29910 - 20.523
11 - 21.047
12 - 26.10513 - 26.596
14 - 32.130
15 - 36.06316 - 36.70317 - 8.124
WVL:220 nm











3 - 5.6454 - 6.179
5 - 8.0286 - 9.292
7 - 16.7488 - 17.270
9 - 17.82310 - 1 .123
11 - 18.486
12 - 18.732
13 - 19.41514 - 19.664
15 - 20.17016 - 20.8077 - .93618 - 21.24219 - 21.478















       
 
Figure A2.3:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Cathepsin G (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
nm and elution time in minutes. 
 

















10 - 37.62711 - 39.142
WVL:220 nm







Marks test sequence #189 Cathepsin G NP1 100um 0H UV_VIS_2
mAU
min
1 - 0.0462 - 1.465
3 - 3.2994 - 3.5005 - 4.5846 - 7.5517 - 9.7888 - 10.0109 - 10.358
10 - 18.547
11 - 18.779
12 - 19.44413 - 19.71214 - 20.23015 - 20.461



















7 - 20.2148 - 20.991
9 - 26.099
10 - 36.58511 - 38.10712 - 38.9241  - 39.203
WVL:220 nm











3 - 6.2004 - 8.1315 - 9.5506 - 9.8867 - 10.945
8 - 18.567
9 - 18.808




16 - 36.39817 - 37.971
WVL:220 nm









Marks test sequence #185 Cathepsin G NP1 100 um 24H UV_VIS_2
mAU
min
1 - 0.0372 - 0.225
3 - 3.454




9 - 20.23610 - 20.45011 - 0.99812 - 21.264
13 - 26.182











               
 
 
Figure A2.4: Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Elastase (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions, linear gradient from 0–60% acetonitrile 
with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and 
elution time in minutes. 
 

















10 - 37.62711 - 39.142
WVL:220 nm











3 - 6.4554 - 6.844
5 - 7.9496 - 9.821
7 - 18.535
8 - 18.766
9 - 20.22210 - 21.00111 - 21.283
12 - 26.175
13 - 27.413
14 - 36.52315 - 37.70916 - 38.8141 - 3 .209
WVL:220 nm












4 - 8.0215 - 9.9096 - 1 .551
7 - 18.558
8 - 18.797
9 - 19.70110 - 20.219
11 - 20.99412 - 21.243
13 - 26.195
14 - 33.755
15 - 37.89816 - 3 .073
WVL:220 nm











3 - 6.4554 - 6.844
5 - 7.9496 - 9.821
7 - 18.535
8 - 18.766
9 - 20.22210 - 21.00111 - 21.283
12 - 26.175
13 - 27.413
14 - 36.52315 - 37.70916 - 38.8141 - 3 .209
WVL:220 nm
































                   
 
 
Figure A2.5:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Thrombin, (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions,  linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 
nm and elution time in minutes. 
 

















10 - 37.62711 - 39.142
WVL:220 nm







Marks test sequence #189 Cathepsin G NP1 100um 0H UV_VIS_2
mAU
min
1 - 0.0462 - 1.465
3 - 3.2994 - 3.5005 - 4.5846 - 7.5517 - 9.7888 - 10.0109 - 10.358
10 - 18.547
11 - 18.779
12 - 19.44413 - 19.71214 - 20.23015 - 20.461











Marks test sequence #201 Thrombin NP1 100 UM 1H UV_VIS_2
mAU
min
1 - 0.0842 - 0.217
3 - 3.382
4 - 5.238





11 - 20.96912 - 21.249
13 - 25.38014 - 26.145
15 - 33.747
16 - 36.51517 - 37.95918 - 39.103
WVL:220 nm





















16 - 36.82217 - 38.0471  - 39.112
WVL:220 nm

















9 - 21.28710 - 21.48311 - 21.6331  - 1.916
13 - 22.639
14 - 26.21715 - 27.389
16 - 33.762
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Figure A2.6:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Kallikrein, (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.   Conditions, linear gradient from 0–60% acetonitrile 
with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and elution time in 
minutes. 
 

















10 - 37.62711 - 39.142
WVL:220 nm











3 - 6.5084 - 6.9255 - 7.473
6 - 8.0267 - 9.7468 - 11.219
9 - 14.84710 - 15.229
11 - 18.542
12 - 18.781
13 - 19.70014 - 19.97915 - 20.20916 - 20.45417 - 20.784
18 - 20.96819 - 21.233
20 - 24.644
21 - 26.137
22 - 37.48323 - 38.78824 - 39.203
WVL:220 nm












4 - 8.0275 - 9.7616 - 1.412
7 - 15.0998 - 15.508






16 - 20.85817 - 21.251
18 - 24.599
19 - 26.04820 - 26.552
21 - 36.65622 - 38.08723 - 38.825
WVL:220 nm












3 - 6.8044 - 7.355
5 - 7.933






13 - 20.85814 - 21.253
15 - 26.10816 - 26.596
17 - 33.721
18 - 35.87119 - 36.60320 - 37.94021 - 38.725
WVL:220 nm














3 - 4.345 4 - 7.9885 - 8.637
6 - 18.907





14 - 26.05115 - 26.60216 - 26.936
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Figure A2.7:  Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after incubation in 
Plasmin (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% acetonitrile 
with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and 
elution time in minutes 

















10 - 37.62711 - 39.142
WVL:220 nm












4 - 8.0315 - 9.823
6 - 18.545
7 - 18.783
8 - 19.7479 - 20.269
10 - 21.00811 - 21.265
12 - 26.193
13 - 34.41214 - 35.77915 - 36.4316 - 37.60817 - 38.75218 - 39.2 8
WVL:220 nm











3 - 7.9934 - 10.408
5 - 18.556
6 - 18.801
7 - 19.4548 - 19.7279 - 20.24510 - 20.470
11 - 20.990
12 - 26.105
13 - 36.58414 - 37.55315 - 39.124
WVL:220 nm












3 - 6.8774 - 7.424
5 - 7.9916 - 9.890
7 - 18.540
8 - 18.789
9 - 19.71610 - 20.231
11 - 20.991
12 - 26.139
13 - 34.38714 - 5.65715 - 3 .47716 - 38.1541  - 39.192
WVL:220 nm







Marks test sequence #186 Plasmin  NP1 100 um 24H UV_VIS_2
mAU
min
1 - 0.0462 - .1293  0.2144 - 0.392
5 - 3.394




11 - 20.21212 - 20.40613 - 20.8314 - .97415 - . 36
16 - 26.121
17 - 31.352
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Figure A2.8: Relative Resistance of N1-IO8 to proteolysis. (A) RP-HPLC chromatographs of 
N1-IO8 before incubation in proteolytic enzymes. RP-HPLC chromatographs of N1-IO8 after 
incubation in Factor X (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–
60% acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 





















10 - 37.62711 - 39.142
WVL:220 nm









Marks test sequence #212 Factor X NP1 1OOUM 0 H UV_VIS_2
mAU
min








11 - 21.02812 - 21.295
13 - 26.143
14 - 33.807
15 - 36.01916 - 36.66517 - 37.49318 - 38.158 - 39.187
WVL:220 nm







Marks test sequence #208 Factor X NP1 100um 1H UV_VIS_2
mAU
min
1 - 0.0632 1113 - 0.2 04  . 9
5 - 3.410
6 - 7.1787 - 7.548
8 - 8.2969 - 10.499
10 - 18.563
11 - 18.791
12 - 19.56413 - 19.980
14 - 20.202
15 - 20.8706 - .9 717 - 21.314
18 - 23.28819 - 23.57320 - 24.256
21 - 26.163
22 - 33.748
23 - 36.69124 - 37.76525 - 38.6232  - 39.129
WVL:220 nm






Marks test sequence #209 Factor X NP1 100um 3H UV_VIS_2
mAU
min
1 - 0.0462 11
3 - 3.394
4 - 6.7815 - 7.299




12 - 21.00213 - 21.265
14 - 26.215
15 - 33.819
16 - 36.44817 - 39.251
WVL:220 nm
















9 - 20.99410 - 21.256
11 - 26.163





 259 | P a g e  
 
 
   
          
Figure A3.1:  Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in Trypsin 
(B) 0 hr   (C) 1 hr  (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution 
time in minutes 
 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm







Marks test sequence #224 Trypsin NP2 100UM 0H UV_VIS_2
mAU
min




11 - 7.46912 - 7.704
13 - 8.019
14 - 9.77115 - 1 .05016 - 12. 2617 - 12.4528 - 12.63319 - 13.00820 - 13. 921 - 13.4182 - .5373 - 1 . 94 - 1 .09825 - 14.346
26 - 14.46727 - 14.75528 - 15.23429 - 15.43230 - 15.5893  - 1 .86732 - 16.075
33 - 16.968
34 - 18.20135 - 18.57736 - 18.84537 - 19.09838 - 19.23939 - 19.49340 - 19.6 641 - 19.97142 - 20.1 943 - 0. 7144 - 20. 204 - 20.86346 - 21.42647 - 2 .60548 - 2.37749 - 23.38650 - 24.09951 - 25.61952 - 27.48353 - 27.94154 - 28.19355 - 28.96456 - 31.04057 - 33.668
58 - 34.019
59 - 38.00560 - 38.70361 - 39.175
WVL:220 nm






Marks test sequence #221 Trypsin NP2 100UM 1H UV_VIS_2
mAU
min
1 - 0.0462 - 0.5823 - .061
4 - 3.441





26 - 18.95227 - 19.18028 - 19.34229 - 19.56230 - 20.0183  - 20.236
32 - 20.45433 - 20.8564 - .98035 - 1.48136 - 21.67037 - 22.5503  - 3.1299 - 23.5560 - 24.124
41 - 25.669
42 - 35.81943 - 38.06944 - 38.8355 - 39.26146 - 3 .563
WVL:220 nm






Marks test sequence #213 Trypsin  NP2 100 UM 3H UV_VIS_2
mAU
min
1 - 0.0462 - 1.1643 - 2.559
4 - 3.403
5 - 7.8756 - 8.8907 - 9.849
8 - 17.954
9 - 18.627































11 - 19.9652 - 20.08013 - 20.220
14 - 21.042
15 - 21.50216 - 22.1137 - .235
18 - 26.144
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Figure A3.2:  Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in 
Chymotrypsin (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
nm and elution time in minutes. 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm












4 - 14.8955 - 15.563
6 - 16.681
7 - 18.282
8 - 18.9859 - 19.18610 - 9.7461 - 20.1752 - .2 713 - 20.9494 - 1.36715 - 22.21916 - .78617 - 23. 8318 - 24.188
19 - 25.176
20 - 27.28321 - 29.30322 - 29.8682  - 31.70124 - 32.1825 - .3226 - 3.60627 - 36.76528 - 38.283
29 - 39. 3830 - 39.6481 - 39.936
WVL:220 nm











3 - 7.7284 - 9.9925 - 12.6166 - 13.0457 - 14.6108 - 14.9479 - 15. 8610 - 15. 10
11 - 16.660
12 - 18.290
13 - 18.97914 - 19.27415 - 1 . 1616 - 20.2307 - 2 . 1218 - 21.1661  - 22.22520 - .7882  - 23.550 - 3.7203 - 3.8784 - 24.19125 - 25.19026 - 25.6 727 - 27.20428 - 28.08229 - 30.75930 - 31.61531 - 31.983
32 - 34.29733 - 38.27934 - 39.3475 - 3 .941
WVL:220 nm











3 - 6.6494 - 7.247
5 - 7.734




17 - 18.95718 - 19.1339 - .27020 - 1 . 1621 - 19.95422 - 20. 83  .25124 - 2 .8 225 - 1.30126 - 1.4767 - 21.7238 - 22.09929 - 22.72230 - 22.87231 - 23.649- 24.12133 - 25.2754 - 25.64335 - 27.900
36 - 31.03737 - 33.55538 - 33.80739 - 37.99740 - 38.58241 - 39.32242 - 39.63343 - 39.902
WVL:220 nm















16 - 18.97817 - 9.20518 - 9.3729 - 19. 4320 - .36021 - 20.64922 - 20.9383 - 1.43224 - 1.5865 - 21. 956 - 22. 4127 - 2.8358 - 2 .98729 - 24.09230 - 25.66531 - 27.94732 - 32.101
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Figure A2.3:  Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in 
Cathepsin G (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
nm and elution time in minutes 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm








Marks test sequence #243 Cathepsin G NP2 100um 0H UV_VIS_2
mAU
min
1 - 0.0462 - 3.245
3 - 3.389




9 - 18. 550 - 1 .14911 - 19.39412 - 19.6873 - 20.2184 - 20. 59 - .3421  - 22.13717 - 22.76918 - 24.10219 - 24.4560 - 25.0931 - 2 .03122 - 27.0263 - 27.88624 - 29.0975 - 29.48826 - 32.02827 - 33.5848 - 4.12829 - 37.93230 - 38.53531 - 38.72132 - 39.337 - 9. 78
WVL:220 nm













5 - 18.2646 - 19.0047 - 2 .2728 - 20. 009 - 20.88110 - 21.11011 - 21.32912 - 24.16013 - 25.16914 - 25.8135 - 27.98116 - 28.502
17 - 33.793 18 - 38.15419 - 38.65220 - .73921 - 39. 1322 - 39.558
WVL:220 nm






Marks test sequence #240 Cathepsin G NP2 100um 3H UV_VIS_2
mAU
min




7 - 18.2318 - 18.6649 - 18.9730 - 20.0221 - 20.2412 - 2 .58113 - 1.31614 - 23.61915 - 24.0876 - 24.35517 - 25.77318 - 28.03319 - 28.208
20 - 31.07021 - 32.13622 - 32.3443 - 32.6 624 - 3. 29 25 - 37.96326 - 38.64627 - 39.41028 - 39.560
WVL:220 nm






Marks test sequence #239 Cathepsin G NP2 100um 24H UV_VIS_2
mAU
min





7 - 18.9608 - 19.1509 - 1 . 200 - 2 .1811 - .79712 - 24.10313 - 25.2341  - 25.8331  - 27.38916 - 28.10017 - 31.65218 - 32.513
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Figure A3.4: Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in 
Elastase (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% acetonitrile 
with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and 
elution time in minutes. 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm









Marks test sequence #251 Elastase NP2 100um 0H UV_VIS_2
mAU
min
1 - 0.0372 - 3.034
3 - 3.435
4 - 3.690
5 - 5.7696 - 6.5967 - 7.1068 - 8.0149 - 8.4211  - 9.4271 - .55612 - 9.66113 - 12.05714 - 13.11315 - 13.43216 - . 697 - 4. 288 - 4.8139 - 15.00220 - 15.46821 - 15.68922 - 16.00623 - 1 .2 74 - 1 .53625 - 1 .72226 - 16.8 727 - 17.01428 - 17. 929 - 1 .47630 - 7.5 93  - 1 .83032 - 1 .9 7
33 - 18.787
34 - 19.967
35 - 20.8286 - .95637 - 21.13338 - 23.02639 - 23.76940 - 23.92241 - 24.94942 - 25.50243 - 26.15744 - 27.32045 - 27.789
46 - 34.66647 - 35.35648 - 38.04949 - 38. 8350 - 39.41851 - 3 .56952 - 3 .725
WVL:220 nm








Marks test sequence #249 Elastase NP2 100um 1H UV_VIS_2
mAU
min
1 - 0.8682 - 2.4313 - 2.984
4 - 3.356
5 - 3.622
6 - 12.2437 - 13.3908 - 13.6589 - 14.15510 - 14.3341 - 14.6502 - 15.06113 - 15.71514 - 16.03015 - 16.27116 - 16.45617 - 16. 6818 - 16.98219 - 17. 7820 - 1 .4342 - 17.69622 - 17.950
23 - 18.831
24 - 19.944
25 - 20.68926 - 20.83827 - 21.07228 - 23.06429 - 23.73230 - 23.90531 - 26.0633  - 27.270
33 - 35.4734 - 35.88335 - 36.5176 - 36.9 87 - 8.09638 - 39.3769 - .50740 - 39.859
WVL:220 nm








Marks test sequence #252 Elastase NP2 100um 3H UV_VIS_2
mAU
min
1 - 0.0372 - 1.4963 - .6034 - 2.9545 3 0116 - . 8
7 - 3.437
8 - 3.702
9 - 12.01210 - 13.15711 - 13.6592 - 14.0643 - 4.2594 - 14. 525 - 14.8416 7317 - 15.49118 - 15.72519 - 16.03120 - 16.3252 - 16. 4722 - 16.71623 - 6.85824 - 17.023- 17.2272  - 7.5947 5728 - 17. 2829 - 8.01530 - 18.280
31 - 18.856
32 - 19.909
33 - 23.04034 - 23.76935 - 23.96436 - 24.99837 - 25.16638 - 25.55039 - 26.145
40 - 27.329
41 - 33.75142 - 34.4484  - 35.3594  - 36.7625 - 37.65546 - 38.08447 - 38. 2148 - 39.36649 - 39.548
WVL:220 nm







Marks test sequence #242 Elastase NP2 100um 24H UV_VIS_2
mAU
min




6 - 9.6177 - 9.8608 - 12.1119 - 12.44310 - 2.7541 - 3.361 - .6393 - 3.85914 - 1 .98715 - 14.6626 - 14. 147 - 15.2 18 - 5.39619 - 16.01620 - 16.230 - .322 - 6.550





30 - 20.08931 - 20.5363  - 21.81833 - 22.1074 - 2.5993  - 22.78536 - 24.09137 - 24.877
38 - 25.985
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Figure A3.5:  Relative Resistance of IO8 to proteolysis. (A) RP-HPLC chromatographs of IO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of IO8 after incubation in Thrombin, (B) 0 
hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions, linear gradient from 0–60% acetonitrile with 0.1%TFA over 
40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution time in minutes. 
 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm






Marks test sequence #264 Thrombin NP2 100um 0H UV_VIS_2
mAU
min
1 - 0.0372 - 3.338
3 - 3.472
4 - 5.353
5 - 9.5386 - 11.6737 - 11.9738 - 2.4019 - 12.7390 - 12.9401 - 13.601 - 13.7973 - . 4114 - 14.39715 - 14. 476 - 15.47417 - 5.67718 - 15.839
19 - 16.632
20 - 18.16721 - 18.70022 - 18.94023 - 1 .58324 - 19.79325 - 20.14426 - 2 .4327 - 21.7672 - 22.262
29 - 23.993
30 - 25.08331 - 25.55232 - 27.09533 - 27.89134 - 30.23835 - 32.38436 - 3.581
37 - 37.95338 - 38.59539 - 39.22840 - 39.944
WVL:220 nm









Marks test sequence #250 Thrombine NP2 100um 1H UV_VIS_2
mAU
min
1 - 0.0462 - 1.0203 - .1624 - 3.026
5 - 3.432
6 - 3.6927 - 5.830
8 - 9.597 - 11.9620 - 13.08611 - 13.44212 - 1 .122 - 1 .6 54 - 15.03515 - 15.4646 - 15.70417 - 16.30918 - 16. 6519 - 1 .74120 - 17.02921 - 17.2302 - .32623 - 1 .4 224 - 18.0105 - .148
26 - 18.826
27 - 18.995
8 - 19.97329 - 21.07530 - 21.23831 - 23.73832 - 24.9993  - 25.50934 - 26.07835 - 27.318
36 - 31.40037 - 34.65838 - 35.39439 - 3 .81540 - 36.04941 - 37.17842 - 38.05543 - 38.4944 - 39.34545 - 39.5126 - 3 .795
WVL:220 nm









Marks test sequence #253 Thrombin NP2 100um 3H UV_VIS_2
mAU
min
1 - 0.0372 - 1.9153 - 2.9224 - 3.035
5 - 3.411
6 - 3.6737 - 5.693
8 - 9.0379 - 9.59310 - 9.88511 - 11.96912 - 13.38613 - 14.26914 - 14.47715 - 14. 46 .73117 - 15.49118 - 15.69919 - 15.88820 - 1 .3192  - 1 .52422 - 16.7003 - 17. 334 - 17.23425 - .3 026 - 1 . 907 - 7.60528 - 7.8 629 - 18.144
30 - 18.981
31 - 19.955
32 - 20.78733 - 20.97334 - 21.1685 - 21.35536 - 23.45237 - 23.78438 - 25.03939 - 25.5040 - 26.14941 - 27.345
42 - 33.84943 - 35.30544 - 35.73845 - 37.55246 - 37.96247 - 38.4 548 - 39.29049 - 39.47750 - 39. 98
WVL:220 nm







Marks test sequence #241 Thrombine NP2 100um 24H UV_VIS_2
mAU
min








21 - 18.94322 - 19.159
23 - 19.61524 - 19.76625 - 20.0036 - . 3827 - 20.32928 - 2 . 552 - 21.14030 - 21.44531 - 21.6133  - .86133 - 22.22134 - 22. 94- 2.730
36 - 24.2837 - 25.84338 - 27.88539 - 28.0930 - 2 .96241 - 2 .2264  - 30.44143 - 31.15344 - 3 .7495 - 3.15746 - 3. 08
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Figure A3.6:  Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in 
Kallikrein, (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
nm and elution time in minutes. 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm









Marks test sequence #246 Kallikrein NP2 100um 0H UV_VIS_2
mAU
min
1 - 0.0462 - 1.9123 - 2.5104 - 2.971
5 - 3.371
6 - 3.625
7 - 6.9328 - 9.1379 - 11.96210 - 12.21411 - 12.5602 8813 - 1 .84814 - 13.32415 - 13.48216 - 13.6447 - 1 .0838 - 1 .23719 - 14.6 40 - .78921 - 15.51522 - 15.71323 - 15.9134 - 6.0285 - 1 . 5126 - 16.32827 - 16. 35
28 - 16.841
29 - 7.25630 - .3743  - 7. 9432 - 17.8993 - .03734 - 8.256
35 - 18.810
6 - 1 .6347 - 19.81238 - 19.9903  - 20.4 140 - 20.965
41 - 23.02642 - 23.202
43 - 23.785
44 - 4.59845 - 24.87646 - .31047 - 25.7 18 - .83649 - 26.17250 - 26.70951 - 27.391
52 - 31.40153 - 34.58754 - 3 .34755 - 3 .08156 - 37.73857 - 37.99958 - 38.54459 - 9.3916  - 3 .53661 - 39.8292 - . 8
WVL:220 nm






Marks test sequence #233 Kallikrein NP2 100um 1 H UV_VIS_2
mAU
min
1 - 0.0462 - 1.558
3 - 3.396
4 - 6.510
5 - 13.0236 - 13.2487 - 14.572
8 - 14.923




14 - 18.97115 - 19.16916 - 19.98617 - 21.00418 - 21.60319 - 21.86120 92721 - 22.2 422 - 22.3 623 - 3.2624 - 23.7165 - 24. 72
26 - 25.23927 - 27.49428 - 28.07829 - 28.943
30 - 39.779
WVL:220 nm














5 - 12.6856 - 12.8597 - .9808 - 13.3869 - 14.3900 - 14.519
11 - 14.825






21 - 20.01722 - 20.93923 - 21.57324 - 21.77325 - 22.02626 - 22.18427 - 2.34528 - 23.2599 - 23.7500 - 24.147
31 - 25.189
32 - 27.04333 - 27.37634 - 28.30935 - 29.04036 - 31.66237 - 31.94938 - 32.14839 - 32.37440 - 32. 9841 - 32. 654  - 3.6483 - 3 .75
44 - 37.5545 - 38.01346 - 39.39847 - 39.678
WVL:220 nm
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Figure A3.7:  Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after incubation in 
Plasmin (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–60% acetonitrile 
with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and 
elution time in minutes 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm






Marks test sequence #260 Plasmin NP2 100um 0 hr UV_VIS_2
mAU
min
1 - 0.0372 - .1713 - 0.3274 - 0.520
5 - 3.5906 - 3.6757 704
8 - 3.829






23 - 16.94124 - 17.11725 - 17.68326 - 8.27727 - 20.410
28 - 22.23029 - 23.145
30 - 24.239 31 - 32.19132 - 33.01033 - 33.66234 - 34.30435 - 34.81336 - 35.60237 - 36.548 - 37.10739 - 37.60040 - 37.78041 - 38.62142 - 38.81143 - 39.1 144 - 39.3065 - 39.69346 - .828
WVL:220 nm









Marks test sequence #261 Plasmin NP2 100um 1hr UV_VIS_2
mAU
min
1 - 0.0792 - 0.2373 - 0.4224 - 0.6185 - 0. 36 - 1. 217 - 1.4 08 - 1.6279 - .0440 - .246 - .3982 - 2.5533 - 2.75114 - .16815 - 3. 706 - .45817 3 5298 - . 739 - 3.8710 - .1791 - 4.3782 - 4.6852  46





30 - 17.90031 - 18.21432 - 19.20133 - 19.5134 - .6 435 - 20.83436 - 21. 3537 - 21.5448 - .6 539 - 21.95140 - 23.0691 - .1 142 - 23. 73
43 - 24.98544 - 28.390 45 - 33.62446 - 33.89047 - 34.90548 - 36.05749 - 37.22950 8251 - 37.49552 - 3 .6873 - .77654 - 38. 0655 - 3 .39756 - 39.02957 - 39.2218 - .31259 - 39.70660 - .847
WVL:220 nm






Marks test sequence #265 Plasmin NP2 100um 3H UV_VIS_2
mAU
min
1 - 0.0372 - 1.995
3 - 3.465
4 - 16.614
5 - 18.1776 - 18.9167 - 9.435 - 1 .6869 - 19.9 50 - 20.1761 - 20.9442 - 21.77213 - 22.74414 - 24.11815 - 24.6376 - .7 5
17 - 25.615 18 - 37.93319 - 38.50420 - 39.224
WVL:220 nm








Marks test sequence #256 Plasmin NP2 100UM 24H UV_VIS_2
mAU
min
1 - 0.1052 - 0.9453 - 1.084 - 1.3925 - 1.5956 - .990
7 - 3.356
8 - 3.622
9 - 12.01010 - 12.8791 - 3.28112 - 13.50213 - 14.30414 - 14.6635 - 15.07516 - 15.7107 - 16.05418 - 16.27419 - 16.45220 - 16. 642  - 17.08022 - 7.2233 - .3 224 - .47725 - 17.8562  - 1 .139
27 - 18.814
 - 19.95829 - 20.76230 - 23.72631 - 25.53132 - 26.10433 - 27.318
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Figure A3.8: Relative Resistance of N2-IO8 to proteolysis. (A) RP-HPLC chromatographs of 
N2-IO8 before incubation in peoteolytic enzymes. RP-HPLC chromatographs of N2-IO8 after 
incubation in Factor X (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs. Conditions, linear gradient from 0–
60% acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 
220 nm and elution time in minutes 
 











3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm







Marks test sequence #269 Factor x NP2 100 um 0 H UV_VIS_2
mAU
min
1 - 0.0372 - 2.509
3 - 3.323
4 - 3.467
5 - 15.1706 - 15.576
7 - 16.729
8 - 19.0049 - 19.7560 - 20.08111 - 2 .7532 - 20.94013 - 21.90114 - 24.20315 - 24.808
16 - 25.63417 - 26.87418 - 29.474 19 - 33.744
20 - 36.70021 - 3 .53022 - 38.23623 - 9.24624 - 39.937
WVL:220 nm












4 - 14.1145 - 14.3116 - 14.5057 - 14.8458 - 15.0989 - 15.496
10 - 16.691
11 - 18.9412 - 1 .53613 - 1 .70514 - 20. 31  - 21.8026 - 22.55717 - 24.158
18 - 25.5999 - 27.05320 - 27.96521 - 30.24722 - 33.716
23 - 38.05324 - 39.215
WVL:220 nm






Marks test sequence #270 Factor x NP2 100 um 3 H UV_VIS_2
mAU
min
1 - 0.0462 - 1.466
3 - 3.252
4 - 3.387
5 - 14.1286 - 14.4947 - 14.8648 - 15.1249 - 15.518
10 - 16.659
11 - 17.432
12 - 18.64913 - 18.96014 - 1 .52415 - 1 .70616 - 20. 377 - 2 . 1418 - 2 .877- 21.34220 - 2 .8631 - 22.30822 - 24.13023 - 25.65624 - 26. 8825 - 28.0872  - 28.986
27 - 31.42928 - 31.96529 - 32.14130 - 3 .56231 - 32.86432 - 33.284 33 - 37.95934 - 39.259
WVL:220 nm







MARKS TEST SEQUENCE #241 Thrombine NP2 100um 24H UV_VIS_2
mAU
min








21 - 18.94322 - 19.159
23 - 19.61524 - 19.76625 - 20.0036 - . 3827 - 20.32928 - 2 . 552 - 21.14030 - 21.44531 - 21.6133  - .86133 - 22.22134 - 22. 94- 2.730
36 - 24.2837 - 25.84338 - 27.88539 - 28.0930 - 2 .96241 - 2 .2264  - 30.44143 - 31.15344 - 3 .7495 - 3.15746 - 3. 08
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Figure A4.1: Plasma stability of IO8 peptide. (A) RP-HPLC chromatographs of IO8 before 
incubation in plasma. RP-HPLC chromatographs of IO8 after incubation in plasma at (B) 0 hr   
(C) 1 hr (D) 3 hrs (E) 24 hrs. (F) 72 hrs. Conditions, linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 nm and elution 
time in minutes 







Marks test sequence #13 IO8 UV_VIS_2
mAU
min
1 - 0.0542 - 0.9593 - 1.5434 - 1. 62
5 - 3.1476 - 3.3087 - 3. 53
8 - 3.7309 - 4.19510 - 4.62711 - 4.76812 - 6.62013 - 7.43314 - 7.58215 - 9.10116 - 11.82917 - 12.03218 - 12.458
19 - 15.16520 - 15.630
21 - 16.177
22 - 16.876
23 - 17.40324 - 17.545
25 - 17.843
26 - 18.11927 - 18. 2328 - 18.74129 - 0.09830 - 20.28131 - 20.6 132 - 21.2023 - 2 .93834 - 2 .74035 - .1 336 - 23.52837 - 23.76838 - 23.92839 - 24.51740 - 5.5601 - 25.7964  - 26.11043 - 27. 91
44 - 28.23245 - 29.05746 - 29.300
47 - 34.15148 - 3 . 6849 - 36.6270 - 37.37251 - 8.475
WVL:220 nm








Marks test sequence #73 Plasma in IO8 1 mM 48hrs UV_VIS_2
mAU
min
1 - 0.0462 - .5983 - 2.2724 - 2.4635 - .595
6 - 3.222
7 - 3.615
8 - 3.8129 - 4.908
10 - 5.321
11 - 6.1692 - 6. 013 - 6.74914 - 7.99615 - .13416 - 10.57717 - 12.15218 - 12.37919 - 12. 5520 - 3.2101 - 14. 53
22 - 14.487
23 - 14.92624 - 15.44325 - 16.24926 - 1 .60527 - 17.1788 - .28029 - 17.59830 - 17. 42
31 - 18.251
32 - 19.36133 - 19.8374 - 20.41235 - 20. 4136 - 21.878
37 - 24.3928  .4679 - 52840  24.6111 - 702  . 973 73844 - 24.85945 - 24.9656 - 5.000
47 - 26.377













Marks test sequence #88 Plasma in IO8 100 uM 3Hr UV_VIS_2
mAU
min
1 - 0.0462 - 3.216
3 - 3.384
4 - 3.5155 77
6 - 4.2497 - 4.5088 - 5.286
9 - 5.470
10 - 6.47811 - 6.77112 - .51313 - .73314 - 11.16215 - 1 .89616 - 14.168
17 - 15.092
18 - 16.17619 - 16.679
20 - 17.037
21 - 17.2752 - .384
23 - 17.632
24 - 18.36725 - 18.8 426 - 19.04327 - 19.3772  - 20.1182 - 20.5563  - 2 .303
31 - 23.23532 - 23.608
33 - 24.875
34 - 25.395
35 - 25.8606  .91837 - 25. 7538 - 26.000
39 - 27.384
40 - 27.619




48 - 33.38049 - 34.406
WVL:220 nm








Marks test sequence #85 Plasma in IO8 100 uM 6Hr UV_VIS_2
mAU
min
1 - 0.105 2 - 3.327
3 - 3.478
4 - 3.674
5 - 4.3876 - 4.653
7 - 5.1778 - 5.6079 - 5.96410 - 7.50411 - 9.86312 - 11.32713 - 1.85714 - 14.124
15 - 15.098
16 - 16.12717 - 16.61418 - 17.03019 - 17. 68
20 - 17.622
21 - 18.35522 - 18.62923 - 18.8 924 - 19.03025 - 19.3 92  - 20.13227 - 2 .57228 - 21.329
29 - 23.27430 - 23.653
31 - 24.949
32 - 25.427
33 - 25.9404 595  . 9136 - 26.017
37 - 27.40938 - 27.647




46 - 33.03247 - 33.842
WVL:220 nm








Marks test sequence #86 Plasma in IO8 100 uM 12Hr UV_VIS_2
mAU
min
1 - 0.0372 - 2.6593 - 3.257
4 - 3.4235 - 3.599
6 - 4.9987 - 5.5058 - 6.4829 - 7.75810 - 9.70111 - 1.24112 - 11.88113 - 14.111
14 - 15.057
15 - 16.10616 - 16.59917 - 17.01318 - 17.2639  .344
20 - 17.606
21 - 18.33022 - 18.79323 - 18.9884 - 19.327
25 - 20.06326 - 20.49027 - 21.259
28 - 23.63329 - 23.913
30 - 24.891
31 - 25.392
32 - 25.9253 50
34 - 27.410
35 - 27.625
36 - 28.55237 - 28.81938 - 29.02039 - 29.307
40 - 30.064
41 - 30.5024  - 31.65843 - 33.386
WVL:220 nm








Marks test sequence #91 Plasma in IO8 100 uM 24Hr UV_VIS_2
mAU
min
1 - 0.079 2 - 3.307
3 - 3.4744 - 3.653
5 - 4.8476 - 5.216
7 - 5.537
 - .7769 - 8.21310 - 10.24611 - 11.13212 - 12.01713 - 14.109
14 - 14.996
15 - 16.59316 - 16. 9217 - 17.27018 - 17. 619 - 18.00520 - 18.758




30 - 25.9171  . 42
32 - 27.371
33 - 27.594
34 - 28.55135 - 28.81436 - 28.99137 - 29.254
38 - 30.037










Figure A4.2: Plasma stability of N1-IO8 peptide. (A) RP-HPLC chromatographs of N1-IO8 
before incubation in plasma. RP-HPLC chromatographs of N1-IO8 after incubation in plasma at 
(B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs (F) 72 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
nm and elution time in minutes. 
 

















10 - 37.62711 - 39.142
WVL:220 nm




















12 - 19.75313 - 19.948
14 - 24.274
15 - 26.265
16 - 26.81417 - 27.39418 - 28.28219 - 29.038
WVL:220 nm


























19 - 26.77520 - 27.3221 - 28.255
22 - 39.822
WVL:220 nm






Marks test sequence #346 NP1 20% plasma 1h UV_VIS_2
mAU
min


























Marks test sequence #309 NP1 50% plasma 24h UV_VIS_2
mAU
min
1 - 0.0912 136
3 - 1.863
4 - 3.484
5 - 3.6916 - 3.758
7 - .118
8 - 4.805














Marks test sequence #315 NP1 50% plasma  72h UV_VIS_2
mAU
min





7 - 7.0238 - 8.0079 - 8.969
10 - 10.19011 - 10.61112 - 12.361
13 - 13.770
14 - 14.236
15 - 15.0956 - .218
17 - 16.47918 - 16.67919 - 16.980
20 - 18.822












Figure A4.3: Plasma stability of N2-IO8 peptide. (A) RP-HPLC chromatographs of N2-IO8 
before incubation in plasma. RP-HPLC chromatographs of N2-IO8 after incubation in plasma at 
(B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs (F) 72 hrs. Conditions, linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C. Absorbance at 220 
















3 - 7.6674 - 9.7395 - 12.5836 - 14.5767 - 14.919
8 - 16.705
9 - 17.99310 - 18.27111 - 18.9852 - 19.18913 - 1 .76814 - 20.39415 - 21.00716 - 21.1531  - 24.17318 - 25.62319 - 27.39320 - 28.05121 - 30.95522 - 32.212
23 - 33.628 24 - 38.17625 - 38.5 426 - 39.26027 - 39. 8328 - 39.968
WVL:220 nm














6 - 7.1287 - 8.0238 - 8.3079 - 9.76910 - 10.311
11 - 11.528


















Marks test sequence #297 NP2 50% Plasma 1h UV_VIS_2
mAU
min
1 - 0.0372 - .825 - 2.1914 - 2.670




10 - 7.17011 - 7.94812 - 8.164
13 - 10.2474 - 11.686
15 - 13.01916 - 13.36317 - 13.8 818 - 14.096
19 - 14.319
















Marks test sequence #295 NP2 50% Plasma 1h UV_VIS_2
mAU
min
1 - 0.0462 - 2.3763 - 2.665
4 - 3.464
5 - 3.7266 - 4.079
7 - 5.844
8 - 11.527
9 - 12.93110 - 13.05611 - 13.416 - 13.9923 - 1 .162
14 - 14.465















Marks test sequence #310 NP2 50% plasma 24h UV_VIS_2
mAU
min
1 - 0.0372 - 1.6583 - 1.9044 - 2.550
5 - 3.345




11 - 10.34612 - 12.103
13 - 14.378
















Marks test sequence #302 NP2 50% Plasma 72h UV_VIS_2
mAU
min
1 - 0.0372 - 2.651
3 - 3.4294 - 3.480
5 - 3.8086 - 4.4507 - 4.917
8 - 5.909
9 - 6.393
10 - 7.15111 - 7.8312 - 8. 44
13 - 10.2624 - 11.899
15 - 14.310
























Reversed-Phase High-Performance Liquid Chromatography of RIO8 and HIO8 
 
This appendix shows the stability of data of RI-IO8 and HIO8  peptides in the 
presence of varying proteolytic enzymes performed using Reversed-Phase High-
Performance Liquid Chromatography (RP-HPLC). Chromatographs from these 
studies are outlined below. Although our study showed that RI-IO8 had no 
inhibitory effect on human amylin aggregation, experiments on RI-IO8 was 
carried out to prove its stability in proteolytic enzymes, particularly trypsin and 
chymotrypsin in which IO8 was readily degraded (figure A1.1- A1.8). The 
stability of our RI-IO8 peptide proves that our retro-inverso approach aimed at 
making IO8 proteolytically stable was successful. The HIO8 peptide was 
designed by replacing the arginine residue in IO8 (RGANFLVHGR-NH2) with 
homoarginin (HarGANFLVHGR-NH2) with the aim of protecting the peptide 


















Figure B1.1:  Relative Resistance of RI-IO8 to proteolysis. (A) RP-HPLC chromatographs of RI-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of RI-IO8 after incubation in Trypsin, 
(B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions,  linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution 
time in minutes. 








Marks test sequence #139 RIO8 100um UV_VIS_2
mAU
min




7 - 21.0738 - 24.221
9 - 25. 4610 - 25.580
11 - 25.832
12 - 26.848
13 - 27.533 14 - 36.49615 - 38.487
WVL:220 nm








Marks test sequence #138 Trypsin in RIO8 100um  0HR UV_VIS_2
mAU
min
1 - 0.0372 - 3.035
3 - 3.414
4 - 3.697 5 - 9.240
6 - 14.0207 - 15.0608 - 15.317
9 - 17.807
10 - 20.309
11 - 21.00912 - 21.996
13 - 25.01914 - 25.531
15 - 25.7746  .846
17 - 26.19818 - 26.635
19 - 27.485
20 - 36.45121 - 37.07222 - 39.085
WVL:220 nm








Marks test sequence #143 Typsin RIIO8 100UM 3 HR UV_VIS_2
mAU
min
1 - 0.0372 - 0.2313 - 1.3444 - .4635 - 2.5006 - 2.9247 - . 848 123
9 - 3.468
10 - 3.770 11 - 9.956
12 - 13.69013 - 14.17714 - 14. 1215 - 14.96016 - 15.48317 - 15.73318 - 1 .1909 - 16.54720 - 16.7152  - 16.89922 - 17.35823 - 17.50824 - 17.6595 - 17. 06
26 - 18.16027 - 18.44928 - 18. 74
29 - 19.497
30 - 21.37031 - 21.54332 - 21. 1033 - 21.906
34 - 23.07335 - 23.72436 - 24.12437 - 24.30538 - 24.51439 - 24.687
40 - 24.950
41 - .2744  - 25. 7443 - 5.683 - 26.029
45 - 26.735
46 - 27.49247 - 27.8 548 - 28.03249 - 28.23950 - 2 .61251 - 28.7 95 - 9.30153 - 30. 72
54 - 33.93655 - 35.0386 - 5.61257 - 36.01558 - 37.235
WVL:220 nm







Marks test sequence #149 Trypsin RIIO8 100um 24HR UV_VIS_2
mAU
min
1 - 0.0372 - 2.5873 - 2.9274  3.009
5 - 3.365
6 - 3.666 7 - 7.0948 - 8.1679 - 8.75410 - 9.695
11 - 13.5282 - 13.94213 - 14.19714 - 14.35615 - 14.9586 - 1 .47117 - 15.69318 - 16.16419 - 16.52220 - 16.8362  - 7.3312 - 1 .46923 - 17. 684 - .7705 - 17.868
26 - 18.14027 - 18.667
28 - 19.441
29 - 21.16630 - 21.34331 - 21.52532 - 21. 94
33 - 23.19834 - 23.51135 - 24.0 136 - 24.465
37 - 24.906
8 - 25.64139 - 2 .983
40 - 26.709
41 - 27.45742 - 27.62743 - 27.80744 - 28.024
45 - 28.294
6 - 28. 434  - 28.91148 - 9.11449 - 9.30350 - .48151 - 30.22252 - 33.89253 - 35.24454 - 35.82255 - 36.44756 - 36.63757 - 37.0 358 - 37.491
WVL:220 nm







Marks test sequence #144 Typsin RIIO8 100UM 1 HR UV_VIS_2
mAU
min




10 - 6.48211 - 6.64112 - 8.0513 - 9.694
14 - 13.62715 - 14.19416 - 14.56817 - 14.94418 - 15. 7119 - 15.69920 - 16.149
21 - 16.50922 - 16.81323 - 17.31624 - 17.46625 - 17.6262  - 17.7757 - .886




33 - 21.16834 - 21.33835 - 21.5116 - 2 .70137 - 2 .872
38 - 23.93139 - 24.08040 - 24.63341 - 24.8774  - 25.2384  - 25.4084  - 25. 3545 - 25.933
46 - 26.685
4  - 27.43048 - 27.61149 - 27.98050 - 28. 8451 - 28.3505  - 28.5325 - 28.68754 - 28.89455 - 29.0826 - 29.263 - 29.4515  - 29.77759 - 30.193























Figure B1.2:  Relative Resistance of RI-IO8 to proteolysis. (A) RP-HPLC chromatographs of RI-IO8 
before incubation in proteolytic enzymes. RP-HPLC chromatographs of RI-IO8 after incubation in 
Chymotrypsin, (B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions,  linear gradient from 0–60% 
acetonitrile with 0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 
nm and elution time in minutes. 








Marks test sequence #139 RIO8 100um UV_VIS_2
mAU
min




7 - 21.0738 - 24.221
9 - 25. 4610 - 25.580
11 - 25.832
12 - 26.848
13 - 27.533 14 - 36.49615 - 38.487
WVL:220 nm






Marks test sequence #142 Chymotrypsin RIIO8 100UM 0 HR UV_VIS_2
mAU
min
1 - 0.0372 - 1.535 - 2.2574 - 3.085
5 - 3.447
6 - 3.749
7 - 14.9518 - 15.3989 - 15.7090 - 16.16411 - 16.5 412 - 16.82413 - 17.3004 - .4255 - 17.75116 - 18.10317 - 18.579
18 - 19.433
19 - 21.20720 - 21.38921 - 21.55822 - 21.734
23 - 23.167
24 - 23.75825 - 23.97626 - 24.634
27 - 24.854
8 - 25.64929 - 26.010
30 - 26.664
31 - 27.47332 - 28.01733 - 28.2053  - 28. 45 - 28.5 06 - 28.7 53  - 29.0943  - 3 .13839 - 30.44440 - 33.908
41 - 4.47442 - 36.119
WVL:220 nm











4 - 3.9615 - 4.056
6 - 5.6007 - 7.651
8 - 8.4269 - 9.875
10 - 16.14811 - 16.411
12 - 17.657
13 - 17.912
14 - 18.53315 - 18.71416 - 19.50017 - 19.755
18 - 22.91919 - 23.34820 - 23.60621 - 24.244
22 - 26.098
23 - 26.708
24 - 34.38225 - 37.68026 - 38.59027 - 39.189
WVL:220 nm







Marks test sequence #147 Chymotrypsin RIIO8 100um 24HR UV_VIS_2
mAU
min




7 - 14.9248 - 15.3 39 - 15.6620 - 16.124 - 1 .32212 - 16.5123 - 16.8044 - .9 3
15 - 17.369
16 - 17.73417 - 18.12518 - 18.5 919 - 18.77120 - 18.944
21 - 19.407
22 - 21.35523 - 21.537
24 - 22.092
25 - 23.16326 - 23.42127 - 23.599
28 - 23.737
29 - 2 .05130 - 24.49631 - 24.69032 - 24.8733 - 25.263 - 25. 4835 - 25.993
36 - 26.697
37 - 27.47638 - 27.62039 - 27.81240 - 28.0 341 - 28. 142 - 2 .37843 - 2 .57244 - 9.09545 - 9.2936 - 29.46047 - 30.187
48 - 37.459
WVL:220 nm








Marks test sequence #138 Trypsin in RIO8 100um  0HR UV_VIS_2
mAU
min
1 - 0.0372 - 3.035
3 - 3.414
4 - 3.697 5 - 9.240
6 - 14.0207 - 15.0608 - 15.317
9 - 17.807
10 - 20.309
11 - 21.00912 - 21.996
13 - 25.01914 - 25.531
15 - 25.7746  .846
17 - 26.19818 - 26.635
19 - 27.485
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Figure B1.3:  Relative Resistance of HIO8 to proteolysis. (A) RP-HPLC chromatographs of HIO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of HIO8 after incubation in Trypsin, (B) 0 hr   
(C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions,  linear gradient from 0–60% acetonitrile with 0.1%TFA 
over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution time in 
minutes. 
 





Marks test sequence #60 HIO8 UV_VIS_2
mAU
min
1 - 0.1072 703 - 0.4264 - .5425 - 0.6946 - 1.3327 - 1.521
8 - 3.351
9 - 3.57010 - 4.06011 - 4.89312 - 5.67313 - .27014 - 7. 7315 - 7.68416 - 8.61317 - 9. 551  - 9.86819 - 10.086
20 - 12.393
21 - 13.61922 - 14.46723 - 15.111
24 - 15.47925 - 15.636
26 - 15.961
27 - 16. 61
28 - 17.362
29 - 17.530
30 - 18.46131 - 19.21732 - 19.65333 - 19.9054 - 20.1865 - 0.4 736 - 21.57437 - 24.06938 - 25.75539 - 27.78940 - 2 .89441 - 31.148 42 - 37.61043 - 38.09444 - 38.6775 - 3 .095
WVL:220 nm








Marks test sequence #67 Trypsin in HIO8 1 mM 0 hr UV_VIS_2
mAU
min
1 - 0.0462 - 1.0683 - 1.4024 - 2.0225 - 3.2026 - 3.476 7 - 6.8518 - 7.1899 - .4310 - 9.05311 - 12.48812 - 15.455
13 - 15.728
14 - 16.046
15 - 17.38416 - 17.97817 - 1 .53018 - 19.920 - 2 .2002  - 1.62121 - 24.08722 - 25.0143 - 25.79124 - 27.82525 - 28.9666 - 9.31727 - 30.01328 - 3 .71129 - 33.5510 - 35.18731 - 35.7362 - 7.21433 - 38.2084 - 38.798
WVL:220 nm







Marks test sequence #65 Trypsin in HIO8 1 mM 1 hr UV_VIS_2
mAU
min
1 - 0.0882 - 0.3093 - .7474 - 0.9565 - 1.942
6 - 3.327
7 - 3.5498 - 3.8039 - 4.36010 - 5.02111 - 5.40612 - 6.46813 - .87114 - 7.60115 - 8.69016 - 9.130







28 - 18.46529 - 19.23830 - 19.90631 - 20.16132 - 20.52933 - 21.54034 - 24.03435 - 25.72736 - 27.7613  - 28.91638 - 30.65339 - 31.01840 - 31.4334  - 31.63042 - 31. 274  - .08144 - 36.08745 - 3 .66646 - 38.11747 - 38. 40
WVL:220 nm








Marks test sequence #71 Plasmin in HIO8 1 mM 3hr UV_VIS_2
mAU
min
1 - 0.0862 1183 - 0.3804 - .4785 - 0.5 46 - .6 97 - . 688 - 0.9 59 - .2540 - 1.85311 - 3.2502 - .52613 - 3.7844 - .91215 3 36 - 4.04017 - 4. 8218 - 4.54519 - .10920 - 6.50221 - 8.622 22 - 12.37923 - 13.66124 - 14.82125 - 15.14526 - 15.457
27 - 15.721
28 - 16.022
29 - 17.36830 - 17.7093  - 18.5012 - 20.14833 - 20.5494 - 21.13335 - 22.07236 - 23.75837 - 4.0308 - 25.72139 - 27.74840 - 28.97541 - 30.70042 - 33.19243 - 3.50644 - 34.32145 - 35. 586 - 36.31747 - 36.63048 - 7.50349 - 3 .89050 - 3 .4965 - 3 .009
WVL:220 nm












3 - 3.4244 - 3.5995 6646 - 4.3567 - 4.9618 - 5.220 - 6.27910 - 6.6541 - .7892 - .36613 - .0004 - 8.1315 - .2451 - 8.5 217 - 9.7978 - .9349 - 10.291
20 - 12.38921 - 14.52722 - 15.149


























Figure B1.4:  Relative Resistance of HIO8 to proteolysis. (A) RP-HPLC chromatographs of HIO8 before 
incubation in proteolytic enzymes. RP-HPLC chromatographs of HIO8 after incubation in Chymotrypsin, 
(B) 0 hr   (C) 1 hr (D) 3 hrs (E) 24 hrs.  Conditions,  linear gradient from 0–60% acetonitrile with 
0.1%TFA over 40 min, at a flow rate of 1 mL/min, 28 °C.  Absorbance at 220 nm and elution 











Marks test sequence #60 HIO8 UV_VIS_2
mAU
min
1 - 0.1072 703 - 0.4264 - .5425 - 0.6946 - 1.3327 - 1.521
8 - 3.351
9 - 3.57010 - 4.06011 - 4.89312 - 5.67313 - .27014 - 7. 7315 - 7.68416 - 8.61317 - 9. 551  - 9.86819 - 10.086
20 - 12.393
21 - 13.61922 - 14.46723 - 15.111
24 - 15.47925 - 15.636
26 - 15.961
27 - 16. 61
28 - 17.362
29 - 17.530
30 - 18.46131 - 19.21732 - 19.65333 - 19.9054 - 20.1865 - 0.4 736 - 21.57437 - 24.06938 - 25.75539 - 27.78940 - 2 .89441 - 31.148 42 - 37.61043 - 38.09444 - 38.6775 - 3 .095
WVL:220 nm








Marks test sequence #66 Chymotrypsin in HIO8 1 mM 0 hr UV_VIS_2
mAU
min
1 - 0.0542 - 2.9003 - 3.3014 - 3.5805 - 3.8346 - 3.9977 - 5.1238 - 7.0509 - 7.44810 - 7.98711 - .43612 - .64713 - 9.03814 - 10.01115 - 12.38016 - 14.77017 - 15.11718 - 15.31819 - 15.431
20 - 15.703
21 - 16.018
22 - 17.3543 - 17.77624 - 18.46125 - 19.24226 - 20.1642 - 20.56828 - 1.2119 - 22.88030 - 23.0713  - 23.98832 - 25.70333 - 27.75034 - 30.69735 - 33.51736 - 3.9227 - 35.08138 - 35.79839 - 37.58940 - 37.9 341 - 38.565
WVL:220 nm






Marks test sequence #68 Chymotrypsin in HIO8 1 mM 1hr UV_VIS_2
mAU
min
1 - 0.0712 - 0.5473 - 0.9994 - 1.2615 - 1.7996 - 2.734




12 - 7.11713 - 7.7094 - .2855 - 9.69816 - 9.97017 - 11.48318 - 11.6419 - .7 720 - 1. 40
21 - 12.318
22 - 13.2363 - 3.6902  - 14.2165  . 9526 - 14.4297 - .5 2
28 - 14.790
29 - 15.008
30 - 15.8851 - .9 1
32 - 16.32833 - 16.918
34 - 17.2833  - 17.473
36 - 17.58037 - 8.042
38 - 18.354
39 - 19.18440 - 19.53841 - 19.98742 - 20.21543 - 20.72644 - .29045 - 22.1886  .26547 - 2.54648 - 3.0754  - 24.07350 - 25.81451 - 27.10552 - 27.82953 - 29.00054 - 30.399
55 - 30.6936 - 31.01757 - 1.6368 - 3 .76159 - 2.810
60 - 33.566
61 - 34.45262 - 35. 856  - 36.36064 - 37.874- 38.2936  - 38.936
WVL:220 nm






Marks test sequence #70 Chymotrypsin in HIO8 1 mM 3hr UV_VIS_2
mAU
min






11 - 6.88312 - 7.78013 - 8.59914 - 9.1435 - 11.46416 - .57517 - 11.7178 - .8019 - 1.9 6
20 - 12.362













42 - 20.16043 - 20.56344 - 21.31845 - 21.57946 - 21.72447 - 22.19348 - 2.52049 - 2.88750 - 3.0715  - 3.2255  - 3.9353 - 25.06754 - 25.7705  - 26.3396 - 27.35357 - 27.8 358 - 28.97559 - 30.33760 - 30.68961 - 31.14562 - 33.5566  - 35.13664 - 35.288
5 - 37.02866 - 37.7557 - 38.1368 - 38.717
WVL:220 nm






Marks test sequence #80 Kallikrein in HIO8 1mM 3 Hr UV_VIS_2
mAU
min
1 - 0.0462 - 1.0723 - 1.2184 - 1.6 45 - .727
6 - 3.2507 - .3648 - 3.5529 605
10 - 3.751
11 - 4.080
12 - 5.73213 - 6.443
14 - 12.66915 - 13.042
16 - 15.89717 - 16.38318 - 16.595
19 - 16.854
20 - 17.173
21 - 18.44122 - 18.687
23 - 19.329
24 - 20.207
25 - 25.14126 - 25.491
27 - 26.140
28 - 27.67529 - 28.68030 - 29.401
31 - 30.11932 - 30.606
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APPENDIX C 













C:\Xcalibur\data\da-I01-1_130508102617 5/8/2013 10:26:17 AM
RT: 0.00 - 40.03































485.43 524.00 357.43 305.14 587.35573.37323.39445.18 445.11 445.16 445.18 445.16445.21 445.15 445.22445.15445.15
NL:
1.84E8





da-I01-1_130508102617 #7824-7954 RT: 26.58-27.01 AV: 44 NL: 7.12E7
T: ITMS + c NSI Full ms [300.00-1800.00]
































514.53 552.87316.29 1160.53641.40 885.66 1796.97982.71 1319.83 1379.34 1492.09 1601.27


















C:\Xcalibur\data\da-I02-01 5/8/2013 1:09:59 PM
RT: 0.00 - 40.03































485.45 402.29 300.40 357.42350.37 445.26305.13473.35445.13445.15 445.13445.20 445.18 445.17 445.14 445.21 445.20 445.15
NL:
1.43E8
Base Peak  
MS 
da-I02-01
da-I02-01 #6607-6710 RT: 22.85-23.18 AV: 35 NL: 5.25E7
T: ITMS + c NSI Full ms [300.00-1800.00]
































493.90302.27 1273.63676.42 872.59 1159.70728.44 1341.981045.73 1736.581494.58 1554.43 1798.65




















C:\Xcalibur\data\da-I03-01 5/8/2013 2:39:24 PM
RT: 0.00 - 40.03





























485.44 402.26 300.33 502.17485.43 357.44 305.15 445.26445.15 445.21 445.18 445.20445.17 445.20 445.22445.21 445.16
NL:
6.19E7
Base Peak  
MS 
da-I03-01
da-I03-01 #8709-8828 RT: 29.93-30.31 AV: 40 NL: 2.81E7
T: ITMS + c NSI Full ms [300.00-1800.00]





























335.11 445.19 1116.54512.52 1002.66659.39 741.14 1252.62846.64 1366.45 1445.24 1531.58 1700.12 1775.15

















C:\Xcalibur\data\da-I04-01 5/8/2013 3:47:51 PM
RT: 0.00 - 40.03





























300.39485.46 402.24 587.40485.47 416.31 357.41 473.32533.35445.20445.20 445.19 445.18445.19445.14445.17
NL:
1.33E8
Base Peak  
MS 
da-I04-01
da-I04-01 #7399-7501 RT: 25.46-25.80 AV: 35 NL: 7.03E7
T: ITMS + c NSI Full ms [300.00-1800.00]





























330.42 1102.52546.28435.05 988.61659.42 868.62 1238.57758.43 1331.00 1429.51 1521.59 1642.66 1784.30


















C:\Xcalibur\data\da-I05-01 5/8/2013 5:07:08 PM
RT: 0.00 - 40.03































416.32 357.39 473.33 473.35 491.30445.16 445.18445.23 445.17 445.14445.20445.17445.17
NL:
1.42E8
Base Peak  
MS 
da-I05-01
da-I05-01 #6713-6877 RT: 23.08-23.61 AV: 55 NL: 4.76E7
T: ITMS + c NSI Full ms [300.00-1800.00]































467.31302.26 1168.57588.32 687.40 1054.66898.59741.30 1304.64 1596.731450.51 1657.21 1758.41















C:\Xcalibur\data\da-I06-01 5/8/2013 6:26:28 PM
RT: 0.00 - 40.03
































416.31485.46 430.35 587.41473.34 573.37445.18445.16 445.16445.18445.21 445.19445.20445.20445.17
NL:
6.63E7
Base Peak  
MS 
da-I06-01
da-I06-01 #6627-6777 RT: 22.06-22.54 AV: 50 NL: 2.00E7
T: ITMS + c NSI Full ms [300.00-1800.00]
































1027.64667.27 741.16 814.55 1277.58968.78 1366.05 1470.36 1579.93 1703.57 1771.90


















c:\xcalibur\data\da-i07-01 5/9/2013 10:05:34 AM
RT: 0.00 - 40.03






























402.27 300.39485.41 416.29 587.37357.40 309.30 367.28445.15445.19445.18 445.13 445.21445.18445.18445.19
NL:
1.27E8
Base Peak  
MS 
da-i07-01
da-i07-01 #6364-6483 RT: 21.47-21.85 AV: 40 NL: 2.69E7
T: ITMS + c NSI Full ms [300.00-1800.00]
































542.26317.42 967.58624.70 811.55 1149.85 1222.25684.23 1362.38 1480.22 1679.63 1767.15


















RT: 0.00 - 60.00 SM: 7B



























































allsop-108_131010180815 #7762-7866 RT: 25.10-25.43 AV: 35 NL: 1.20E7
T: ITMS + c NSI Full ms [300.00-1800.00]









































659.46 758.51 1283.691127.00 1382.251022.06956.63 1444.12906.83 1515.95 1594.56 1705.46 1756.09






















RT: 0.00 - 60.00 SM: 7B























































allsop-108R #8291-8350 RT: 26.55-26.74 AV: 20 NL: 1.96E7
T: ITMS + c NSI Full ms [300.00-1800.00]











































1413.921282.66775.58 1631.851547.131159.85 1683.701032.09980.35 1761.63866.65










Figure D1: Examples of ThT fluorescence curves for time-dependent aggregation of human 
amylin alone and peptide inhibitors alone. Amylin alone at 25 μM displayed a characteristic 
increase in ThT fluorescence corresponding to the lag, sigmoidal and plateau phases of fibril 
formation, while the inhibitors alone, at 100 μM, showed no characteristic of fibril formation  
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Islet amyloid polypeptide, also known as amylin, is themain component of the
amyloid deposits present in approximately 90% of people with type 2 diabetes
mellitus (T2DM). In this disease, amylin aggregates into multimeric b-pleated
sheet structures which cause damage to pancreatic islet b-cells. Inhibitors of
early-stage amylin aggregation could therefore provide a disease-modifying
treatment for T2DM. In this study, overlapping peptides were designed to
target the ‘binding’ region (RLANFLVHSS, residues 11–20) of human
amylin, and their effects on amyloid fibril formation were determined by thio-
flavin-T assay. The first generation peptides showed less than 50% inhibition of
aggregation, but a second generation peptide (H2N-RGANFLVHGR-CONH2)
showed strong inhibitory effects on amylin aggregation, and this was con-
firmed by negative stain electron microscopy. Cytotoxicity studies revealed
that this peptide protected human pancreatic 1.4E7 (ECACC 10070102)
insulin-secreting cells from the toxic effects of human amylin. Unlike the
retro-inverso version of this peptide, which stimulated aggregation, two
N-methylated peptides (H2N-RGAmNFmLVmHGR-CONH2 and H2N-
RGANmFLmVHmR-CONH2) gave very clear dose-dependent inhibition of
fibril formation. These two peptideswere also stable against a range of different
proteolytic enzymes, and in human plasma. These N-methylated peptides
could provide a novel treatment for slowing progression of T2DM.
1. Introduction
Amyloid is a generic term for pathological protein deposits that accumulate in
many different organs and tissues when protein molecules in a predominantly
b-pleated sheet conformation self-associate, mainly by hydrogen bonds, to form
long and unbranching 8–10 nm diameter fibrils [1,2]. More than 30 different
proteins are known to form these fibrils in a wide variety of diseases in
humans, including various forms of systemic and inherited amyloidosis
[3–5], Alzheimer’s disease (AD) [6] and other neurodegenerative diseases [7],
and type 2 diabetes mellitus (T2DM) [8–10]. One of the most prevalent of
these diseases (along with AD) is T2DM, where the amyloid deposits are
found in the islets of Langerhans of the pancreas, and are composed of islet
amyloid polypeptide (IAPP), also known as amylin [10]. Amylin is a
37 amino acid peptide belonging to the calcitonin family, members of which
have a disulfide bridge between Cys residues 2 and 7, as well as an amidated
carboxyl terminus [10,11]. Amyloid deposits have been reported in around 90%
of cases of T2DM [12,13] and amylin aggregation has been strongly linked with
the development of islet b-cell failure in this disease [13,14]. Early studies
demonstrated the toxicity of human amylin to cultured islet cells, through
induction of membrane damage, Ca2þ ion influx, and apoptosis, and suggested
that this toxicity resides in the amyloid fibrils themselves [15–18]. However, as
is the case with other amyloids, more recent studies have indicated that smaller


































Figure 1. Example of ThT fluorescence curves for human amylin in the presence of different concentrations of an inhibitor (IO4). Data are means for a single
experiment carried out in triplicate, with readings taken every 10 min. Amylin alone (at 25 mM) displays a characteristic increase in fluorescence corresponding
to the ‘sigmoidal’ and ‘plateau’ phases of amyloid fibril formation, while the addition of the inhibitor, at varying concentrations, has a dose-dependent effect
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have diabetes and this figure is expected to rise to 642 million
by the year 2040 [22]. Moreover, total deaths from diabetes
have been predicted to increase by 50% in the next 10 years
[23]. Diabetes leads to a number of secondary complica-
tions including blindness, heart disease, kidney failure and
stroke. A healthy diet, weight control, and exercise, are all
necessary for management of T2DM [24,25]. In addition to
these lifestyle changes, a number of drug treatment options
are available, including insulin therapy. However, these
drugs do not provide a cure for diabetes, or prevent second-
ary complications. There is, therefore, a great need for
more research to develop new and potentially more effective
treatment options for diabetes.
Compounds that inhibit the self-assembly of amylin are a
potential therapeutic target for limiting damage to pancreatic
islet cells in T2DM, and this would be expected to slow pro-
gression of this disease (i.e. have a disease-modifying effect).
The objective of this study was to develop novel peptide-
based inhibitors of amylin aggregation that impede the
spontaneous assembly of amylin into oligomers and fibrils
in vitro. In general, it has been challenging to find suitable
drug-like therapeutic agents that inhibit the aggregation of
amyloid proteins.However, small organicmolecules, peptides,
peptidomimetics and nanoparticles have all been developed
for this purpose. In the case of AD, where this type of therapy
is most advanced, a number of inhibitors of aggregation
of the Ab peptide found in senile plaques, including small
molecules and peptides, have been developed over the
years, but none of these compounds have been successful
yet in human clinical trials [26,27]. This is partly due to the
fact that inhibition of amyloid aggregation involves blocking
the interactions between protein monomers, and protein–
protein interactions are recognized as difficult therapeutic
targets [28,29]. Generally, regions for protein–protein inter-
actions are 1500–3000 A˚ in size [30,31], while the region for
protein-small molecule interactions is only 300–1000 A˚
[32,33]. Therefore, small molecules are not able to build ade-
quate steric interruptions to inhibit protein aggregation [34].
These challenges make it difficult to develop potent and
selective small molecule inhibitors of amyloid aggregation.
An alternative strategy for inhibition of amyloid aggrega-
tion is the use of peptide-based inhibitors. Peptide-basedinhibitors directed against specific amyloid sub-regions rep-
resent the first generation of amyloid-based therapeutics,
which can then be developed further into more drug-like
molecules, and this could be a promising avenue for develop-
ment of a new disease-modifying therapy for T2DM. In the
case of amylin, previous studies along these lines have
focused almost exclusively on the primary ‘amyloidogenic’
region of the peptide (amino acid residues 22–28, with
sequence NFGAILS), which is the main region involved in
protein misfolding into the toxic b-sheet conformational
structure [35,36]. These peptide inhibitors are designed to
act as ‘b-sheet breakers’ and are typically compounds that
consist of this amyloidogenic motif in combination with a
b-sheet breaker element. The latter can be comprised, for
example, of methylated amino acids, or prolines [37,38].
However, these ‘b-breaker’ peptides do not completely inhi-
bit fibril formation and their inhibitory effects are often
seen only at high concentrations, when the peptides are pre-
sent in molar excess compared to amylin [39–41]. In contrast,
the peptide inhibitors described in this report are designed
to interact with amylin at the 11–20 ‘binding’ region
(RLANFLVHSS), peptide derivatives from which show maxi-
mum binding to full-length human amylin [42]. Many
peptides face the challenge of insolubility in aqueous solution
and/or susceptibility to proteolytic degradation. To improve
the solubility of the peptides described here, and to limit
their self-aggregation, arginine–glycine residues (RG. . .GR)
were placed at both N- and C-termini (figure 1). This
approach differs from the ‘b-sheet blockers’ presented in
other studies [43–45] and this rationale follows previous suc-
cessful research where a peptide inhibitor (OR2) with the
sequence H2N-RGKLVFFGR-CONH2 was found to inhibit
Ab oligomer and fibril formation [46]. A proteolytically
stable retro-inverso version of this peptide (RI-OR2), with
sequence reversal and substitution of L-amino acids with
D-amino acids, was then developed [47]. The next step was
to attach a ‘TAT’ transit sequence (trans-activator of transcrip-
tion fromHIV) to RI-OR2 to allow it to penetrate into cells, and
cross the blood–brain barrier [48]. In a final iteration, RI-OR2-
TAT was covalently bound to the surface of nanoliposomes to
produce a highly potent multivalent inhibitor [49,50]. Here,
the first steps of a similar strategy are described for
inhibition of aggregation of the amylin peptide in T2DM.






























The amino acid sequence of human amylin, showing the binding region for amylin self-association [42] and the
main amyloidogenic region [35]. All of the short peptide inhibitors are designed to interact with the binding
region of full-length amylin, except for the last peptide. The arginine–glycine ﬂanking residues (RG. . .GR)
impede peptide self-aggregation. In the retro-inverted peptide (RI-IO8), D amino acids are in lower case. N-
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2.1. Peptides
Full length human amylin (1–37 amide) was purchased from
American Peptide Company, California, USA. Structures of the
new peptides designed for this study are presented in table 1.
Seven peptide inhibitors (IO1-IO7) derived from the 11–20 bind-
ing region of amylin (RLANFLVHSS), together with IO8 (the
combined amino acid sequences of IO4 and IO5), and NFGAILS
(H2N-RGNFGAILSGR-CONH2, from the primary amyloidogenic
region), were purchased from ChinaPeptide Company, Shanghai,
China. RI-IO8 (retro-inverso IO8), and two N-methylated pep-
tides (N1-IO8, N2-IO8), were synthesized by Cambridge
Peptides, Birmingham, UK. The effects of two previously pub-
lished inhibitors were also assessed. The first of these is the
hexapeptide H2N-NF(N-Me)GA(N-Me)IL-COOH (abbreviated
here to NMeG24 NMeI26) which is a modification of the amylin
22–27 fragment (NFGAIL), with an N-methylation of the amide
bonds at G24 and I26 [51], and was purchased from Anaspec
EGT Group, California, USA. The second of these peptides, with
amino acid sequence H2N-ANFLVH-COOH [52], was syn-
thesized by ChinaPeptide Company. All peptides were analysed
for purity (table 1) and had their mass confirmed by highperformance liquid chromatography (HPLC)-mass spectrometry
(MS) (electronic supplementary material, figure S1).
2.2. Determination of peptide aggregation by
thioflavin-T assay
Amylin was ‘deseeded’ in trifluoroacetic acid (TFA), followed
by 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), to remove any pre-
formed aggregates prior to these experiments. ThT assays
were carried out in 384-well clear-bottomed microtitre plates
(NUNC) by incubating the amylin peptide (25 mM) in the
presence of ThT (15 mM) in 10 mM phosphate-buffered saline
(PBS), pH7.4, at 308C.The inhibitors,whenpresent,were at varying
molar ratios relative to amylin, with the total volume of solution in
eachwell set at 60 ml. The plates were shaken every 10 min, and the
fluorescencewas then read (lex ¼ 442 nm, andlem ¼ 483 nm) in a
BioTek Synergy 2 plate reader. Triplicate readings were taken for
each condition, with each experiment being repeated three times.
2.3. Cell toxicity experiments
Humanpancreatic 1.4E7 (ECACC10070102) insulin-secreting cells
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culture of human pancreatic islets with PANC-1, a human pan-
creatic ductal carcinoma cell line (ECACC 87092802). These cells
were routinely grown in RPMI-1640 medium with L-glutamine
(Gibco Life Technologies), supplemented with 10% fetal calf
serum and 1% penicillin/streptomycin. Monolayers of cells were
grown in 75 cm3 flasks with incubation at 378C, 5% CO2. Cell via-
bility was assessed using the Promega CellTiter 96 aqueous one
solution cell proliferation (MTS) assay. A confluent layer of cells
was detached using trypsin, washed, and then suspended and
replated, at 250 000 cells/ml, in culture medium. After 24 h, the
medium was replaced with fresh medium containing amylin (10
or 20 mM), with the required concentration of peptide inhibitor,
with replicates of six wells. After incubation for 24 h, 20 ml
of CellTiter 96 aqueous one solution reagent was added to each
well and the plate was incubated for a further 3 h. Absorbance at
490 nm was determined using a Wallac Victor2 1420 multilabel
counter (PerkinElmer). Each experiment was repeated three times.
2.4. Determination of peptide stability
Reverse-phase (RP) HPLC was used to determine the stability of
the peptide inhibitors in plasma, and in the presence of the stated
proteolytic enzymes. A C18 column (Phenomenex, 250  4 mm)
was used for these experiments, with elution by a gradient of
acetonitrile, containing 0.01% trifluoro acetic acid (TFA). A
sample of human plasma was obtained, with ethical approval
(Oldham Ethics Committee), from Prof. David Mann (University
of Manchester). Each peptide (5 ml of 100 mM peptide) was
added to 95 ml of 50% plasma. To assess the stability of peptides
in the presence of proteolytic enzymes, 2 ml of enzyme
(1 mg ml21) was added to 98 ml of peptide (100 mM) in PBS.
After incubation, the samples were injected onto the RP-HPLC
column and eluted with a linear gradient of 0–60% acetonitrile,
with continuous monitoring of absorbance (l ¼ 220 nm).
2.5. Transmission electron microscopy
Solutions of amylin (25 mM), and amylin in the presence of
inhibitors at varying concentrations, were incubated in PBS at
room temperature for 48 h, with continuous orbital shaking,
and a 5 ml sample was applied to a carbon-coated formvar
grid. After 3 min, the liquid was adsorbed by filter paper, then
5 ml of 2% aqueous phosphotungstic acid (PTA) (adjusted to
pH 7.3 using 1N NaOH) was applied, and left for 1 min.
Excess liquid was removed, and the grid was allowed to dry
overnight before observation under a Jeol JEM-1010 electron
microscope. Five fields were photographed at random for each
sample, after first examining the grids for uniformity.
2.6. Statistical analysis
Data for ThT and cell toxicity assays are expressed as mean+
standard error of mean (s.e.m.), for one representative exper-
iment. Statistical analysis was performed using a two-tailed
Student’s t test. ANOVA and confidence interval (CI) analysis
( p, 0.05 þ 95% CI) was used to compare mean values.3. Results
The aggregation of human amylin at 25 mM in the presence of
varying concentrations of peptides IO1-IO7 was monitored
by ThT assay. Figure 1 shows typical examples of ThT
aggregation curves, demonstrating the effects of one of
these peptides (IO4) on fibril formation. Figure 2 presents
data for percentage aggregation of amylin when incubated
in the presence of different concentrations of each peptide,as determined by ThT fluorescence after 48 h incubation (cor-
responding to the level of the final plateau phase of fibril
formation). Surprisingly, IO1 (H2N-RGRLANFLVHSSGR-
CONH2), which spans the entire binding region of amylin,
gave no significant inhibition. Lower concentrations (0.6
and 2 mM) of all of the peptides IO1-IO7 appeared to stimu-
late fibril formation, and no peptide inhibited aggregation to
less than 50% of the non-treated control. The most convincing
inhibition of amylin aggregation was obtained with IO4 and
IO5, and particularly with IO5 (H2N-RGNFLVHGR-CONH2)
which inhibited at all concentrations 12.5 mM, and so
another inhibitor, IO8 (H2N-RGANFLVHGR-CONH2), was
designed by combining the sequences of these two peptides.
In order to protect IO8 from proteolysis, a retro-inverso ver-
sion (RI-IO8, Ac-rGhvlfnaGr-CONH2) was also made, by
reversing the peptide sequence and replacing the L-amino
acids with D-amino acids. IO8 displayed pronounced inhibi-
tory effects on amylin aggregation at all concentrations
1 mM (i.e. down to 1 : 25 molar ratio of inhibitor to
amylin), with 100 mM IO8 decreasing ThT fluorescence to
levels comparable with a buffer only control (figure 3a). In
contrast, RI-IO8 showed no inhibitory effects on amylin
aggregation, but appeared to enhance fibril formation at all
concentrations 50 mM (figure 3a). In addition to retro-inver-
sion, another method to improve the physiochemical
properties of IO8 is through N-methylation, and so the next
step was to carry out ThT assays with two different
N-methylated peptides, N1-IO8 and N2-IO8. Both of these
peptides displayed a clear and almost identical dose-depen-
dent inhibition of amylin aggregation (figure 3b). Results for
IO8 and related peptides from three independent experiments,
each carried out in triplicate, are presented in electronic sup-
plementary material, figure S2. Inhibitor IO8 was then
compared with peptide ‘NFGAILS’ (H2N-RGNFGAILSGR-
CONH2) which was derived from the amyloidogenic region
of human amylin. NFGAILS enhanced amylin aggregation at
all concentrations 25 mM. The effects of NMeG24 NMeI26
[51] and ANFLVH [52], which are inhibitors reported in the lit-
erature to reduce amylin fibril formation, were also assessed.
ANFLVH did not dissolve in aqueous solution, and NMeG24
NMeI26 showed no inhibitory effects (figure 3d).
Figure 4 focusses on the early stages of amylin (25 mM)
aggregation in the presence of varying concentrations
(0.1–100 mM) of N1-IO8 (figure 4a) and N2-IO8 (figure 4b).
It can be seen that increasing concentrations of these inhibi-
tors were found to progressively reduce the steepness of the
curve during the fibril growth phase, indicating a reduction
in the rate of fibril growth. There was also a progressive
decrease in the level of the final plateau phase, indicating a
reduction in the amount of fibrils formed (it has been demon-
strated previously that ThT fluorescence correlates linearly
with amyloid fibril concentration [53]). The ThT curves,
both in the absence and presence of inhibitors, showed vir-
tually no ‘lag’ phase, and so any effects of the inhibitors on
the initial nucleation steps are not clearly defined.
TEM was used to monitor the effects of IO8, RI-IO8,
N1-IO8 and N2-IO8 peptides on amylin aggregation, with
samples being negatively stained by 2% phosphotungstic
acid (PTA). Amylin (at 25 mM) was incubated with 100, 50,
25, 5 and 0 mM (non-inhibited control) of each of these pep-
tides. Figure 5a shows the typical dense meshwork of
amyloid fibrils that was observed after 48 h incubation of




















































































































Figure 2. ThT data showing effects of IO1, IO2, IO3, IO4, IO5, IO6 and IO7 peptides on amylin aggregation, after 48 h incubation. All peptides were assayed at 0.6,
2.5, 5, 12.5, 25, 50 and 100 mM concentrations in the presence of 25 mM amylin. Results are means+ s.e.m., n ¼ 3, for a single experiment. Student’s t-test was






 on October 23, 2017http://rsfs.royalsocietypublishing.org/Downloaded from (i.e. 4 : 1, 2 : 1 and 1 : 1 molar ratios of IO8 to amylin), no fibrils
were observed (illustrated for 25 mM IO8 in figure 5b). At 5 mM
IO8 (1 : 5 molar ratio of IO8 to amylin) some fibrils were
observed, but at a lower density than that seen in the amylin
control. On addition of 100, 50, 25 or 5 mM RI-IO8 to 25 mM
amylin, very dense fibrillar aggregates of amylin were
observed (illustrated for 25 mMRI-IO8 in figure 5c). In the pres-
ence of 100, 50 or 25 mM of either N1-IO8 or N2-IO8, no fibrils
were seen after 48 h incubation (illustrated for 25 mM N1-IO8
and N2-IO8 in figure 5d,e). At 5 mM of N1-IO8, a few fibrils
were observed, but no fibrils were seen with 5 mM of N2-IO8.
None of the peptides tested showed any tendency to form oli-
gomers or fibrils when incubated alone (figure 5f– i). These
TEM results support the ThT data and confirm that IO8, N1-
IO8 and N2-IO8 are effective inhibitors of amylin aggregation,
whereas RI-IO8 has no inhibitory effect, and may even
stimulate fibril formation.
The stability of the most promising inhibitory peptides (IO8,
N1-IO8 and N2-IO8) towards individual proteolytic enzymes
(see electronic supplementary material, figure S3), and inhuman plasma, was assessed by RP-HPLC. The data are sum-
marized in table 2, with examples of RP-HPLC traces of
peptides in plasmapresented in figure 6. IO8was highly suscep-
tible to the effects of trypsin and chymotrypsin, which rapidly
degraded this peptide, but it was also degraded by cathepsin
G, elastase, thrombin, kallikrein, plasmin, and factor X. Not sur-
prisingly, therefore, IO8 was very unstable in human plasma
(figure 6A). In contrast, both N1-IO8 and N2-IO8 were stable
for up to 24 h incubation in plasma (figure 6B,C), and, unlike
IO8, remained intact after 3 h incubation with each of the indi-
vidual proteolytic enzymes, although some degradation was
noted after 24 h incubation (table 2).
The toxic effect of human amylin (20 and 10 mM) on
human pancreatic 1.4E7 cells was determined by MTS
assay, in the presence and absence of 1 : 1 and 1 : 4 molar
ratios (inhibitor:amylin) of the IO8, N1-IO8 and N2-IO8 pep-
tides (for results see figure 7). Amylin at 20 mMwas cytotoxic
to PANC-1 cells and consistently reduced cell viability to
approximately 40% of untreated control cells, whereas at
10 mM amylin the results were more variable and cell












































Figure 4. ThT fluorescence curves for the first 10 h of incubation of amylin in the presence of different concentrations of (a) N1-IO8 and (b) N2-IO8. Data are means
for a single experiment carried out in triplicate, with readings taken every 10 min. Amylin alone (at 25 mM) displays a characteristic increase in fluorescence cor-
responding to the ‘sigmoidal’ and ‘plateau’ phases of amyloid fibril formation (top curve in both cases). In both (a) and (b), the stepwise decrease in the final level
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Figure 3. ThT data showing the effects of IO8 and related peptides, as well NFGAILS and NMeG24 NMeI26, on amylin aggregation, after 48 h incubation. (a) IO8
and RI-IO8. (b) N1-IO8 and N2-IO8. (c) NFGAILS (H2N-RGNFGAILSGR-CONH2). (d ) NMeG24 NMeI26. All peptides were assayed at 0.6, 2.5, 5, 12.5, 25, 50 and 100 mM
in the presence of 25 mM amylin. Results show means+ s.e.m., n ¼ 3, for a single experiment. See electronic supplementary material, figure S2 for the data from
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tides, at both molar ratios, rescued the cells from the toxic
effect of 20 mM amylin and 10 mM amylin. None of the
inhibitors alone, at concentrations of up 20 mM, had anyeffect on cell viability. Cell toxicity results for IO8 and related
peptides from three independent experiments, each carried
out with n ¼ 6 replicates, are presented in electronic sup-




(e) ( f )
(g) (h) (i)
Figure 5. Negative stain EM images of amylin incubated in the presence and absence of inhibitors. (a) Sample of amylin (25 mM) incubated for 48 h in PBS at
room temperature and stained with phosphotungstic acid (2% w/v). (b) Amylin (25 mM) þ IO8 (25 mM); (c) amylin (25 mM) þ RI-IO8 (25 mM); (d ) amylin
(25 mM) þ N1-IO8 (25 mM); (e) amylin (25 mM) þ N2-IO8 (25 mM); ( f ) IO8 alone (100 mM); (g) RI-IO8 alone (100 mM); (h) N1-IO8 alone (100 mM);
and (i) N1-IO8 alone (100 mM). Scale bar, 100 nm.
Table 2. Stability of peptide-inhibitors to proteolysis.
p
, stable; X,
degraded, after 3 h incubation with the enzyme.



















aSome degradation seen after 24 h incubation. HPLC traces for IO8, N1-IO8
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T2DM is the most widespread endocrine disorder [54], and is
characterized by a reduction in b-cell mass, insulin resistance,
and the presence of amyloid deposits in the pancreatic
islets, the main component being amylin [55]. The 22–28(NFGAILS) segment of amylin is regarded as the most highly
amyloidogenic region of this peptide, and will itself assemble
into amyloid fibrils [39,56]. However, residues 8–20 [57],
14–20 [58], and 30–37 [59] have also been reported to form
b-sheet fibrils. Although several amyloidogenic regions of
human amylin have been proposed, this study was concerned
with developing peptide inhibitors from the ‘binding’ region
of human amylin, corresponding to amino acid residues 11–
20 (RLANFLVHSS), and on studying their impact on the fibril-
logenesis of full-length human amylin. This region is thought to
be involved in the initial interactions between two misfolded
amylin molecules, after which they begin to aggregate [42].
Thus, preventing this interaction should impede aggregation.
This strategy, to target the binding region, has been successfully
applied to the development of inhibitors of Ab aggregation as a
potential disease-modifying treatment for AD [47–50].
Seven potential inhibitor peptides were derived from this
binding region, and investigated for their ability to influence
amylin fibril formation, based on the ThT fluorescence assay
[60]. Peptides IO2, IO3, IO4, IO5 and IO7 (table 1) showed
some inhibitory effects, but IO4 and IO5 gave the most promis-
ing results, and were considered for further investigation.
These two amino acid sequences were combined to give IO8
(amino acid sequence: H2N-RGANFLVHGR-CONH2). Retro-
inverso peptides often retain bioactivity and are stable to
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Figure 6. Reverse-phase HPLC traces showing stability of peptide inhibitors in human plasma. Column (A) IO8; column (B) N1-IO8; column (C) N2-IO8. For each
column, the top trace shows elution of the peptide standard without plasma; the middle trace is for 0 h incubation in plasma; and the lower trace is after 48 h
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and D-amino acid substitution. The IO8 peptide showed a strong
inhibitory effect on amylin aggregation, and, unlike peptides
IO1-IO7, did not stimulate amylin aggregation at low concen-
trations. However, RI-IO8 had no inhibitory effect on amylin
aggregation, except at a 4 : 1 molar ratio RI-IO8 to amylin,
where the peptide reduced amylin aggregation to only 77% of
a non-inhibited control (figure 3). At lower concentrations, RI-
IO8 actually stimulated amylin aggregation. This finding was
unexpected and suggests that RI-IO8 does not interact in the
sameway as IO8 to full-length human amylin. Congo red bind-
ing experiments have also confirmed the inhibitory effect of IO8,
and the stimulatoryeffect ofRI-IO8, onamylin aggregation (data
not shown). This findingwas further supported byTEMstudies,
where IO8 abolished and RI-IO8 increased amylin fibril for-
mation (figure 5). This result with RI-IO8 is contrary to a
previous study, where the retro-inverso peptide RI-OR2, devel-
oped against b-amyloid (Ab) aggregation, was shown to
inhibit amyloid fibril formation, and also rescue cells from
the toxic effects of Ab, as well as being highly resistant to
proteolysis [47].
Since RI-IO8 did not inhibit amylin aggregation,
N-methylation was considered as an alternative means to
improve its stability and pharmacokinetic properties. It is not sur-
prising that IO8 was rapidly degraded in plasma, and in the
presence of proteolytic enzymes, because L-peptides are quickly
metabolized in this way [62]. IO8 would be cleaved after amino
acid 5 (Phe) by high specificity chymotrypsin, and after aminoacids 5, 6 and 8 (Phe, Leu, His) by low specificity chymotrypsin,
while trypsin will cleave after position 1 (Arg). N-methylation
has been shown to improve the pharmacokinetic properties of
peptides, by protecting them from proteolysis [63]. Also,
N-methylation of alternate amino acid residues gives one face of
the peptide molecule that is not available for H-bonding, which
impedes amyloid fibril formation [64]. N-methylated derivatives
of Ab(25–35) have been reported to impede the aggregation of
fibrils and prevent Ab cytotoxicity, andN-methylated analogues
of amylin do not form fibrils [18,65]. Here, IO8 was stabilized
against proteolytic degradation through N-methylation of
alternate amino acid residues, to give N1-IO8 (H2N-R-G-Am-N-
Fm-L-Vm-H-G-R-CONH2) and N2-IO8 (H2N-R-G-A-Nm-F-
Lm-V-Hm-G-R-CONH2). ThT and TEM data showed that both
NI-IO8 and N2-IO8 are excellent and highly convincing inhibi-
tors of amylin aggregation (figures 3–5) and are relatively stable
against proteolytic degradation (figure 6).
New inhibitors of amylin aggregation are desired, as many
of the reported inhibitors only work when present in molar
excess over amylin [65–67]. For example, a study on peptide
fragments corresponding to human amylin residues 20–25
(SNNFGA) and 24–29 (GAILSS) showed an inhibitory effect
on b-sheet transition and amyloid aggregation at 10 : 1 and 20
: 1 molar ratios of peptide to amylin, and the GAILSS peptide
had no significant effect on amylin-induced cytotoxicity [41].
The inadequacy of some previously published inhibitors is
also highlighted by the comparison of the effects of IO8,





































































Figure 7. Cytotoxic effect of amylin on human pancreatic 1.4E7 insulin-secreting
cells in the presence or absence of inhibitor peptides. (a) Cells were incubated for
24 h with 20 mM or 10 mM human amylin in RPMI-1640 medium, with or with-
out IO8 inhibitor, and viability was measured using the MTS assay. (b) Results for
N1-IO8. (c) Results for N2-IO8. In all cases, results show mean+ s.e.m., n ¼ 6.
ANOVA followed by Student’s t-test established significance at *p, 0.05,
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sequence as IO8, butwithout the flanking cationic arginine resi-
dues together with their glycine spacers. Although ANFLVH
was reported to inhibit amylin fibril formation in vitro and to
protect against amylin cytotoxicity, the latter effect was only
observed at 10-fold and 20-fold molar excess concentrations
of the peptide [52]. In contrast, the IO8 peptide inhibits
amylin aggregation at much lower concentrations than this,
and, given the inability to dissolve ANFLVH in aqueous sol-
ution, is clearly much more soluble. Moreover, IO8, N1-IO8
and N2-IO8 were seen to rescue human pancreatic 1.4E7 cellsfrom the toxic effects of amylin at a 1 : 4molar ratio of thesepep-
tides toamylin. In contrast toaprevious report [51], no evidence
of inhibition of aggregation was observed upon addition of
NMeG24 NMeI26, at reasonable concentrations, to amylin. In
fact, NMeG24 NMeI26 was seen to promote fibril formation
(figure 3). This discrepancy could be due to the fact that
NMeG24 NMeI26 was reported to inhibit IAPP aggregation
when added before nucleation [68] but the aggregation
system reported here lacks any lag-phase (figure 4), and so
nucleation may be too rapid for this inhibitor to be effective.
Two human amylin-derived peptides, with sequences
NFGAIL and SNNFGAILSS, were unable to inhibit fibrillation
of human amylin [69]. Another study has indicated that
NFGAILcauses an immediate shift of amylin to theb-sheet con-
formation, suggesting that this peptide promotes fibril
formation [41]. These results, together with the lack of effect
of the H2N-RGNFGAILSGR-CONH2 peptide in this study
(figure 3), justify the decision to focus on the RLANFLVHSS
(residues 11–20) amylin binding region.
Asnotedabove,modified full-length amylinwithN-methyl-
ation at positions 24 and 26 has been shown to impede amylin
aggregation and its associated cytotoxicity [65]. In addition, a
human amylin derived peptide marketed as pramlintide, with
proline substitutions at positions 25, 28 and 29, has undergone
clinical trials [70–73]where itwas administered, alongside insu-
lin, for management of T2DM. This combination of drugs was
able to maintain near-normal glycaemic levels, but pramlintide
peptide does not appear to have been assessed as an inhibitor
of human amylin aggregation. The short peptides described in
this report would be much easier and less expensive to syn-
thesize than these full-length human amylin analogues, and
would, potentially, be less immunogenic. N1-IO8 and N2-IO8
in particular appear to be potent and stable aggregation inhibi-
tors that are suitable for further development and testing in
human amylin transgenic rodent models as potential disease-
modifyingagents forT2DM.However, theeffectsof these inhibi-
tors on oligomer formation are not clear from the data presented
here, and will need to be examined in further studies. Also, it is
emerging that a significant component of amylin toxicity is
mediatedby inflammation [74], and so the abilityof these inhibi-
tors to attenuate amylin-mediated macrophage activation and
associated b-cell dysfunction will also need to be determined.
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